<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">80690</article-id><article-id pub-id-type="doi">10.7554/eLife.80690</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Continuous sensing of IFNα by hepatic endothelial cells shapes a vascular antimetastatic barrier</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-281632"><name><surname>Tran</surname><given-names>Ngoc Lan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4270-376X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-281633"><name><surname>Ferreira</surname><given-names>Lorena Maria</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4262-0406</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-281634"><name><surname>Alvarez-Moya</surname><given-names>Blanca</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2573-7909</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-281635"><name><surname>Buttiglione</surname><given-names>Valentina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="pa2">§</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281636"><name><surname>Ferrini</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-281637"><name><surname>Zordan</surname><given-names>Paola</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6915-5535</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-281638"><name><surname>Monestiroli</surname><given-names>Andrea</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5818-2028</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-281639"><name><surname>Fagioli</surname><given-names>Claudio</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9889-4695</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-281640"><name><surname>Bezzecchi</surname><given-names>Eugenia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8838-4736</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-281641"><name><surname>Scotti</surname><given-names>Giulia Maria</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-281642"><name><surname>Esposito</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-281643"><name><surname>Leone</surname><given-names>Riccardo</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-281644"><name><surname>Gnasso</surname><given-names>Chiara</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8005-5439</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-281645"><name><surname>Brendolan</surname><given-names>Andrea</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0109-6879</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281646"><name><surname>Guidotti</surname><given-names>Luca G</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0205-2678</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-281647"><name><surname>Sitia</surname><given-names>Giovanni</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1024-9128</contrib-id><email>sitia.giovanni@hsr.it</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04tfzc498</institution-id><institution>Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute</institution></institution-wrap><addr-line><named-content content-type="city">Milan</named-content></addr-line><country>Italy</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01gmqr298</institution-id><institution>Vita-Salute San Raffaele University</institution></institution-wrap><addr-line><named-content content-type="city">Milan</named-content></addr-line><country>Italy</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04tfzc498</institution-id><institution>Center for Omics Sciences, IRCCS San Raffaele Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Milan</named-content></addr-line><country>Italy</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04tfzc498</institution-id><institution>Experimental Imaging Center, IRCCS San Raffaele Scientific Institute</institution></institution-wrap><addr-line><named-content content-type="city">Milan</named-content></addr-line><country>Italy</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04tfzc498</institution-id><institution>Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute</institution></institution-wrap><addr-line><named-content content-type="city">Milan</named-content></addr-line><country>Italy</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Bautch</surname><given-names>Victoria L</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0130frc33</institution-id><institution>University of North Carolina, Chapel Hill</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rathmell</surname><given-names>W Kimryn</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013v7fk41</institution-id><institution>Vanderbilt University Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="present-address" id="pa1"><label>‡</label><p>University of Geneva, Geneva, Switzerland</p></fn><fn fn-type="present-address" id="pa2"><label>§</label><p>Ipsen Spa, Assago, Italy</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>25</day><month>10</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e80690</elocation-id><history><date date-type="received" iso-8601-date="2022-06-01"><day>01</day><month>06</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-09-18"><day>18</day><month>09</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-05-11"><day>11</day><month>05</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.05.10.491298"/></event></pub-history><permissions><copyright-statement>© 2022, Tran, Ferreira, Alvarez-Moya et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Tran, Ferreira, Alvarez-Moya et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-80690-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-80690-figures-v1.pdf"/><abstract><p>Hepatic metastases are a poor prognostic factor of colorectal carcinoma (CRC) and new strategies to reduce the risk of liver CRC colonization are highly needed. Herein, we used mouse models of hepatic metastatization to demonstrate that the continuous infusion of therapeutic doses of interferon-alpha (IFNα) controls CRC invasion by acting on hepatic endothelial cells (HECs). Mechanistically, IFNα promoted the development of a vascular antimetastatic niche characterized by liver sinusoidal endothelial cells (LSECs) defenestration extracellular matrix and glycocalyx deposition, thus strengthening the liver vascular barrier impairing CRC trans-sinusoidal migration, without requiring a direct action on tumor cells, hepatic stellate cells, hepatocytes, or liver dendritic cells (DCs), Kupffer cells (KCs) and liver capsular macrophages (LCMs). Moreover, IFNα endowed LSECs with efficient cross-priming potential that, along with the early intravascular tumor burden reduction, supported the generation of antitumor CD8<sup>+</sup> T cells and ultimately led to the establishment of a protective long-term memory T cell response. These findings provide a rationale for the use of continuous IFNα therapy in perioperative settings to reduce CRC metastatic spreading to the liver.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>Colorectal cancer remains one of the most widespread and deadly cancers worldwide. Poor health outcomes are usually linked to diseased cells spreading from the intestine to create new tumors in the liver or other parts of the body. Treatment involves surgically removing the initial tumors in the bowel, but patient survival could be improved if, in parallel, their immune system was ‘boosted’ to destroy cancer cells before they can form other tumors.</p><p>Interferon alpha is a small protein which helps to coordinate how the immune system recognizes and deactivates foreign agents and cancerous cells. It has recently been trialed as a colorectal cancer treatment to prevent tumors from spreading to the liver, but only with limited success. This partly because interferon-alpha is usually administered in high and pulsed doses, which cause severe side effects through the body.</p><p>Instead, Tran, Ferreira, Alvarez-Moya et al. aimed to investigate whether continuously delivering lower amounts of the drug could be a better approach. This strategy was tested on mice in which colorectal cancer cells had been implanted into the wall of the large intestine. Continuous administration minimized the risk of the implanted cancer cells spreading to the liver while also creating fewer side effects. The team was able to identify an optimum delivery strategy by varying how much interferon-alpha the animals received and when.</p><p>Further experiments also revealed a new mechanism by which interferon-alpha prevented the spread of colorectal cancer. Upon receiving continuous doses of the drug, a group of liver cells started to generate a physical barrier which stopped cancer cells from being able to invade the organ. The treatment also promoted long-term immune responses that targeted diseased cells while being safe for healthy tissues. If confirmed in clinical trials, these results suggest that colorectal patients undergoing tumor removal surgery may benefit from also receiving interferon-alpha through continuous delivery.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>liver metastases</kwd><kwd>colorectal cancer</kwd><kwd>interferon-alpha</kwd><kwd>HECs</kwd><kwd>LSECs</kwd><kwd>cross-priming</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005010</institution-id><institution>Associazione Italiana per la Ricerca sul Cancro</institution></institution-wrap></funding-source><award-id>22737</award-id><principal-award-recipient><name><surname>Guidotti</surname><given-names>Luca G</given-names></name><name><surname>Sitia</surname><given-names>Giovanni</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005010</institution-id><institution>Associazione Italiana per la Ricerca sul Cancro</institution></institution-wrap></funding-source><award-id>18468</award-id><principal-award-recipient><name><surname>Sitia</surname><given-names>Giovanni</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005010</institution-id><institution>Associazione Italiana per la Ricerca sul Cancro</institution></institution-wrap></funding-source><award-id>22820</award-id><principal-award-recipient><name><surname>Sitia</surname><given-names>Giovanni</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100009882</institution-id><institution>Regione Lombardia</institution></institution-wrap></funding-source><award-id>229452</award-id><principal-award-recipient><name><surname>Guidotti</surname><given-names>Luca G</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>Ministero dell'Istruzione, dell'Università e della Ricerca</institution></institution-wrap></funding-source><award-id>2017MPCWPY</award-id><principal-award-recipient><name><surname>Guidotti</surname><given-names>Luca G</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Continuous perioperative IFNα therapy stimulates hepatic endothelial cells to build up physical vascular barrier that limits tumor cell entry into the liver and promotes long-term antitumor immunity.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related death worldwide (<xref ref-type="bibr" rid="bib93">Sung et al., 2021</xref>). Surgical resection of the primary CRC tumor is the mainstay of treatment (<xref ref-type="bibr" rid="bib3">Argilés et al., 2020</xref>; <xref ref-type="bibr" rid="bib24">Cunningham et al., 2010</xref>; <xref ref-type="bibr" rid="bib85">Seo et al., 2013</xref>) unfortunately, up to 50% of these patients – despite chemotherapy and targeted adjuvant therapies – often develop life-threatening liver metastatic disease in the following years (<xref ref-type="bibr" rid="bib3">Argilés et al., 2020</xref>; <xref ref-type="bibr" rid="bib82">Sargent et al., 2009</xref>). While the overall benefit of surgery is well established (<xref ref-type="bibr" rid="bib85">Seo et al., 2013</xref>), it has been also proposed that this procedure may foster liver metastases by increasing the dissemination of CRC cells into the portal circulation (<xref ref-type="bibr" rid="bib21">Chow and Chok, 2019</xref>; <xref ref-type="bibr" rid="bib27">Denève et al., 2013</xref>), enhancing the adhesion of CRC cells to the liver endothelium (<xref ref-type="bibr" rid="bib17">Chambers et al., 2002</xref>; <xref ref-type="bibr" rid="bib44">Gül et al., 2011</xref>) or promoting transient immunosuppression awakening dormant intrahepatic micrometastases (<xref ref-type="bibr" rid="bib2">Ananth et al., 2016</xref>).</p><p>Accordingly, there is growing recognition that the use of perioperative immunotherapies in CRC patients undergoing surgical resection may represent a unique treatment window to prevent metastatic colonization and control minimal residual disease (<xref ref-type="bibr" rid="bib5">Badia-Ramentol et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Bakos et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Horowitz et al., 2015</xref>). In this context, interferon-alpha (IFNα), a pleiotropic cytokine with multiple antitumor effects such as the direct inhibition of cancer cell growth and angiogenesis (<xref ref-type="bibr" rid="bib48">Indraccolo, 2010</xref>), the sustained upregulation of major histocompatibility complexes (<xref ref-type="bibr" rid="bib39">Gessani et al., 2014</xref>) and the induction of innate and adaptive antitumor immune responses (<xref ref-type="bibr" rid="bib1">Aichele et al., 2006</xref>; <xref ref-type="bibr" rid="bib25">Curtsinger et al., 2007</xref>; <xref ref-type="bibr" rid="bib37">Fuertes et al., 2013</xref>), has been used as adjuvant immunotherapy in various solid cancers such as renal cell carcinoma (<xref ref-type="bibr" rid="bib33">Flanigan et al., 2001</xref>), melanoma (<xref ref-type="bibr" rid="bib58">Lens and Dawes, 2002</xref>) and colorectal cancer (<xref ref-type="bibr" rid="bib55">Köhne et al., 1997</xref>; <xref ref-type="bibr" rid="bib64">Link et al., 2005</xref>). Unfortunately, systemic administration of IFNα has shown limited clinical efficacy, likely due to its short plasma half-life (~1 hr) (<xref ref-type="bibr" rid="bib11">Bocci, 1994</xref>) and the use of high and pulsed doses, which often resulted in systemic side effects (<xref ref-type="bibr" rid="bib104">Weber et al., 2015</xref>). To overcome these limitations, several strategies to prolong IFNα half-life and target the tumor microenvironment have been tested (<xref ref-type="bibr" rid="bib32">Fioravanti et al., 2011</xref>; <xref ref-type="bibr" rid="bib45">Herndon et al., 2012</xref>; <xref ref-type="bibr" rid="bib50">Jeon et al., 2013</xref>; <xref ref-type="bibr" rid="bib59">Li et al., 2017</xref>; <xref ref-type="bibr" rid="bib61">Liang et al., 2018</xref>; <xref ref-type="bibr" rid="bib109">Yang et al., 2014</xref>), including a preclinical gene/cell therapy approach that can deliver constant amounts of IFNα into the liver to significantly curb CRC metastatic growth (<xref ref-type="bibr" rid="bib16">Catarinella et al., 2016</xref>).</p><p>Herein, we adopted a continuous intraperitoneal (ip) IFNα delivery strategy to show that steady and tolerable IFNα doses reduce liver CRC metastatic spreading and improves survival in several CRC mouse models. Our results showed that the antimetastatic effects of IFNα rely neither on the direct inhibition of tumor cell proliferation nor on the indirect stimulation of hepatocytes, hepatic stellate cells, liver DCs, Kupffer cells (KCs) and liver capsular macrophages (LCMs). Rather, the results identify HECs, including LSECs, as key mediators of IFNα-dependent anti-tumor activities that involve the impairment of CRC trans-sinusoidal migration and the development of long-term anti-tumor CD8<sup>+</sup> T cell immunity.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Selection of the optimal IFNα dosing regimen</title><p>To avoid well-known toxicities, especially myelotoxicity, caused by high IFNα doses (<xref ref-type="bibr" rid="bib104">Weber et al., 2015</xref>) and to define a delivery strategy providing prolonged and non-fluctuating IFNα levels in blood and tissues, normal inbred mice were implanted intraperitoneally with mini-osmotic pumps (MOP) constantly releasing different rates (i.e. 50 ng/day, 150 ng/day, or 1050 ng/day) of recombinant mouse IFNα1 (termed IFNα from now on) over time. Serum IFNα levels peaked at day 2 after MOP implantation and relative IFNα amounts (from ~100 pg/ml to ~1200 pg/ml) reflected the different MOP loading doses (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Serum IFNα levels decreased, albeit not uniformly, at days 5 and 7 post implantation (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), mirroring the pharmacokinetic-pharmacodynamic (PK-PD) behavior of other long-lasting formulations of IFNα (<xref ref-type="bibr" rid="bib50">Jeon et al., 2013</xref>). A reduction in circulating white blood cells (WBCs) but not in platelet (PLT) counts or hematocrit (HCT) was detected only with the highest dose (<xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A,B</xref>). Looking at liver toxicity, we observed no increases in serum alanine aminotransferase (sALT) at all tested doses and time points (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>) and no abnormal changes in liver morphology at autopsy (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). Looking at the intrahepatic induction of the interferon-stimulated gene (ISG) <italic>Irf7</italic> (<xref ref-type="bibr" rid="bib20">Cheon et al., 2014</xref>) at day 7, we observed a proportional dose response, with a six-fold increase in <italic>Irf7</italic> expression at the 150 ng/day dosing regimen (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Notably, this increase paralleled the increase that we previously documented to be associated with protection against liver CRC colonization following a gene/cell therapy based IFNα delivery strategy (<xref ref-type="bibr" rid="bib16">Catarinella et al., 2016</xref>). Lack of bone marrow and liver toxicity, proper induction of hepatic <italic>Irf7</italic> expression and maintained responsiveness of hepatic liver cells to IFNα (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>) prompted us to select the 150 ng/day dosing regimen for follow-up investigations.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Selection of the optimal IFNα dosing regimen.</title><p>(<bold>A</bold>) Quantification of plasma IFNα concentration from mice continuously treated with different IFNα doses at the indicated time points. Mean values ± SEM are shown; p-values were calculated by one-way ANOVA Tukey’s multiple comparison test. Significant p-values refer to the IFNα 50 ng/day group, since NaCl-treated animals had IFNα plasma levels below the assay detection limit. p≤0.05; **p≤0.01; ***p≤0.001. (<bold>B</bold>) White blood cell (WBC) counts of mice treated with different IFNα doses at indicated time points. Horizontal dashed lines delimit normal WBC range. Mean value ± SEM are shown; p-values were calculated by one-way ANOVA Tukey’s multiple comparison test. Significant p-values are referred to the NaCl group. *p≤0.05; **p≤0.01. (<bold>C</bold>) Quantitative real-time PCR analysis of <italic>Irf7</italic> mRNA expression from liver tissues of mice treated with different IFNα doses for 7 days. Basal <italic>Irf7</italic> mRNA expression level was determined in control mice (NaCl; n=9) and the relative expression of <italic>Irf7</italic> upon IFNα treatment is shown (n=3, for each IFNα-treated group). Mean values ± SEM are shown; p-values were calculated by Mann-Whitney test.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Data for the dose-response curves in the figure.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80690-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Selection of the optimal IFNα dosing regimen.</title><p>(<bold>A</bold>) Platelet (PLT) count from mice treated with NaCl (n=9) or different IFNα doses at the indicated time points (n=3 each). Horizontal dashed lines delimit normal PLT range. Mean value ± SEM are shown; p-values were calculated by one-way ANOVA Tukey’s multiple comparison test. Significant p-values are referred to NaCl group. **p≤0.01. (<bold>B</bold>) Hematocrit (HCT) from mice treated with NaCl or different IFNα doses at indicated time points. Horizontal dashed lines delimit normal HCT range. Mean value ± SEM are shown; p-values were calculated by one-way ANOVA Tukey’s multiple comparison test. Significant p-values are referred to NaCl group. **p≤0.01. (<bold>C</bold>) Serum Alanine Aminotransferases (sALT) quantification in plasma of mice treated with NaCl or different IFNα doses at indicated time points. Horizontal dashed line delimits normal sALT range. Mean values ± SEM are shown. (<bold>D</bold>) Representative hepatic H&amp;E micrographs from NaCl and IFNα-treated mice with the indicated IFNα doses 7 days after MOP implantation. Scale bar = 100 µm. (<bold>E</bold>) Representative microscopic images of phospho-STAT1 (pSTAT1) IHC of the liver of mice treated continuously with NaCl or 150 ng/day IFN for 7 days and euthanized 30 min after ip injection with NaCl or 1 µg IFNα. Scale bar = 50 µm. Note that pSTAT1 is expressed only in small clusters of cells in close proximity to the portal circulation (i.e. HECs, stellate cells, or leukocytes) in mice continuously treated with IFNα at day 7 after treatment initiation. Of note, injection of pSTAT1-synchronising doses of IFNα resulted in complete activation of all hepatic cells in both groups of mice, suggesting that IFNα-dependent counterregulatory mechanisms are not induced by continuous IFNα treatment.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Data for the dose-response curves in the figure.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig1-figsupp1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80690-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Continuous IFNα administration reduces liver CRC metastatic burden and improves survival</title><p>We next tested the ability of continuous IFNα administration (150 ng/day for 28 days) to reduce CRC metastatic growth in the liver. Groups of H-2<sup>bxd</sup> F1 hybrids of C57BL/6 J x BALB/c (CB6) mice were implanted with either control MOP-NaCl (termed NaCl) or MOP-IFNα (termed IFNα) (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Seven days later, a time frame compatible with the perioperative period in humans (<xref ref-type="bibr" rid="bib46">Horowitz et al., 2015</xref>), CB6 mice were intrasplenically challenged with either the immunogenic microsatellite instable (MSI) MC38 CRC cell line (<xref ref-type="bibr" rid="bib30">Efremova et al., 2018</xref>; <xref ref-type="bibr" rid="bib80">Rosenberg et al., 1986</xref>) or the poorly immunogenic microsatellite stable (MSS) CT26 CRC cell line (<xref ref-type="bibr" rid="bib15">Brattain et al., 1980</xref>; <xref ref-type="bibr" rid="bib30">Efremova et al., 2018</xref>). Rapid removal of the spleen after CRC cell injection was implemented to avoid intrasplenic tumor growth (<xref ref-type="bibr" rid="bib16">Catarinella et al., 2016</xref>). Each CRC cell line was injected at doses known to induce similar survival rates in age- and sex-matched CB6 recipients that, carrying hybrid H-2<sup>bxd</sup> alleles, are immunologically permissive to both MC38 and CT26 cells (<xref ref-type="bibr" rid="bib16">Catarinella et al., 2016</xref>). After treatment initiation, well-tolerated serum IFNα levels of ~300 pg/ml at day 2 and ~100 pg/ml thereafter were observed (<xref ref-type="fig" rid="fig2">Figure 2B</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A,B</xref>), which subsequently declined to undetectable levels. The intrahepatic expression of <italic>Irf7</italic> monitored at day 21 after continuous IFNα therapy (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C, D</xref>) was like that observed earlier at day 7 (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Magnetic resonance imaging (MRI)-based longitudinal analyses – in MC38- (<xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>) or CT26-challenged (<xref ref-type="fig" rid="fig2">Figure 2D</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>) animals – revealed that 100% of NaCl-treated mice (<xref ref-type="fig" rid="fig2">Figure 2E and F</xref>) develop multiple metastatic tumor lesions by days 21 and 28 after challenge and no mice displayed detectable tumors in other organs. Liver lesions increased in volume afterwards, ultimately resulting in imposed humane euthanization of both MC38 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1I</xref>) or CT26 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1J</xref>) tumor carriers in the intervening weeks. Conversely, 45% and 66% of IFNα-treated mice challenged with MC38 or CT26 cells, respectively, showed absence of liver metastases throughout the entire duration of the experiment (<xref ref-type="fig" rid="fig2">Figure 2E and F</xref>). All the remaining mice scoring disease-positive at days 21 and 28 displayed lesions that were reduced in number and size when compared to those detected in NaCl-treated counterparts (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1G, J</xref>). Of note, metastatic lesions eventually regressed and achieved complete remission by day 50 in approximately 33% of IFNα-treated mice that were challenged with MC38 cells and scored disease-positive at day 21 (<xref ref-type="fig" rid="fig2">Figure 2C and E</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>), whereas none of the few CT26-challenged mice scoring disease-positive at day 21 survived long-term (<xref ref-type="fig" rid="fig2">Figure 2D and F</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>), with tumors confined only to the liver. Continuous IFNα administration also improved survival, with similar rates for both MC38- and CT26-challenged mice (<xref ref-type="fig" rid="fig2">Figure 2G and H</xref>). These results indicate that the continuous IFNα administration safely and efficiently limits the liver metastatic colonization of CRC cell lines intrinsically carrying different immunogenic or genetic properties.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Continuous IFNα administration reduces liver CRC metastatic burden and improves survival.</title><p>(<bold>A</bold>) Schematic representation of the experimental procedure. Intrasplenic injection of 7x10<sup>4</sup> MC38 or 5x10<sup>3</sup> CT26 cells was performed 7 days after continuous NaCl or IFNα therapy. (<bold>B</bold>) Quantification of plasma IFNα concentration at different time points after continuous IFNα administration (n=6). The time of intrasplenic CRC cell injection has also been depicted. Mean values ± SEM are shown. (<bold>C–D</bold>) Representative T1 contrast-enhanced magnetic resonance images (MRI) of the liver of mice treated with NaCl (red frame) and IFNα (blue frame) at 21, 28, and 50 days after MC38 (<bold>C</bold>) or CT26 (<bold>D</bold>) cells injection. Red dashed lines highlight CRC liver metastases, characterized as hypointense regions in T1-weighted sequences. n.a.=not assessed, is referred to mice euthanized before the specified time point; scale bar = 5 mm. (<bold>E–F</bold>) Percentage of mice treated with NaCl (MC38 n=3 + 3; CT26 n=5 + 5 for each of two independent experiments) or IFNα (MC38 n=5 + 6; CT26 n=5 + 6 for each of two independent experiments) bearing at least one CRC liver metastasis estimated by MRI analysis at indicated time points after MC38 or CT26 injection. The oblique black line pattern within columns depicts the percentage of mice euthanized before the indicated time point. Mean values are shown; p-values were calculated by Fisher’s exact test. (<bold>G–H</bold>) Kaplan-Meier survival curves of Sham (n=3), NaCl- (MC38 n=6; CT26 n=10) or IFNα-treated (MC38 n=11; CT26 n=11) mice after MC38 or CT26 cells injection. The blue pattern indicates the time frame of IFNα ip release; p-values were calculated by log-rank/Mantel-Cox test.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Data for the graphs in the figure.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig2-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80690-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Continuous intraperitoneal IFNα administration reduces MC38 and CT26 metastatic tumor burden without causing significant hematologic toxicity.</title><p>(<bold>A–B</bold>) WBC counts of mice treated with NaCl or IFNα and injected with MC38 (<bold>A</bold>) or CT26 (<bold>B</bold>) at the indicated time points. Horizontal dashed lines delimit normal WBC range. (Arrows indicate the time of MC38 or CT26 cells injection.) Mean values ± SEM are shown; p-values were calculated by one-way ANOVA Tukey’s multiple comparison test. Significant p-values are referred to NaCl group. *p≤0.05; **p≤0.01; ***p≤0.001. (<bold>C–D</bold>), Quantitative real-time PCR analyses of the relative expression levels of the <italic>Irf7</italic> mRNAs within the metastatic liver tissue of mice treated with NaCl (n=5) or IFNα (n=5) at 14 days after intrasplenic injection of MC38 or CT26 cells. The basal <italic>Irf7</italic> mRNA expression was estimated in the liver tissue of Sham control mice (n=3) and the relative expressions of <italic>Irf7</italic> are shown as mean value ± SEM; p-values were calculated by Mann-Whitney test relative to NaCl treated mice. (<bold>E–F</bold>) Representative T2 MRI analysis of the liver of mice treated with MOP-NaCl (red frame) and MOP-IFNα (blue frame) at 21, 28, and 50 days after injection of MC38 (<bold>E</bold>) or CT26 (<bold>F</bold>) cells. Red dashed lines mark CRC liver metastases characterized as slightly-hyperintense regions in T2-weighted Sequences. n.a.=not assessed, is referred to mice euthanized before the specified time point; scale bar: 5 mm. (<bold>G–H</bold>) Quantification of the number of lesions in the liver of mice treated with MOP-NaCl and MOP-IFNα at indicated time points after MC38 (<bold>G</bold>) and CT26 (<bold>H</bold>) cells injection by MRI analysis. Mean values ± SEM are shown; p-values were calculated by Mann-Whitney test; n.a.=not assessed, is referred to mice euthanized before the specified time point. (<bold>I–J</bold>), Quantification of the total tumor volume in the liver of mice treated with MOP-NaCl and MOP-IFNα at indicated time points after MC38 (<bold>I</bold>) and CT26 (<bold>J</bold>) cells injection by MRI analysis. Mean values ± SEM are shown; p-values were calculated by Mann-Whitney test; n.a.=not assessed, is referred to mice euthanized before the indicated time point.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Data for the graphs in the figure.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig2-figsupp1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80690-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Continuous IFNα administration prevents spontaneous hepatic colonization of orthotopically implanted CT26<sup>LM3</sup> cells</title><p>To confirm the above-mentioned results in a different metastatic setting, we developed an orthotopic CRC model of liver metastases by implanting invasive CRC cells into the mouse cecal wall. As previously reported (<xref ref-type="bibr" rid="bib112">Zhang et al., 2013</xref>), invasive CRC cells were generated by serial intracecal injections of the parental CT26 cells into CB6 mice (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). The percentage of metastatic livers in intracecally implanted mice significantly increased as CT26 cells were passaged, with an almost 100% of animals bearing multiple liver metastases after 3 rounds of in vivo selection (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B-D</xref>). Three-time passaged cells (termed CT26<sup>LM3</sup>) were then orthotopically implanted in the cecal wall of CB6 mice and 7 days later the animals were treated with either NaCl or IFNα (<xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Continuous IFNα administration prevents spontaneous hepatic colonization of orthotopically implanted CT26<sup>LM3</sup> cells.</title><p>(<bold>A</bold>) Schematic representation of the experimental procedure. Seven days after intracecal injection of 2x10<sup>5</sup> CT26<sup>LM3</sup> cells, mice were randomly assigned to receive either continuous NaCl (n=7) or IFNα (n=6) administration and analyzed by MRI 14 days later. (<bold>B</bold>) Quantification of plasma IFNα concentration at the indicated time point after cecal wall injection of CT26<sup>LM3</sup> cells in mice described in a. The arrow indicates the time of NaCl or IFNα therapy initiation. Mean values ± SEM are shown. (<bold>C</bold>) WBC counts from mice described in (<bold>A</bold>) continuously treated with NaCl or IFNα at indicated time points. Horizontal dashed lines delimit the normal WBC range. The time of MOP implantation has also been depicted. Mean value ± SEM are shown; p-values were calculated by one-way ANOVA Tukey’s multiple comparison test. Significant p-values are referred to NaCl group. ***p≤0.001. (<bold>D</bold>) Representative images (top panels) of the hepatic lesions and intracecal tumors observed in NaCl- (red frame) and IFNα-treated (blue frame) mice, 21 days after CT26<sup>LM3</sup> cells intracecal wall injection, and the corresponding hepatic contrast-enhanced MRI, T1-weighted (middle panels) and T2-weighted (bottom panels) sequences. Red dashed lines identify macroscopic liver metastatic lesions. Scale bars = 5 mm. (<bold>E</bold>) Quantification of the weight of primary CRC tumors 21 days after CT26<sup>LM3</sup> cells intracecal wall injection of mice described in D. (<bold>F</bold>) Quantification of the number of hepatic lesions and total tumor volume of liver metastases by MRI analysis of mice described in D. Mean values ± SEM are shown; p-values were calculated by Mann-Whitney test. (<bold>G</bold>) Representative H&amp;E, Ki67, CD34, F4/80, and CD3 immunohistochemical micrographs of liver metastatic lesions found in NaCl- (red frame) and IFNα-treated (blue frame) mice, 21 days after intracecal injection of CT26<sup>LM3</sup> cells. Scale bar = 100 μm. (<bold>H</bold>) Quantification of the percentage of mice bearing liver metastases, as well as the percentage of tumor area and the number of cells expressing Ki67, CD34, F4/80, and CD3 per mm<sup>2</sup> determined by IHC. Immunohistochemical measurements were conducted on at least 1000 mm<sup>2</sup> of total liver area for both experimental conditions. Mean values ± SEM are shown; p-values were calculated by Mann-Whitney test.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Data for the graphs in the figure.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig3-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80690-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>In vivo selection of CT26<sup>LM3</sup> cells with increased spontaneous liver metastatic potential.</title><p>(<bold>A</bold>) Schematic representation of the experimental procedure. (1) 2x10<sup>6</sup> CT26 cells were grown subcutaneously (sc) c into NSG immunodeficient mice. (2) Excised tumors were disaggregated and cultured in vitro to generate CT26<sup>sc</sup> cells. (3) 2x10<sup>6</sup> CT26<sup>sc</sup> cells were injected into the cecal wall of immunocompetent CB6 mice. (4) After 28 days, the number of liver metastatic foci that arised from primary cecal tumors were counted and (5) metastatic liver tumor cells were isolated and cultured in vitro to generate CT26<sup>LM1</sup> cells. (6) 2x10<sup>5</sup> CT26<sup>LM1</sup> cells were injected into the cecal wall of a new immunocompetent mice to obtain CT26<sup>LM2</sup> cells. The procedure was repeated with 2x10<sup>5</sup> CT26<sup>LM2</sup> cells to obtain CT26<sup>LM3</sup> cells. (<bold>B</bold>) Percentage of mice bearing at least one macroscopic liver metastasis 28 days after intracecal wall injection of CT26<sup>LM1</sup> (n=5), CT26<sup>LM2</sup> (n=7) or CT26<sup>LM3</sup> (n=5) cells. Mean values are shown; p-value was calculated by Fisher’s exact test. (<bold>C</bold>) Number of hepatic lesions in the same mice described in (<bold>B</bold>). Mean values ± SEM are shown; p-values were calculated by Mann-Whitney test. (<bold>D</bold>) Representative image of the hepatic lesions observed in mice 28 days after intracecal injection of CT26<sup>LM3</sup>. Black dashed line identifies macroscopic cecal primary tumor whereas white dashed lines delineate liver metastatic lesions.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Data for the graphs in the figure.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig3-figsupp1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80690-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Immunophenotypic analysis of primary tumors and liver metastases in the orthotopic CT26<sup>LM3</sup> model.</title><p>(<bold>A</bold>) Representative H&amp;E, Ki67, CD34, F4/80, and CD3 immunohistochemical micrographs of primary CRC cecal tumors developed in NaCl- (red frame) and IFNα-treated (blue frame) mice, 21 days after intracecal injection of CT26<sup>LM3</sup> cells. Scale bar = 100 μm. (<bold>B</bold>) Quantification of the number of cells expressing Ki67, CD34, F4/80, and CD3 per mm<sup>2</sup> determined by IHC. Immunohistochemical measurements were conducted on at least 1000 mm<sup>2</sup> of total liver area of sham mice and within all metastatic lesions found in both experimental conditions. Mean values ± SEM are shown; p-values were calculated by Mann-Whitney test. (<bold>C</bold>) Representative H&amp;E, Ki67, CD34, F4/80, and CD3 immunohistochemical micrographs showing liver tumor characteristics of metastases found in NaCl- (red frame) and IFNα-treated (blue frame) mice, 21 days after intracecal injection of CT26<sup>LM3</sup> cells. Scale bar = 100 μm. (<bold>D</bold>) Quantification of the number of cells expressing Ki67, CD34, F4/80, and CD3 per mm<sup>2</sup> determined by IHC. Immunohistochemical measurements were conducted on at least 1000 mm<sup>2</sup> of total liver area of sham mice and within all metastatic lesions found in both experimental conditions. Mean values ± SEM are shown; p-values were calculated by Mann-Whitney test.</p><p><supplementary-material id="fig3s2sdata1"><label>Figure 3—figure supplement 2—source data 1.</label><caption><title>Data for the graphs in the figure.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig3-figsupp2-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80690-fig3-figsupp2-v1.tif"/></fig></fig-group><p>Consistent with our previous results (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), serum IFNα levels peaked at day 2 after MOP implantation (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), without causing myelotoxicity (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), and MRI analyses performed 14 days later revealed that continuous IFNα therapy did not alter the growth of primary intracecal tumors (<xref ref-type="fig" rid="fig3">Figure 3D and E</xref>), while IFNα treatment significantly reduced both number and size of hepatic lesions (<xref ref-type="fig" rid="fig3">Figure 3D and F</xref>) with 60% of mice spared from metastatic lesions (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). The primary intracecal tumors (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>) and liver metastases (<xref ref-type="fig" rid="fig3">Figure 3G</xref>) detected after orthotopic implantation of CT26<sup>LM3</sup> cells were also characterized by immunohistochemistry (IHC). This analysis showed that primary intracecal tumors and liver metastatic lesions of NaCl-treated control mice were highly proliferative (as denoted by Ki67 positivity), exhibited marked signs of angiogenesis (as denoted by CD34 staining) and, accordingly with previous reports (<xref ref-type="bibr" rid="bib16">Catarinella et al., 2016</xref>; <xref ref-type="bibr" rid="bib96">Tauriello et al., 2018</xref>), were devoted of F4/80<sup>+</sup> resident macrophages and CD3<sup>+</sup> T cells (<xref ref-type="fig" rid="fig3">Figure 3G and H</xref>). Similar results were also observed in IFNα-treated primary intracecal tumors (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A, B</xref>). The absence of liver metastases in the majority of IFNα-treated mice is reflected by a reduced Ki67 or CD34 staining and an apparently normal distribution of F4/80<sup>+</sup> macrophages and CD3<sup>+</sup> T cells (<xref ref-type="fig" rid="fig3">Figure 3G and H</xref>). The few small hepatic lesions detected in 40% of mice continuously treated with IFNα (<xref ref-type="fig" rid="fig3">Figure 3H</xref> and <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C, D</xref>) did not show differences in Ki67 positivity, CD34 staining or amount of F4/80<sup>+</sup> resident macrophages and CD3<sup>+</sup> T cells in relation to NaCl-treated mice (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C, D</xref>), consistent with the notion that CRC tumors may deregulate the <italic>Ifnar1</italic> receptor and, thus, become refractory to IFNα therapy (<xref ref-type="bibr" rid="bib14">Boukhaled et al., 2021</xref>; <xref ref-type="bibr" rid="bib52">Katlinski et al., 2017</xref>).</p><p>Altogether, these results indicate that continuous IFNα therapy does not significantly alter the growth of primary established CRC tumors but reduces the liver metastatic potential of invasive CRC cells emerging from the cecum.</p></sec><sec id="s2-4"><title>HECs mediate the anti-metastatic activity of IFNα</title><p>As the <italic>Ifnar1</italic> surface receptor subunit is necessary to mediate the pleiotropic anti-tumor properties of IFNα (<xref ref-type="bibr" rid="bib20">Cheon et al., 2014</xref>), we deleted this molecule from CRC cells and from hepatic parenchymal and non-parenchymal cells to identify the mechanism of action (MoA) of continuous IFNα administration in our in vivo system. We restricted these studies to MC38 CRC cells because the genetic background of the mouse models did not allow us to use CT26 CRC MHC-I mismatched cell lines in C57BL/6 recipients. We also adopted a new seeding approach that – involving the injection of CRC cells through the superior mesenteric vein – potentially avoids immune deregulations linked to the splenectomy procedure. Seven days after NaCl or IFNα administration, C57BL/6 mice were challenged with wild-type MC38 cells or with MC38 cells that were CRISPR-Cas9-edited to lack a functional <italic>Ifnar1</italic> receptor (MC38<italic><sup>Ifnar1</sup></italic><sup>_KO</sup>). To this end, MC38-edited clones showed mismatches in a T7E1 assay and clone C8 (MC38<sup>C8</sup>) carrying <italic>Ifnar1</italic> deleting mutations failed to express <italic>Irf7</italic> upon in vitro IFNα stimulation (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A-C</xref>).</p><p>MRI analysis at day 21 after CRC challenge revealed that, in comparison with liver metastases observed in NaCl-treated controls, the lesions produced by MC38- or MC38<italic><sup>Ifnar1</sup></italic><sup>_KO</sup> cells in IFNα-treated mice were similarly reduced in number and size (<xref ref-type="fig" rid="fig4">Figure 4A and C–D</xref>) and this resulted in comparable mouse survival rates (<xref ref-type="fig" rid="fig4">Figure 4E</xref>) in the absence of apparent myelotoxicity (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>). These data support the hypothesis that in our experimental setting the continuous IFNα administration has no direct antiproliferative activity towards CRC cells consistent with our previous reported data (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A-C</xref>; <xref ref-type="bibr" rid="bib16">Catarinella et al., 2016</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>HECs mediate the antimetastatic activity of IFNα.</title><p>(<bold>A</bold>) Representative hepatic contrast-enhanced MRI of wild-type mice (C57BL/6) at day 21 after injection of 5x10<sup>4</sup> MC38 cells or 5x10<sup>4</sup> MC38<italic><sup>Ifnar1</sup></italic><sup>_KO</sup> cells. Treatment with NaCl (red frame) and IFNα (blue frame) was initiated 7 days prior to intrasplenic injection of CRC cells. Red dashed lines highlight CRC liver metastases, characterized as hypointense and slightly-hyperintense regions in T1- and T2-weighted sequences, respectively. Scale bar = 5 mm. The number of mice for each experimental condition is also indicated. (<bold>B</bold>) Representative hepatic contrast-enhanced MRI at day 21 after MC38 intrasplenic injection of <italic>Ifnar1<sup>fl/fl</sup></italic> mice and mice lacking <italic>Ifnar1</italic> on hepatocytes (<italic>Alb<sup>Ifnar1</sup></italic><sup>_KO</sup>), hepatic stellate cells (<italic>Pdgfrb<sup>Ifnar1</sup></italic><sup>_KO</sup>), CD11c-expressing DCs/KCs/LMCs (<italic>Itgax<sup>Ifnar1</sup></italic><sup>_KO</sup>) and endothelial cells (<italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup>) injected with 5x10<sup>4</sup> MC38 cells. Treatment with NaCl (red frame) and IFNα (blue frame) was initiated 7 days before MC38 cells intrasplenic injection. Red dashed lines highlight CRC liver metastases, characterized as hypointense and slightly-hyperintense regions in T1- and T2-weighted sequences, respectively. Scale bar = 5 mm. Number of mice for each experimental condition are also indicated. (<bold>C</bold>) Quantification of the number of hepatic lesions by MRI analysis, 21 days after CRC cells injection, of NaCl and IFNα-treated mice found in C57BL/6 mice, <italic>Ifnar1<sup>fl/fl</sup></italic> mice and all conditional <italic>Ifnar1</italic>_KO mouse models described in (<bold>A</bold>) and (<bold>B</bold>). Mean values ± SEM are shown; p-values were calculated by Mann-Whitney test. (<bold>D</bold>) Quantification of total tumor volume of liver metastases by MRI analysis at day 21 after CRC intrasplenic injection of NaCl- and IFNα-treated mice found in C57BL/6 mice, <italic>Ifnar1<sup>fl/fl</sup></italic> mice and all conditional <italic>Ifnar1</italic>_KO mouse models analyzed. Mean values ± SEM are shown; p-values were calculated by Mann-Whitney test. (<bold>E</bold>) Kaplan-Meier survival curves of C57BL/6 mice injected with MC38 cells (top) or MC38<italic><sup>Ifnar1_KO</sup></italic> cells (bottom) described in (<bold>A</bold>). Sham injected animals (n=3) were used as control. The blue pattern indicates the time frame of IFNα ip release; p-values were calculated by log-rank/Mantel-Cox test. (<bold>F</bold>) Kaplan-Meier survival curves of the indicated groups of mice described in (<bold>B</bold>). Sham injected animals (n=3 per group) were used as control. The blue pattern indicates the time frame of IFNα ip release. The total number of mice for each experimental group were: NaCl-C57BL/6 n=8; IFNα-C57BL/6 n=6; NaCl-MC38<italic><sup>Ifnar1</sup></italic><sup>_KO</sup>-C57BL/6 n=5; IFNα-MC38<italic><sup>Ifnar1</sup></italic><sup>_KO</sup>-C57BL/6 n=6; NaCl-<italic>Ifnar1<sup>fl/fl</sup></italic> n=6; IFNα<italic>-Ifnar1<sup>fl/fl</sup></italic> n=11; NaCl-<italic>Alb<sup>Ifnar1</sup></italic><sup>_KO</sup> n=6; IFNα-<italic>Alb<sup>Ifnar1</sup></italic><sup>_KO</sup> n=8; NaCl-<italic>Pdgfrb<sup>Ifnar1</sup></italic><sup>_KO</sup> n=5; IFNα-<italic>Pdgfrb<sup>Ifnar1</sup></italic><sup>_KO</sup> n=7; NaCl-<italic>Itgax<sup>Ifnar1</sup></italic><sup>_KO</sup> n=8; IFNα-<italic>Itgax<sup>Ifnar1</sup></italic><sup>_KO</sup> n=8 and NaCl-<italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> n=10; IFNα-<italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> n=9. Data pooled from at least two independent experiments of each experimental group; p-values were calculated by log-rank/Mantel-Cox test.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Data for the graphs in the figure.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig4-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80690-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Characterization of conditional <italic>Ifnar1</italic> knockout MC38 cells and liver specific <italic>Ifnar1</italic> knockout mouse models.</title><p>(<bold>A</bold>) T7E1 mismatch detection assay was used to screen three representative single-cell MC38 clones (MC38<sup>B2</sup> and MC38<sup>C8</sup> transfected with crRNA1 or MC38<sup>H11</sup> transfected with crRNA2). Additionally, untransfected MC38, the bulk crRNA1 MC38 line (defined as MC38<sup>Bulk</sup>) and a no DNA control were also treated or not with T7E1 and analyzed as further controls. A 100 bp Marker lane was used as reference. Note that only MC38 transfected with crRNA1 showed cleaved mismatched products and were further characterized. (<bold>B</bold>) Sanger sequencing was performed to validate the location and nature of indel events of the MC38<sup>C8</sup> cell clone. The location of crRNA1 is depicted in red, insertions are highlighted in blue and dashed lines indicate deleted regions. Sequence alignment of MC38 and the two <italic>Ifnar1</italic> alleles of MC38<sup>C8</sup> confirmed a 296 bp deletion in allele 1 and a 2 bases insertion in allele 2, causing a non-functional frame shift. (<bold>C</bold>) Functional screening of MC38<sup>B2</sup> and MC38<sup>C8</sup> cells and MC38 controls, was determined by quantitative real-time PCR of the <italic>Irf7</italic> gene after 4 hours of in vitro stimulation with 300 ng/ml IFNα (n=3). Mean values ± SEM are shown; p-values were calculated by one-way ANOVA Tukey’s multiple comparison test. (<bold>D</bold>) <italic>VeCad</italic><sup>CreERT2</sup>, <italic>Pdgfrb</italic><sup>CreERT2</sup>, <italic>Alb</italic><sup>Cre</sup> and <italic>Itgax</italic><sup>Cre</sup> mice were crossed with <italic>Ifnar1<sup>fl/fl</sup></italic> mice to generate progenies with <italic>Ifnar1</italic> conditional deletion in the corresponding cell type. Amplified <italic>Ifnar1</italic> products from hepatic genomic DNA of C57BL/6 (WT), <italic>Ifnar1<sup>fl/fl</sup></italic>, <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup>, <italic>Pdgfrb<sup>Ifnar1</sup></italic><sup>_KO</sup>, <italic>Alb<sup>Ifnar1</sup></italic><sup>_KO</sup> and <italic>Itgax<sup>Ifnar1</sup></italic><sup>_KO</sup> mice and a no DNA control are shown. A 100 bp Marker lane was used as reference. The expected PCR amplicons size are 1100 bp for <italic>Ifnar1</italic> WT, 669 bp for <italic>Ifnar1</italic><sup>fl</sup> and 389 bp for <italic>Ifnar1</italic> deleted alleles. Note that the ratio between each floxed band and deleted band is consistent with the relative abundance of each cell type within the liver. (<bold>E</bold>) Composite immunofluorescent characterization of the patterns of Cre recombination in <italic>Alb</italic><sup>Cre</sup>, <italic>Pdgfrb</italic><sup>CreERT2</sup>, <italic>Itgax</italic><sup>Cre</sup> , and <italic>VeCad</italic><sup>CreERT2</sup> mice crossed to Rosa26-ZsGreen reporter mice. Representative IF show specific recombination in hepatocytes, hepatic stellate cells (PDGFRβ<sup>+</sup>), endothelial cells (CD31<sup>+</sup>), and CD11c<sup>+</sup> hepatic DCs and F4/80<sup>+</sup> KCs, respectively; Scale bar = 100 µm. (<bold>F</bold>) Immunofluorescent quantification of the percentage of GFP<sup>+</sup> cells that colocalize with specific cell type markers (PDGFRβ<sup>+</sup>, CD11c<sup>+</sup>F4/80<sup>+</sup>, and CD31<sup>+</sup>) for the most relevant Cre recombinant mouse models (<italic>Pdgfrb</italic><sup>CreERT2</sup>, <italic>Itgax</italic><sup>Cre</sup>, and <italic>VeCad</italic><sup>CreERT2</sup>, respectively).</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Original gel file and uncropped gel with labeling of panel (<bold>A</bold>).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig4-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4—figure supplement 1—source data 2.</label><caption><title>Data for the graphs in the figure.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig4-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata3"><label>Figure 4—figure supplement 1—source data 3.</label><caption><title>Original gel file and uncropped gel with labeling of panel (<bold>D</bold>).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig4-figsupp1-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80690-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>LSECs mediate the antimetastatic activity of IFNα.</title><p>(<bold>A</bold>) WBC counts at indicated time point from C57BL/6, injected with MC38 or MC38<italic><sup>Ifnar1</sup></italic><sup>_KO</sup> cells and treated with NaCl or IFNα. Sham injected animals (n=3) were used as controls. Horizontal dashed lines delimit normal WBC range. Arrows indicate the time of MC38 cells injection. Mean values ± SEM are shown; p-values were calculated by two-way ANOVA mixed-effect analysis. Significant p-values are referred to NaCl group. *p≤0.05; **p≤0.01. (<bold>B</bold>) WBC counts at indicated time point from <italic>Ifnar1<sup>fl/fl</sup></italic>, <italic>Alb</italic><sup>Cre</sup>, <italic>Pdgfrb</italic><sup>CreERT2</sup>, <italic>Itgax</italic><sup>Cre</sup>, and <italic>VeCad</italic><sup>CreERT2</sup> mice injected with MC38 cells and treated with NaCl or IFNα. Sham injected animals (n=3) were used as controls. Horizontal dashed lines delimit normal WBC range. Arrows indicate the time of MC38 cells injection. Mean values ± SEM are shown; p-values were calculated by two-way ANOVA mixed-effect analysis. Significant p-values are referred to NaCl group. *p≤0.05; **p≤0.01; ***p≤0.001. (<bold>C</bold>) Kaplan-Meier survival curves of <italic>Ifnar1<sup>fl/fl</sup></italic> mice injected with MC38 cells. Sham injected animals per group (n=3) were used as control. The blue pattern indicates the time frame of IFNα ip release. Mean values are shown; p-values were calculated by log-rank/Mantel-Cox test. (<bold>D</bold>) Kaplan-Meier survival analysis of MOP-NaCl-treated <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice in relation to all cell type-specific conditional <italic>Ifnar1</italic>_KO mice and <italic>Ifnar1<sup>fl/fl</sup></italic> mice showing that upon <italic>Ifnar1</italic> loss from endothelial cells mouse survival was compromised. Mean values are shown; p-values were calculated by log-rank/Mantel-Cox test.</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>Data for the graphs in the figure.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig4-figsupp2-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80690-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Characterization of liver metastases developed in <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice at day 21 after intramesenteric MC38 cells injection.</title><p>(<bold>A</bold>) Representative H&amp;E, CD34, F4/80 and CD3 immunohistochemical micrographs of liver metastatic lesions found in NaCl- (red frame, n=4) and IFNα-treated (blue frame, n=7) <italic>Ifnar1<sup>fl/fl</sup></italic> mice or in NaCl- (red frame, n=4) and IFNα-treated (blue frame, n=4) <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice. Scale bar = 100 μm. (<bold>B</bold>) Quantification of the percentage of tumor area and the number of cells expressing CD34, F4/80, and CD3 per mm<sup>2</sup> determined by IHC. Immunohistochemical measurements were conducted on at least 1000 mm<sup>2</sup> of total liver area for both experimental conditions. Mean values ± SEM are shown; p-values were calculated by Mann-Whitney test.</p><p><supplementary-material id="fig4s3sdata1"><label>Figure 4—figure supplement 3—source data 1.</label><caption><title>Data for the graphs in the figure.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig4-figsupp3-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80690-fig4-figsupp3-v1.tif"/></fig></fig-group><p>Next, we crossed <italic>Ifnar1-</italic>floxed mice (termed <italic>Ifnar1<sup>fl/fl</sup></italic>) (<xref ref-type="bibr" rid="bib77">Prigge et al., 2015</xref>) with transgenic mice selectively expressing Cre recombinase in parenchymal and non-parenchymal liver cells (<xref ref-type="bibr" rid="bib38">Gerl et al., 2015</xref>; <xref ref-type="bibr" rid="bib75">Postic et al., 1999</xref>; <xref ref-type="bibr" rid="bib102">Wang et al., 2010</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>). Cell type-specific recombination was confirmed by crossing each parental mouse line with Rosa26-ZsGreen reporter mice. Note that by crossing the parental Cre-expressing lines with Rosa26-ZsGreen reporter mice (<xref ref-type="bibr" rid="bib67">Madisen et al., 2010</xref>) the resultant mice showed specific recombination in most hepatocytes (identified by morphology), and liver fibroblast (GFP<sup>+</sup>/PDGFRβ<sup>+</sup>), with about 98.2 ± 0.72% hepatic stellate cells that co-expressed GFP<sup>+</sup> and PDGFRβ<sup>+</sup> signals (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E, F</xref>). Similarly, hepatic DCs (GFP<sup>+</sup>/CD11c<sup>+</sup>) had 94.17 ± 2.16% colocalization with GFP, while the colocalization percentage of F4/80<sup>+</sup> KCs or LCMs (GFP<sup>+</sup>/F4/80<sup>+</sup>) was 78.14 ± 5.03% (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E,F</xref>; <xref ref-type="bibr" rid="bib10">Blériot and Ginhoux, 2019</xref>; <xref ref-type="bibr" rid="bib51">Karmaus and Chi, 2014</xref>; <xref ref-type="bibr" rid="bib67">Madisen et al., 2010</xref>). Finally, HECs, including LSECs, (GFP<sup>+</sup>/CD31<sup>+</sup>) showed 85.3 ± 5.03% colocalization (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E, F</xref>), with no expression of GFP signals in cells other than CD31<sup>+</sup>. <italic>Ifnar1<sup>fl/fl</sup></italic> control mice and mice lacking <italic>Ifnar1</italic> in hepatocytes (termed <italic>Alb<sup>Ifnar1</sup></italic><sup>_KO</sup>), hepatic stellate cells (termed <italic>Pdgfrb<sup>Ifnar1</sup></italic><sup>_KO</sup>), <italic>Itgax</italic><sup>+</sup> (CD11c) DCs/KCs/LCMs (termed <italic>Itgax<sup>Ifnar1</sup></italic><sup>_KO</sup>) or <italic>Cdh5<sup>+</sup></italic> + cells (termed <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup>) were intramesenterically injected with MC38 cells 7 days after NaCl or IFNα therapy initiation and did not show signs of hematotoxicity during IFNα infusion (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>). Metastatic growth was assessed by MRI at day 21 (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Loss of <italic>Ifnar1</italic> on hepatocytes, hepatic stellate cells or DCs/KCs/LCMs did not significantly alter the anti-metastatic activity of IFNα treatment (<xref ref-type="fig" rid="fig4">Figure 4C, D and F</xref> and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C</xref>). By contrast, the depletion of <italic>Ifnar1</italic> on HECs allowed the lesions to grow undisturbed (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Indeed, <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice treated with either NaCl or IFNα displayed very similar numbers and sizes of hepatic lesions (<xref ref-type="fig" rid="fig4">Figure 4C and D</xref>) or survival rates (<xref ref-type="fig" rid="fig4">Figure 4F</xref>), indicating that the antimetastatic properties of IFNα requires <italic>Ifnar1</italic> signaling on HECs. <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice exhibited increased tumor burden (<xref ref-type="fig" rid="fig4">Figure 4D</xref>) and mortality rates (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2D</xref>) when compared to NaCl-treated <italic>Ifnar1<sup>fl/fl</sup></italic> mice, suggesting that hepatic endothelial <italic>Ifnar1</italic> signaling exerts significant anti-tumor activity even in the context of physiologic endogenous intrahepatic levels of type I interferons. Furthermore, histological analysis of hepatic CRC lesions from NaCl- and IFNα-treated <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice euthanized at day 21 after MC38 intramesenteric injection indicated that these tumors resembled NaCl-treated <italic>Ifnar1<sup>fl/fl</sup></italic> lesions, showing signs of angiogenesis (as denoted by CD34 positivity) and similar content of F4/80<sup>+</sup> macrophages and CD3<sup>+</sup> T cells within the intrahepatic CRC foci (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A, B</xref>).</p></sec><sec id="s2-5"><title>Continuous IFNα administration limits trans-sinusoidal migration of CRC cells by strengthening the liver vascular barrier</title><p>We next took advantage of fluorescence-based techniques to investigate the initial steps of liver colonization. First, we assessed the intrahepatic localization of GFP-expressing MC38 cells (MC38<sup>GFP</sup>) (<xref ref-type="bibr" rid="bib94">Talamini et al., 2021</xref>) that were intramesenterically challenged 5 min earlier. Most MC38<sup>GFP</sup> cells in <italic>Ifnar1<sup>fl/fl</sup></italic> or <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice appeared physically trapped at the beginning of the sinusoidal circulation in both mouse lineages. This was evidenced by the close contact of MC38<sup>GFP</sup> cells with LYVE-1-expressing LSECs in the proximity of the portal tracts (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Further, MC38<sup>GFP</sup> cells arrested where the sinusoidal diameter (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>) is smaller than their own (12±0.1 µm), similar to what we previously reported (<xref ref-type="bibr" rid="bib16">Catarinella et al., 2016</xref>). As the process of trans-sinusoidal migration – a critical limiting step in the metastatic cascade – is known to occur within 24 hr of CRC challenge (<xref ref-type="bibr" rid="bib17">Chambers et al., 2002</xref>; <xref ref-type="bibr" rid="bib99">Valastyan and Weinberg, 2011</xref>; <xref ref-type="bibr" rid="bib108">Wolf et al., 2012</xref>), the intrahepatic number and localization of MC38<sup>GFP</sup> cells were then studied at this time point. Confocal IF quantification revealed that, compared to NaCl-treated <italic>Ifnar1<sup>fl/fl</sup></italic> animals, MC38<sup>GFP</sup> cells were about ~twofold less abundant in IFNα-treated <italic>Ifnar1<sup>fl/fl</sup></italic> mice and ~threefold more abundant in <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice treated with NaCl or IFNα (<xref ref-type="fig" rid="fig5">Figure 5A</xref> top). Moreover, confocal 3D reconstructions of liver sinusoids from IFNα-treated <italic>Ifnar1<sup>fl/fl</sup></italic> mice unveiled that by 24 hr most MC38<sup>GFP</sup> cells localize intravascularly (i.e. they did not invade the liver parenchyma), while in NaCl-treated <italic>Ifnar1<sup>fl/fl</sup></italic> controls and in NaCl- or IFNα-treated <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice only few MC38<sup>GFP</sup> cells remain within the liver vasculature (i.e. they invaded the liver parenchyma) (<xref ref-type="fig" rid="fig5">Figure 5A</xref> bottom, 5B and <xref ref-type="video" rid="fig5video1 fig5video2 fig5video3 fig5video4">Figure 5—videos 1–4</xref>). These results indicate that HECs, including LSECs, negatively control trans-sinusoidal CRC migration upon IFNα sensing.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Continuous IFNα administration limits trans-sinusoidal migration of CRC cells by strengthening the hepatic vascular barrier.</title><p>(<bold>A</bold>) Total number of MC38<sup>GFP</sup> cells per area (top) and total number of intravascular MC38<sup>GFP</sup> cells per tissue area (bottom). The total hepatic area was approximately 5 mm<sup>2</sup> for each experimental group. Intravascular localization was measured on 20 x images, 5 randomly selected images per mouse (n=3 per group). Mean values ± SEM are shown; p-values were calculated by Mann-Whitney test. (<bold>B</bold>) Confocal reconstruction of the liver vasculature from <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice 24 hr after MC38<sup>GFP</sup> cells (green) intramesenteric vein injection in mice that were treated with NaCl or IFNα for 7 days. CD31 is shown in grey. To allow visualization of intravascular MC38<sup>GFP</sup> cells and to enhance image clarity, the transparency of the sinusoidal rendering was increased up to 80% (bottom). Scale bars = 20µm. (<bold>C</bold>) Fenestrae frequency histogram (top) and percentage of vessel porosity (the percentage of liver endothelial surface area occupied by fenestrae, bottom) in liver sections of control <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>-KO</sup> mice treated for 7 days with continuous NaCl or IFNα therapy. Quantification was performed on 17.000 x SEM images, 10 randomly selected images per mouse (n=3 per group). A total area of approximately 720 µm<sup>2</sup> of sinusoidal surface was analyzed for each mouse. Mean values ± SEM are shown; p-values were calculated by Mann-Whitney test. (<bold>D</bold>) Representative scanning electron micrographs (SEM, top) and transmission electron micrographs (TEM, bottom) images from liver sections of mice described in (<bold>C</bold>), showing hepatic fenestrations and endothelial features. Arrow indicates the increased endothelial thickness observed after continuous IFNα therapy in <italic>Ifnar1<sup>fl/fl</sup></italic> mice. SEM scale bars = 1 µm; TEM scale bars = 500 nm. (<bold>E</bold>) Quantification of the arithmetical mean deviation or Ra coefficient (top) and the percentage of hepatic area positive for HS staining (bottom) on <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> livers treated with continuous NaCl or IFNα therapy for 7 days. Quantification was performed on at least 3 <italic>Ifnar1</italic><sup>fl/fl</sup> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> livers per group. Mean values ± SEM are shown; p-values were calculated by Mann-Whitney test. (<bold>F</bold>) Liver sinusoidal endothelial glycocalyx (GCX) visualization by scanning electron micrographs (SEM, top) from <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> livers that were perfused with lanthanum nitrate (a heavy metal that allows GCX visualization by stabilizing negatively charged GCX structures) 7 days after continuous NaCl or IFNα therapy. Scale bars = 1 µm. Inserts display a representation of the 3D topographic surface of a selected area within the liver sinusoid of each experimental condition. Representative immunofluorescence micrographs of Heparan sulfate (HS; green) and CD31 (red) staining from <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1_KO</sup></italic> mice treated with continuous NaCl or IFNα therapy for 7 days, showing increased HS accumulation after IFNα therapy only in <italic>Ifnar1<sup>fl/fl</sup></italic> mice (bottom). Hoechst (blue) was used for nuclear counterstaining. Scale bars = 20µm.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Data for the graphs in the figure.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig5-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>High-magnification immunofluorescence images of each channel.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig5-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80690-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Continuous IFNα administration induces hepatic endothelial capillarization strengthening the liver vascular barrier.</title><p>(<bold>A</bold>) Representative composite immunofluorescence images showing a pan-endothelial cell marker (CD31, blue) and a liver sinusoidal marker (LYVE-1; red) 5 min after MC38<sup>GFP</sup> cells (green) injection in <italic>Ifnar1<sup>fl/fl</sup></italic> or <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice. Colocalization between CD31 and LYVE-1 is shown in magenta. ×3 magnification shows entrapment of CRC cells at the beginning of the hepatic sinusoid. Scale bar = 20 µm. (<bold>B</bold>) Quantitative analysis of hepatic sinusoids diameter from transmission electron micrographs (TEM) images of <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice after 7 days of continuous NaCl or IFNα therapy. Quantification was performed on 3.400 x TEM images of three animals per group, nine randomly selected images per mouse. A total area of approximately 286 µm<sup>2</sup> was analyzed for each mouse. Mean values ± SEM are shown; p-values were calculated by Mann-Whitney test. (<bold>C</bold>) FACS analysis showing the percentage of ITGB2<sup>+</sup> (top graph) and ITGA4<sup>+</sup> (bottom graph) cells within the hepatic CD31<sup>+</sup> non-parenchymal cells (NPC) population of <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice after 7 days of continuous NaCl or IFNα therapy. For each experimental group, five animals were analyzed. Mean values ± SEM are shown; p-values were calculated by Mann-Whitney test. (<bold>D</bold>) Table displaying the quantification of endothelial thickness (nm), the Space of Disse density (%), the amount of collagen deposits (expressed as the percentage of hepatic sinusoids exhibiting visible collagen fibers) and the presence of basal lamina (expressed as the percentage of hepatic sinusoids exhibiting continuous basal lamina) quantified in TEM images of three animals per group. Randomly selected images (10 fields/mouse) were acquired from <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mouse livers treated for 7 days with continuous NaCl or IFNα therapy. Mean values ± SEM are shown; p-values were calculated by Mann-Whitney test. *p&lt;0.05. (<bold>E</bold>) Representative composite immunofluorescent micrographs of mouse liver cryosections, from <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice treated for 7 days with continuous NaCl or IFNα therapy and stained with CD31 pan-endothelial marker (red) and the ECM components, Collagen IV (green, top images) or Laminin (green, bottom images). Hoechst (blue) was used for nuclear counterstaining. Scale bars = 20µm. (<bold>F</bold>) Quantification of the percentage of hepatic area positive for Collagen type IV (top graph) or Laminin (bottom graph) staining on <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> livers treated with continuous NaCl or IFNα therapy for 7 days. Quantification was performed on 20 x images of at least 3 mice per group, 10 randomly selected images per mouse. Mean values ± SEM are shown; p-values were calculated by Mann-Whitney test. (<bold>G</bold>) Representative composite immunofluorescent micrographs of mouse liver cryosections, from <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice treated for 7 days with continuous NaCl or IFNα therapy, with CD31 pan-endothelial marker (red) and the cell-adhesion molecules ICAM1 (green, top images) or E-selectin (green, bottom images). Hoechst (blue) was used for nuclear counterstaining. Scale bars = 20 µm. (<bold>H</bold>) Quantification of the percentage of hepatic area positive for ICAM1 (top graph) or E-selectin (bottom graph) staining on <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> livers treated with continuous NaCl or IFNα therapy for 7 days. Quantification was performed on 20 x images of at least 3 mice per group, 10 randomly selected images per mouse. Mean values ± SEM are shown; p-values were calculated by Mann-Whitney test.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Data for the graphs in the figure.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig5-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata2"><label>Figure 5—figure supplement 1—source data 2.</label><caption><title>Collagen type IV.</title><p>High magnification immunofluorescence images of each channel.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig5-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata3"><label>Figure 5—figure supplement 1—source data 3.</label><caption><title>Laminin.</title><p>High-magnification immunofluorescence images of each channel.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig5-figsupp1-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata4"><label>Figure 5—figure supplement 1—source data 4.</label><caption><title>ICAM1.</title><p>High-magnification immunofluorescence images of each channel.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig5-figsupp1-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata5"><label>Figure 5—figure supplement 1—source data 5.</label><caption><title>E-Selectin.</title><p>High-magnification immunofluorescence images of each channel.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig5-figsupp1-data5-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80690-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Continuous IFNα administration induces hepatic endothelial capillarization that is reversed after discontinuation of IFNα therapy.</title><p>(<bold>A</bold>) Representative composite immunofluorescent micrographs of mouse liver cryosections, from <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice treated for 7 days with continuous NaCl or IFNα therapy, with CD31 (red) and LYVE-1 (green). Hoechst (blue) was used for nuclear counterstaining. Scale bars = 20 µm. (<bold>B</bold>) Quantification of the percentage of hepatic area positive for LYVE-1 staining of mice described in (<bold>A</bold>). Quantification was performed on 20 x images of at least 3 mice per group. Mean values ± SEM; p-values Mann-Whitney test. (<bold>C</bold>) Representative scanning electron micrographs (SEM) images from liver sections from IFNα-treated <italic>Ifnar1<sup>fl/fl</sup></italic> mice 40 days after continuous IFNα therapy discontinuation (n=3 per group), showing hepatic fenestrations. Scale bars = 1 µm. (<bold>D</bold>) Histograms depicting fenestrae frequency (left) and percentage of vessel porosity (right) quantified in liver sections of IFNα treated <italic>Ifnar1<sup>fl/fl</sup></italic> mice 40 days after treatment discontinuation of mice described in (<bold>C</bold>). Dashed lines represent the average of fenestrae frequency (left) or porosity (right) from 6 randomly selected NaCl-treated images. Quantification was performed on 17.000 x SEM images, 2 randomly selected images per mouse. A total area of approximately 300 µm<sup>2</sup> of sinusoidal surface was analyzed. Mean values ± SEM are shown. (<bold>E–I</bold>) White blood cell (WBC) counts (<bold>E</bold>), Platelet (PLT) count (<bold>F</bold>), Hematocrit (HCT) (<bold>G</bold>) and serum Alanine Aminotransferases (sALT) quantification (<bold>H</bold>) of NaCl-treated control mice and mice described in (<bold>C</bold>). Horizontal dashed lines delimit normal ranges. Mean values ± SEM are shown. (<bold>I</bold>) Representative hepatic H&amp;E micrographs from NaCl-treated mice at day 7 after MOP implantation and IFNα-treated <italic>Ifnar1<sup>fl/fl</sup></italic> mice at day 40 after IFNα therapy discontinuation. Scale bar = 100 µm.</p><p><supplementary-material id="fig5s2sdata1"><label>Figure 5—figure supplement 2—source data 1.</label><caption><title>LYVE-1.</title><p>High-magnification immunofluorescence images of each channel.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig5-figsupp2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s2sdata2"><label>Figure 5—figure supplement 2—source data 2.</label><caption><title>Data for the graphs in the figure.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig5-figsupp2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80690-fig5-figsupp2-v1.tif"/></fig><media mimetype="video" mime-subtype="mp4" xlink:href="elife-80690-fig5-video1.mp4" id="fig5video1"><label>Figure 5—video 1.</label><caption><title>3D reconstruction of a representative extravasated MC38<sup>GFP</sup> cell found within the liver parenchyma of a NaCl-treated <italic>Ifnar1<sup>fl/fl</sup></italic> mouse.</title><p>Confocal reconstruction of the liver vasculature of a <italic>Ifnar1<sup>fl/fl</sup></italic> NaCl-treated mouse 24 hr after MC38<sup>GFP</sup> cells (green) intramesenteric injection. CD31 is shown in grey. To allow visualization of intravascular MC38<sup>GFP</sup> cells and to enhance image clarity, the transparency of the sinusoidal rendering was increased up–to 80%. Scale bar = 20µm.</p></caption></media><media mimetype="video" mime-subtype="mp4" xlink:href="elife-80690-fig5-video2.mp4" id="fig5video2"><label>Figure 5—video 2.</label><caption><title>3D reconstruction of an intravascular MC38<sup>GFP</sup> cell found within a blood vessel of an IFNα-treated <italic>Ifnar1<sup>fl/fl</sup></italic> mouse.</title><p>Confocal reconstruction of the liver vasculature of a <italic>Ifnar1<sup>fl/fl</sup></italic> IFNα-treated mouse 24 hr after MC38<sup>GFP</sup> cells (green) intramesenteric injection. CD31 is shown in grey. To allow visualization of intravascular MC38<sup>GFP</sup> cells and to enhance image clarity, the transparency of the sinusoidal rendering was increased up–to 80%. Scale bar = 20µm.</p></caption></media><media mimetype="video" mime-subtype="mp4" xlink:href="elife-80690-fig5-video3.mp4" id="fig5video3"><label>Figure 5—video 3.</label><caption><title>3D reconstruction of an extravasated MC38<sup>GFP</sup> cell found within the liver parenchyma of a NaCl-treated <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mouse.</title><p>Confocal reconstruction of the liver vasculature of a <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> NaCl-treated mouse 24 hr after MC38<sup>GFP</sup> cells (green) intramesenteric vein injection. CD31 is shown in grey. To allow visualization of intravascular MC38<sup>GFP</sup> cells and to enhance image clarity, the transparency of the sinusoidal rendering was increased up to 80%. Scale bar = 20µm.</p></caption></media><media mimetype="video" mime-subtype="mp4" xlink:href="elife-80690-fig5-video4.mp4" id="fig5video4"><label>Figure 5—video 4.</label><caption><title>3D reconstruction of extravasated MC38<sup>GFP</sup> cells found within the liver parenchyma of an IFNα-treated <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mouse.</title><p>Confocal reconstruction of the liver vasculature of a <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> IFNα treated mouse 24 hr after MC38<sup>GFP</sup> cells (green) intramesenteric vein injection. CD31 is shown in grey. To allow visualization of intravascular MC38<sup>GFP</sup> cells and to enhance image clarity, the transparency of the sinusoidal rendering was increased up to 80%. Scale bar = 20µm.</p></caption></media></fig-group><p>To unravel phenotypic modifications associated with such antitumor function of HECs, including LSECs, the liver microvasculature of NaCl- or IFNα-treated <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1_KO</sup></italic> mice was analyzed by scanning electron microscopy (SEM) and transmission electron microscopy (TEM). IFNα treatment of <italic>Ifnar1<sup>fl/fl</sup></italic> mice significantly decreased the frequency of sinusoidal fenestrae and the overall porosity of LSECs (<xref ref-type="fig" rid="fig5">Figure 5C and D</xref> top), while it increased: (i) the endothelial thickness (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>), (ii) the space of Disse density (an indirect measure of hepatocyte microvilli density) (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>; <xref ref-type="bibr" rid="bib40">Gissen and Arias, 2015</xref>), (iii) the subendothelial deposition of collagen fibrils (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>) and (iv) the appearance of a basal lamina (<xref ref-type="fig" rid="fig5">Figure 5D</xref> bottom and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>). These results were corroborated by immunofluorescence analysis assessing an enhanced perivascular expression of Collagen type IV and Laminin (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E, F</xref>), two components of the basal lamina previously shown to form a barrier against tumor cell invasion (<xref ref-type="bibr" rid="bib68">Mak and Mei, 2017</xref>; <xref ref-type="bibr" rid="bib95">Tanjore and Kalluri, 2006</xref>). By contrast, IFNα treatment of <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice failed to significantly support these changes, leaving the liver microvasculature of these animals highly similar to that of liver metastases-permissive NaCl-treated <italic>Ifnar1<sup>fl/fl</sup></italic> controls (<xref ref-type="fig" rid="fig5">Figure 5C and D</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D-F</xref>). Moreover, IFNα treatment of <italic>Ifnar1<sup>fl/fl</sup></italic> mice significantly increased the expression of LYVE-1, a marker of hepatic capillarization (<xref ref-type="bibr" rid="bib72">Pandey et al., 2020</xref>; <xref ref-type="bibr" rid="bib107">Wohlfeil et al., 2019</xref>). By contrast, IFNα treatment of <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice showed no effect (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A,B</xref>).</p><p>Next, we evaluated the status of the vascular glycocalyx (GCX), a fibrous network of glycoproteins and proteoglycans that lines the LSECs and projects intraluminally (<xref ref-type="bibr" rid="bib78">Reitsma et al., 2007</xref>). Notably, enhanced GCX deposits can act as a repulsive barrier that prevents tumor cell interactions with endothelial cells, adhesion molecules or chemokines have been previously identified as negative correlates of transendothelial migration (<xref ref-type="bibr" rid="bib41">Glinskii et al., 2005</xref>; <xref ref-type="bibr" rid="bib69">Mitchell and King, 2014</xref>; <xref ref-type="bibr" rid="bib71">Offeddu et al., 2021</xref>; <xref ref-type="bibr" rid="bib105">Wilkinson et al., 2020</xref>). Continuous IFNα treatment modified this network as well, increasing its thickness (<xref ref-type="fig" rid="fig5">Figure 5E and F</xref> top) and the expression of one of its major components, the heparan sulfate (HS) (<xref ref-type="bibr" rid="bib78">Reitsma et al., 2007</xref>; <xref ref-type="fig" rid="fig5">Figure 5E and F</xref> bottom). Of note, <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice displayed reduced GCX thickness independently of NaCl- or IFNα-treatment (<xref ref-type="fig" rid="fig5">Figure 5E and F</xref>). Additionally, we evaluated the vascular and perivascular status of cell adhesion molecules such as selectins and integrins, which have been positively associated with the transendothelial migration of tumor cells (<xref ref-type="bibr" rid="bib41">Glinskii et al., 2005</xref>; <xref ref-type="bibr" rid="bib105">Wilkinson et al., 2020</xref>). The expression of ICAM1, E-Selectin (CD62E) (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1G,H</xref>) and the integrins ITGB2 (CD18) or ITGA4 (CD49d) (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>) was up-regulated in IFNα-treated <italic>Ifnar1<sup>fl/fl</sup></italic> controls, while significantly reduced or attenuated in IFNα-treated <italic>VeCad<sup>Ifnar1_KO</sup></italic> mice. The notion that a more modest upregulation of some these markers was still evident in the latter mice may reflect the capacity of liver cells other than HECs to respond to IFNα. Altogether, these results indicate that numerous phenotypic modifications of the liver microvasculature previously associated with the deficient extravasation of both normal and transformed cells of different origin (<xref ref-type="bibr" rid="bib43">Guidotti et al., 2015</xref>; <xref ref-type="bibr" rid="bib99">Valastyan and Weinberg, 2011</xref>) also occur because of continuous IFNα sensing by HECs, including LSECs. Notably, these microvascular modifications were reverted after the discontinuation of IFNα therapy with no impact on long-term liver functionality/viability (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2C-I</xref>).</p></sec><sec id="s2-6"><title>HECs acquire an antimetastatic transcriptional profile upon continuous IFNα sensing</title><p>To confirm the above-mentioned data and to shed new light on the transcriptional changes that HECs adopt to limit CRC trans-sinusoidal migration, we performed RNA-seq analyses on CD31<sup>+</sup> endothelial cells isolated from the liver of <italic>Ifnar1<sup>fl/fl</sup></italic> or <italic>VeCad<sup>Ifnar1_KO</sup></italic> mice 7 days after NaCl or IFNα treatment (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). Using SEM to assess the % of CD31<sup>+</sup> cells bearing the typical sinusoidal fenestrae, we determined that our preparations contain ~96% of bona-fide LSECs (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>), consistently to previous reports (<xref ref-type="bibr" rid="bib65">Liu et al., 2011</xref>; <xref ref-type="bibr" rid="bib91">Su et al., 2021</xref>). When compared to HECs isolated from NaCl-treated <italic>Ifnar1<sup>fl/fl</sup></italic> mice, HECs derived from IFNα-treated animals of the same lineage showed 381 transcripts that were differentially expressed (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). As expected, many of these up-regulated transcripts belonged to the ISG family, including <italic>Irf7, Irf9, Mx1, Mx2, Isg15, Stat1,</italic> and <italic>Oasl1</italic> (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>). Pre-ranked gene set enrichment analyses (GSEA) of IFNα-treated LSECs also revealed a significant enrichment of transcripts involved in interferon signaling or in the induction of varying cytokines and chemokines (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Several transcripts related to the ECM/GCX organization or the cell-cell/cell-matrix adhesion pathways were upregulated as well (<xref ref-type="fig" rid="fig6">Figure 6B and D</xref>). Of note, the expression of <italic>Itga4</italic> and <italic>Itgb2</italic> – previously shown to be increased by IFNα treatment at the protein level (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>) – was also enhanced at the transcriptional level (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). A similar association did not hold true for <italic>Icam1</italic> and <italic>Sele</italic>, suggesting that the increased protein expression we observed earlier (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1G</xref>) occurred independently of transcriptional activity (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Notably, GSEA also identified gene sets involved in the IFNα-dependent activation of innate and adaptive immune responses or in TCR-dependent signaling pathways (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>HECs acquire an antimetastatic transcriptional profile upon continuous IFNα sensing.</title><p>(<bold>A</bold>) Volcano plots of differential gene expression (DGE) results obtained from the comparisons between HECs-derived from <italic>Ifnar1<sup>fl/fl</sup></italic> mice treated with NaCl and IFNα for 7 days (left) and between HECs-derived from <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> and <italic>Ifnar1<sup>fl/fl</sup></italic> NaCl-treated mice (right) (<italic>Ifnar1<sup>fl/fl</sup></italic> n=3; <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> n=4). Significant false discovery rate (FDR &lt;0.05) up- and down-regulated genes are highlighted in red and blue colors, respectively, not significant genes are depicted in grey. (<bold>B</bold>) Heatmap of the expression values (log2-transformed rpkm) of manually selected genes retrieved from differentially regulated pathways. (<bold>C</bold>) Pre-ranked Gene Set Enrichment Analysis (GSEA) enrichment plots of the indicated pathways between CD31<sup>+</sup> cells from <italic>Ifnar1<sup>fl/fl</sup></italic>-IFNα and <italic>Ifnar1<sup>fl/fl</sup></italic>-NaCl (left) and between <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup>-NaCl and <italic>Ifnar1<sup>fl/fl</sup></italic>-NaCl-treated animals (right). (<bold>D</bold>) Bar charts showing the adjusted p-values (-log10 transformed) of selected pathways from the enrichment analysis performed on comparisons between <italic>Ifnar1<sup>fl/fl</sup></italic>-IFNα and <italic>Ifnar1<sup>fl/fl</sup></italic>-NaCl CD31<sup>+</sup> cells (left graph) and between <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup>-NaCl and <italic>Ifnar1<sup>fl/fl</sup></italic>-NaCl CD31<sup>+</sup> cells (right graph).</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Gene Ontology (GO) of biological process enrichment analysis of all differentially expressed genes.</title><p>Excel spreadsheet with all significant pathways found in the comparison between IFNα-treated <italic>Ifnar1<sup>fl/fl</sup> vs</italic> NaCl-treated <italic>Ifnar1<sup>fl/fl</sup> HECs/</italic>LSECs and NaCl-treated <italic>VeCad<sup>Ifnar1_KO</sup></italic>-NaCl <italic>vs</italic> NaCl-treated <italic>Ifnar1<sup>fl/fl</sup></italic> LSECs were generated using GO Biological Processes 2018 collection.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig6-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80690-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>HECs acquire an antimetastatic transcriptional profile upon continuous IFNα sensing.</title><p>(<bold>A</bold>) Flow cytometry gating strategy for the sorting and isolation of CD31<sup>+</sup> HECs isolated from the livers of <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice 7 days after continuous NaCl and IFNα therapy. Viable cells were first selected on their morphology (using FSC/SSC parameters), followed by the exclusion of doublets and 7AAD<sup>+</sup> dead cells. (<bold>B</bold>) Representative SEM micrograph of the hepatic CD31<sup>+</sup>-sorted cell 12 hr after in vitro adhesion onto fibronectin-coated coverslips. ×1,3 magnification highlights LSEC fenestration. Scale bar = 2 µm. The presence of LSEC fenestrations on ~96% of CD31<sup>+</sup> cells indicates that most sorted cells represent bona vide LSECs (n=24 cells). (<bold>C</bold>) Pre-ranked Gene Set Enrichment Analysis (GSEA) enrichment plots of the indicated pathways evaluated on the comparisons between IFNα-treated <italic>Ifnar1<sup>fl/fl</sup></italic> and NaCl-treated <italic>Ifnar1<sup>fl/fl</sup></italic> CD31<sup>+</sup> HECs. (<bold>D</bold>) Pre-ranked Gene Set Enrichment Analysis (GSEA) enrichment plots of the indicated pathways evaluated on the comparisons between <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> and <italic>Ifnar1<sup>fl/fl</sup></italic> NaCl-treated CD31<sup>+</sup> HECs.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Data for the graphs in the figure.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig6-figsupp1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80690-fig6-figsupp1-v1.tif"/></fig></fig-group><p>Keeping the HECs transcriptional profile of NaCl-treated <italic>Ifnar1<sup>fl/fl</sup></italic> mice as a point of reference, a total of 566 genes were differentially expressed (DEGs) in HECs isolated from NaCl-treated <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice, of which 373 (mostly ISGs and genes involved in the immune response or in the antigen processing) were downregulated (<xref ref-type="fig" rid="fig6">Figure 6A–C</xref>). These latter results indirectly suggest that – when compared to HECs capable of sensing low levels of endogenous type I IFNs, as those present in NaCl-treated <italic>Ifnar1<sup>fl/fl</sup></italic> mice – LSECs devoted of <italic>Ifnar1</italic> may be less prepared to stimulate innate and adaptive immunity (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). The downregulation of transcripts involved in cell-cell adhesion molecules and matrix remodeling (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D</xref>) further suggests a relative unpreparedness of <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> HECs at accommodating changes that may confer protection against CRC trans-sinusoidal cell migration. Along these lines, the upregulation of the transcripts for <italic>Gata4</italic> -a master-regulator of liver sinusoidal differentiation which leads to liver fibrosis deposition upon its loss (<xref ref-type="bibr" rid="bib106">Winkler et al., 2021</xref>)- and <italic>Smad7 –</italic> an inhibitor of transforming growth factor-beta (TGF-β)-dependent subendothelial matrix deposition causative of sinusoidal capillarization (<xref ref-type="bibr" rid="bib96">Tauriello et al., 2018</xref>) – in HECs isolated from NaCl-treated <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice (<xref ref-type="fig" rid="fig6">Figure 6A</xref>) could be interpreted as a diminished capacity to shape a vascular antimetastatic barrier. Finally, Gene Ontology (GO) analysis of HECs confirmed that <italic>Ifnar1</italic>-proficient, but not <italic>Ifnar1-</italic>deficient, HECs upregulate transcriptional pathways involved in the production of immunostimulatory cytokines and chemokines, the capacity to process and present antigens or the regulation of immune responses (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). Altogether, the data support the hypothesis that, upon IFNα sensing, HECs and particularly LSECs not only acquire a transcriptional profile that can reinforce their barrier function, but they may also enhance HECs/LSECs immunostimulatory functions contributing to antitumor activity.</p></sec><sec id="s2-7"><title>Continuous IFNα sensing improves immunostimulatory properties of HECs to provide long-term tumor protection</title><p>First, HECs/LSECs isolated from the liver of <italic>Ifnar1<sup>fl/fl</sup></italic> or <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice 7 days after continuous NaCl or IFNα treatment were assessed for the relative surface protein expression of MHC-I, CD86 (a costimulatory molecule <xref ref-type="bibr" rid="bib53">Katz et al., 2004</xref>) or the interleukin 6 receptor alpha (IL-6RA, a molecule that LSECs use to properly cross-prime antigens to naïve CD8<sup>+</sup> T cells <xref ref-type="bibr" rid="bib13">Böttcher et al., 2014</xref>). Following IFNα treatment, <italic>Ifnar1-</italic>bearing LSECs significantly increased MHC-I, CD86 and IL-6RA expression (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>), while no induction was detected in <italic>Ifnar1-</italic>negative LSECs (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>). We then analyzed the ability of IFNα-treated LSECs or splenic DCs (sDCs) from <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice to stimulate the cross-priming of naive CD8<sup>+</sup> T cells in vitro. To this end, viable CD31<sup>+</sup> HECs and CD11c<sup>+</sup> sDCs were isolated and purified (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A</xref>, B). sDCs were cultured to acquire mature CD8α<sup>+</sup> (~25%) or plasmacytoid (45%–50%) phenotypes endowed with cross-priming capacity (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2C, D</xref>; <xref ref-type="bibr" rid="bib36">Fu et al., 2020</xref>). HECs and sDCs from <italic>Ifnar1<sup>fl/fl</sup></italic> or <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice previously pulsed with the SIINFEKL peptide or soluble ovalbumin (sOVA) in the presence or absence of either IFNα or NaCl were then co-cultured with naive OT-I CD8<sup>+</sup> T cells and their relative cross-priming capacity was defined by the percentage of these latter cells to express both CD44 and IFNγ (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>). IFNα stimulation of <italic>Ifnar1-</italic>bearing HECs (HECs from <italic>Ifnar1<sup>fl/fl</sup></italic> mice or sDCs from <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice) pulsed with SIINFEKL or sOVA promptly increased their cross-priming capacities, while the same IFNα treatment failed to do so in <italic>Ifnar1-</italic>negative cells (HECs from <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice) (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B, C</xref>). Once exposed to IFNα and pulsed with sOVA, HECs and sDCs from <italic>Ifnar1<sup>fl/fl</sup></italic> mice cross-primed naïve OT-I CD8<sup>+</sup>T cells to a similar extent (<xref ref-type="fig" rid="fig7">Figure 7B</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1C</xref>), highlighting once more the immunostimulating potential of IFNα treatment on HECs, including LSECs. We also evaluated the splenic composition of central memory T cell populations (Tcm, CD8<sup>+</sup>CD44<sup>+</sup>CD62L<sup>+</sup>) (<xref ref-type="fig" rid="fig7">Figure 7C</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D</xref>) as a proxy of potential systemic memory responses against tumor antigens (<xref ref-type="bibr" rid="bib81">Sallusto et al., 2004</xref>; <xref ref-type="bibr" rid="bib90">Stone et al., 2009</xref>; <xref ref-type="bibr" rid="bib110">Yu et al., 2019</xref>). Splenic naive T cells (Tn, CD8<sup>+</sup>CD44<sup>-</sup>CD62L<sup>+</sup>) were also evaluated. Looking at <italic>Ifnar1<sup>fl/fl</sup></italic> or <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice continuously treated with NaCl or IFNα and euthanized by day 21 after challenge, we found that only IFNα-treated <italic>Ifnar1<sup>fl/fl</sup></italic> mice showed an increased proportion of Tcm and decreased percentage of Tn when compared to NaCl<italic>-</italic>treated <italic>Ifnar1<sup>fl/fl</sup></italic> controls (<xref ref-type="fig" rid="fig7">Figure 7C</xref>), suggesting that IFNα-responsive LSECs may promote antitumor immune memory in secondary lymphoid organs.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Continuous IFNα sensing improves immunostimulatory properties of HECs to provide long-term tumor protection.</title><p>(<bold>A–B</bold>) Quantification of the percentage of OT-I CD8<sup>+</sup> T cells expressing CD44<sup>+</sup>IFNγ<sup>+</sup> generated after the co-cultured with HECs, including LSECs, or sDCs isolated from <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>-KO</sup> mice and stimulated with SIINFEKL peptide (<bold>A</bold>) or soluble OVA protein (sOVA) (<bold>B</bold>) in the presence of NaCl or IFNα. Mean values ± SEM are shown; p-values were calculated by two-way ANOVA test from two independent experiments with three biological replicates each. (<bold>C</bold>) Quantification of the percentage of splenic T central memory (Tcm, CD8<sup>+</sup>CD44<sup>+</sup>CD62L<sup>+</sup>) and naïve T cells (Tn, CD8<sup>+</sup>CD44<sup>-</sup>CD62L<sup>+</sup>) populations 21 days after intramesenteric MC38 cells injection into NaCl- or IFNα-treated <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice. Quantification was performed on least 4 mice per group. Mean values ± SEM are shown; p-values were calculated by Mann-Whitney test. (<bold>D</bold>) Schematic representation of the experimental procedure used for tumor rechallenge. IFNα-<italic>Ifnar1<sup>fl/fl</sup></italic>-cured mice and naïve <italic>Ifnar1<sup>fl/fl</sup></italic> mice were subcutaneously rechallenged with 5x10<sup>3</sup> MC38 cells and received no further treatment. Tumor growth was monitored weekly for 35 days. Note that we used aged-matched <italic>Ifnar1<sup>fl/fl</sup></italic> naïve mice because NaCl-treated mice had to be euthanized for ethical reasons by day 50. (<bold>E</bold>) Kinetics of subcutaneous tumor growth in naïve (n=10) and IFNα-cured (n=7) mice. Both, mean tumor volume and individual animal measurements are shown. Mean values ± SEM are shown; p-values were calculated by two-way ANOVA test. (<bold>F</bold>) Schematic model: CRC cells emerging from the primary tumor reach the hepatic sinusoids via the portal circulation and arrest - mostly because of size constrains - at the portal side of the sinusoidal circulation (1), CRC cells trans-sinusoidally migrate into the liver parenchyma (2) and develop micro-metastases that will eventually grow overtime (3; red frame), promoting the generation of an immunosuppressive microenvironment leading to dysfunctional T cells (4; red frame). Conversely, IFNα therapy (blue frame), by modifying LSECs porosity, thickness, deposition of basal membrane and GCX depth, builds up a vascular antimetastatic barrier (5), that impairs CRC trans-sinusoidal migration, promoting intravascular containment of invading tumor cells (6) that together with IFNα-mediated increased cross-presentation and cross-priming by HECs/LSEC, will lead to naïve CD8<sup>+</sup> T cell activation and secondary generation of long-term antitumor immunity and protection from secondary tumor challenge (7). Created with <ext-link ext-link-type="uri" xlink:href="https://biorender.com/">https://biorender.com/</ext-link>.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Data for the graphs in the figure.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig7-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80690-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Continuous IFNα sensing improves immunostimulatory properties of HECs to provide long-term tumor protection.</title><p>(<bold>A</bold>) FACS analysis showing the mean fluorescence intensity (MFI) of MHC-I (left) and the percentage of CD86 (middle) and IL-6RA cells (right) within the hepatic CD31<sup>+</sup> non-parenchymal cells (NPC) population of <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice after 7 days of continuous NaCl or IFNα therapy. For each experimental group, three animals were analyzed. Mean values ± SEM are shown; p-values were calculated by two-way ANOVA test. (<bold>B–C</bold>) Representative FACS profiles showing the percentage of OT-I CD8<sup>+</sup> T cells expressing CD44<sup>+</sup>IFNγ<sup>+</sup> obtained from the co-cultured with HECs (top) or sDCs (bottom) isolated from <italic>Ifnar1</italic><sup>fl/fl</sup> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>-KO</sup> mice and stimulated with SIINFEKL peptide (<bold>b</bold>) or soluble OVA protein (<bold>c</bold>). (<bold>D</bold>) Representative FACS analysis of splenic T naïve (Tn; CD44<sup>-</sup>CD62L<sup>+</sup>) and T central memory (Tcm; CD44<sup>+</sup>CD62L<sup>+</sup>) endogenous CD8<sup>+</sup> T cells identified 21 days after intramesenteric MC38 cells injection into NaCl- or IFNα-treated <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice.</p><p><supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>Data for the graphs in the figure.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80690-fig7-figsupp1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80690-fig7-figsupp1-v1.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Isolation and flow cytometry characterization of HECs and sDCs.</title><p>(<bold>A</bold>) Schematic diagram of the protocol used to isolate HECs, including LSECs, from murine liver tissue (left) and sDCs from mouse spleen (right). (<bold>B</bold>) Assessment of LSEC purity by flow cytometry using CD31 as a pan-endothelial marker, CD146 as a specific marker for LSECs and F4/80 to identify Kupffer cells contaminants. Analysis was performed in <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup>-derived LSECs. (<bold>C</bold>) Schematic representation of the experimental procedure used for cross-priming analysis of in vitro cultured HECs and sDCs, pulsed with SIINFEKL peptide or sOVA and co-cultured with naïve OT-I CD8<sup>+</sup> T cells for 3 days to evaluate the percentage of CD8<sup>+</sup> T cells that co-express both CD44 and IFNγ. (<bold>D</bold>) Evaluation by flow cytometry of the purity and the characteristics of sDCs isolated from <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1-KO</sup></italic> mice. The percentage of conventional DCs was estimated by analyzing the amount of CD8α<sup>+</sup> cells within CD11c<sup>+</sup> DCs. Plasmacytoid DCs (pDCs) were measured by B220<sup>+</sup>CD11c<sup>+</sup> staining and the maturation status of DCs was evaluated with MHC-I and MHC-II markers.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80690-fig7-figsupp2-v1.tif"/></fig></fig-group><p>To assess whether IFNα-stimulated HECs and LSECs promoted memory responses endowed with antitumor potential, <italic>Ifnar1<sup>fl/fl</sup></italic>-cured mice (defined as animals that 7 days after IFNα treatment initiation were intramesenterically challenged with MC38 cells and survived as disease-free animals until day 50) or naive <italic>Ifnar1<sup>fl/fl</sup></italic> control mice were subcutaneously rechallenged with MC38 cells (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). Notably, while the latter animals developed subcutaneous tumors that increased in size over time, none of the <italic>Ifnar1<sup>fl/fl</sup></italic>-cured mice showed detectable lesions at any time point studied (<xref ref-type="fig" rid="fig7">Figure 7E</xref>). These results indicate that continuous IFNα treatment promotes protection against secondary tumor challenge even after IFNα therapy discontinuation. The results also suggest that this effect may be dependent on the capacity of IFN-sensitive HECs and LSECs to foster antitumor immunity, especially tumor-specific effector CD8<sup>+</sup> T cell responses that are well-known to control tumor growth in vivo in different experimental settings (<xref ref-type="bibr" rid="bib29">Dobrzanski et al., 2000</xref>; <xref ref-type="bibr" rid="bib52">Katlinski et al., 2017</xref>; <xref ref-type="bibr" rid="bib54">Klebanoff et al., 2005</xref>; <xref ref-type="bibr" rid="bib110">Yu et al., 2019</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, we used different mouse models of CRC liver metastasis to show that the continuous perioperative administration of relatively low IFNα doses provides significant antitumor potential in vivo without provoking overt toxicity. Moreover, under the pharmacological conditions we defined (route, dosage, treatment duration, and chemical nature of the recombinant protein), we did not observe counter-regulatory mechanisms affecting IFNα efficacy (<xref ref-type="bibr" rid="bib52">Katlinski et al., 2017</xref>), or significant systemic side effects, as our strategy avoids the short tissue-oscillatory IFNα bursts that are often achieved after high and pulsed administrations, often associated with efficacy-limiting toxicities (<xref ref-type="bibr" rid="bib104">Weber et al., 2015</xref>). These results are consistent with previous preclinical work indicating that the intrahepatic delivery of IFNα through a gene/cell therapy approach curbs CRC liver metastases by acting primarily on unidentified non-hematopoietic stromal cell populations (<xref ref-type="bibr" rid="bib16">Catarinella et al., 2016</xref>).</p><p>Given the pleotropic nature of IFNα, we demonstrated that the antimetastatic activity of IFNα is neither based on the direct inhibition of primary intracecal tumor growth, favoring the hypothesis that IFNα therapy does not modify the number of cells that spread from primary tumors and seed into the liver – nor on the direct inhibition of metastatic cell growth within the liver. These data are consistent with the high IFNα concentrations required to activate the ‘tunable’ direct antiproliferative functions of this cytokine, likely exceeding the levels achieved in our system (<xref ref-type="bibr" rid="bib16">Catarinella et al., 2016</xref>; <xref ref-type="bibr" rid="bib84">Schreiber, 2017</xref>). In addition, IFNα therapy does not require indirect stimulation of hepatocytes, HSCs, DCs, KCs, or LCMs to exert its antimetastatic functions. Rather, the results pinpointed HECs/LSECs as key local and early sensors of IFNα that ultimately limit CRC cell invasion into the liver.</p><p>Mechanistically, we showed that IFNα-stimulated LSECs inhibit the trans-sinusoidal migration of circulating CRC cells normally occurring within 24 hr of their initial intrahepatic landing. This effect is associated with phenotypic changes that IFNα-stimulated LSECs acquire or induce in the liver microenvironment. Among these changes, we observed a reduction in the overall LSEC porosity (i.e. sinusoidal fenestrae were reduced in number and size), an enhancement in the subendothelial deposition of basal membrane components (including Collagen IV and Laminin) and an upregulation of LYVE-1, a marker of hepatic capillarization (<xref ref-type="bibr" rid="bib72">Pandey et al., 2020</xref>; <xref ref-type="bibr" rid="bib107">Wohlfeil et al., 2019</xref>). Along these lines, it is noteworthy that in the ‘healthy’ liver, functioning as a common site for CRC metastases, LSECs contain numerous fenestrae of up to 200 nm in diameter and normally lack the typical basal membrane that characterizes the microvasculature of most other tissues and organs (<xref ref-type="bibr" rid="bib49">Jacobs et al., 2010</xref>). It is also interesting to note that IFNα-stimulated LSECs promote microvascular alterations like those typifying pathological conditions (e.g. initial hepatic capillarization and liver fibrosis <xref ref-type="bibr" rid="bib72">Pandey et al., 2020</xref>; <xref ref-type="bibr" rid="bib107">Wohlfeil et al., 2019</xref>) associated with impaired immune cell extravasation and reduced immune surveillance (<xref ref-type="bibr" rid="bib43">Guidotti et al., 2015</xref>) and reduction of hepatic metastases from solid tumors including CRCs (<xref ref-type="bibr" rid="bib107">Wohlfeil et al., 2019</xref>). This fits with the evidence that CRC patients suffering from chronic viral liver fibrotic diseases characterized by hepatic endogenous type I interferon production display lower incidence of hepatic metastases (<xref ref-type="bibr" rid="bib4">Augustin et al., 2013</xref>; <xref ref-type="bibr" rid="bib6">Baiocchini et al., 2019</xref>; <xref ref-type="bibr" rid="bib62">Li Destri et al., 2013</xref>). The existence that fibrotic liver diseases not associated with reduced metastatic risk (<xref ref-type="bibr" rid="bib56">Kondo et al., 2016</xref>) suggests that changes in the vascular hepatic niche other than matrix deposition play additional roles in this process. Indeed, IFNα stimulated LSEC-governed changes hampering CRC extravasation including the modification of the sinusoidal GCX that, by increasing its thickness and modifying its chemical composition, recapitulated conditions known to negatively regulate the trans-endothelial migration of tumor cells in other settings (<xref ref-type="bibr" rid="bib41">Glinskii et al., 2005</xref>; <xref ref-type="bibr" rid="bib69">Mitchell and King, 2014</xref>; <xref ref-type="bibr" rid="bib71">Offeddu et al., 2021</xref>; <xref ref-type="bibr" rid="bib105">Wilkinson et al., 2020</xref>). The continuous administration of therapeutic low-doses of IFNα thus stimulate HECs/LSECs to shape a vascular antimetastatic barrier preventing the interaction between tumor cells and endothelial cells that are known to promote the extravasation of the former cells (<xref ref-type="bibr" rid="bib41">Glinskii et al., 2005</xref>; <xref ref-type="bibr" rid="bib69">Mitchell and King, 2014</xref>; <xref ref-type="bibr" rid="bib105">Wilkinson et al., 2020</xref>). Accordingly, the enhanced expression of ‘pro-migratory’ adhesion molecules and integrins that we observed in the liver of animals bearing IFNα-responsive LSECs appear to be efficiently counteracted by the creation of such vascular barrier.</p><p>Of note, the functional consequences of LSEC capillarization (especially the induction of hepatic fibrosis) during states of chronic liver injury highly depend on the relative magnitude and duration of the underlying liver disease (<xref ref-type="bibr" rid="bib26">DeLeve, 2015</xref>). Additionally, both LSEC capillarization and hepatic fibrosis are reversed when chronic liver injury resolves (<xref ref-type="bibr" rid="bib26">DeLeve, 2015</xref>). In keeping with these concepts and the absence of sALT elevation or morphological evidence of liver disease during continuous IFNα therapy, it is not surprising that we observed a complete recovery of fenestrae abundance and LSEC porosity 40 days after therapy discontinuation. This supports the notion that a continuous but relatively short IFNα therapy promotes changes in the structure and function of LSECs that are mild and reversible and should not result in persistent hepatic fibrinogenesis. Such notion is also supported by the absence of hepatic toxicity (<xref ref-type="bibr" rid="bib104">Weber et al., 2015</xref>) and the significant reduction in established fibrosis in patients with chronic viral liver diseases treated with recombinant IFNα for up to 48 weeks (<xref ref-type="bibr" rid="bib60">Li et al., 2019</xref>; <xref ref-type="bibr" rid="bib76">Poynard et al., 2002</xref>). The notion that IFNα treatment failed to shape the vascular antimetastatic barrier in mice carrying the <italic>Ifnar1</italic>-deficiency only in endothelial cells further strengthens this hypothesis and places HECs/LSECs at a center of a relevant antitumor process ultimately limiting CRC liver invasion. This concept is also indirectly supported by the fact that the increased expression <italic>Gata4</italic> -a master-regulator of liver sinusoidal differentiation which leads to liver fibrosis deposition upon its loss (<xref ref-type="bibr" rid="bib106">Winkler et al., 2021</xref>) - and <italic>Smad7 –</italic> an inhibitor of transforming growth factor-beta (TGF-β) dependent subendothelial matrix deposition and sinusoidal capillarization (<xref ref-type="bibr" rid="bib96">Tauriello et al., 2018</xref>) were not downregulated by IFNα treatment in mice in which all cell types except LSECs could sense this cytokine, thus loosening the hepatic vascular barrier.</p><p>In addition, to hindering the initial trans-sinusoidal migration of CRC cells in vivo, IFNα-stimulated LSECs efficiently cross-presented nominal tumor antigens to naive CD8<sup>+</sup> T cells in vitro, enabling degrees of T cell priming and effector differentiation that were comparable to those induced by professional APCs. In keeping with this, we demonstrated that the in vivo IFNα stimulation of LSECs resulted in the upregulation of proteins and transcripts associated with antigen processing and presentation or co-stimulation (e.g. MHC-I, CD86, IL-6RA, <italic>B2m, Tap1, Psmb-8/9 and H2-d1, H2-k1/2</italic>) (<xref ref-type="bibr" rid="bib13">Böttcher et al., 2014</xref>; <xref ref-type="bibr" rid="bib53">Katz et al., 2004</xref>; <xref ref-type="bibr" rid="bib70">Montoya et al., 2002</xref>; <xref ref-type="bibr" rid="bib79">Rodriguez et al., 1999</xref>). Moreover, our results also suggest that IFNα-stimulated LSECs may play a key role in antitumor immunity, as mice were protected from secondary tumor rechallenge even after discontinuation of IFNα treatment. The fact that the same IFNα therapy also significantly increased the overall number of central memory T cells in the spleen while decreasing that of naive T cells (<xref ref-type="bibr" rid="bib81">Sallusto et al., 2004</xref>; <xref ref-type="bibr" rid="bib110">Yu et al., 2019</xref>) further suggests a role for IFNα-stimulated LSECs in the generation of systemic and protective long-term antitumor immunity.</p><p>These data are consistent with the notion that IFNα-stimulated LSECs, due to their anatomical proximity and efficient endocytosis capacity that is among the highest of all cell types in the body (<xref ref-type="bibr" rid="bib88">Sorensen and Smedsrod, 2020</xref>) – rapidly remove CRC-derived antigens from the intravascular space and productively and rapidly contribute to the development of effective antitumor immunity, since this process does not require the time-consuming step of migration to lymphatic tissue (<xref ref-type="bibr" rid="bib13">Böttcher et al., 2014</xref>). This concept is also supported by the upregulation by IFNα-stimulated LSECs of <italic>Cxcl9</italic> and <italic>Cxcl10</italic>, two chemokines involved in the attraction and retention of naïve T cell populations of lymphocytes into the liver (<xref ref-type="bibr" rid="bib35">Franciszkiewicz et al., 2012</xref>), a necessary step for the generation of an efficient antitumor immune response. Additionally, other cell types within the hepatic niche could further amplify this IFNα-initiated cascade, as it has been shown that dendritic cells releasing IFNα also reduce liver metastatic colonization by CRC cells (<xref ref-type="bibr" rid="bib98">Toyoshima et al., 2019</xref>) and that this cytokine properly polarizes the tumor microenvironment (<xref ref-type="bibr" rid="bib16">Catarinella et al., 2016</xref>; <xref ref-type="bibr" rid="bib28">De Palma et al., 2008</xref>). On the contrary, the notion that a minority of IFNα-treated animals develop small intrahepatic lesions that display similar proliferation, neoangiogenic and immunologic markers than untreated lesions highlights the possibility that CRC tumors, once established as macroscopic metastases, may become refractory and resistant to IFNα therapy by downregulating <italic>Ifnar1</italic> (<xref ref-type="bibr" rid="bib14">Boukhaled et al., 2021</xref>; <xref ref-type="bibr" rid="bib52">Katlinski et al., 2017</xref>). This would be consistent with the lack of efficacy of our approach in established orthotopic tumors within the cecal wall.</p><p>Altogether, we have identified a novel MoA by which IFNα functions as antitumor drug against CRC liver metastases. Whether the adoption of similar LSEC-stimulating IFNα treatments may also curb the hepatic growth of metastatic cells originating from other solid tumors, or if continuous IFNα treatment promote the generation of vascular barriers in other metastasis-prone organs remains to be determined (<xref ref-type="bibr" rid="bib23">Crist and Ghajar, 2021</xref>). Based on the findings of this report, we propose the following model: CRC cells emerging from the primary tumor reach the hepatic sinusoids via the portal circulation and arrest – mostly because of size constrains – at the portal side of the sinusoidal circulation. CRC cells then trans-sinusoidally migrate into the liver parenchyma and develop micrometastases that will eventually grow overtime, promoting the generation of an immunosuppressive microenvironment. Continuous therapy with well-tolerated doses of recombinant IFNα, stimulates HECs/LSECs to limit CRC trans-sinusoidal migration and parenchymal invasion by building up a vascular barrier typified by the reduction of LSECs porosity, the increased thickness of GCX and the appearance of a basal membrane. Continuous IFNα therapy also promotes long-term antitumor immunity in cured mice and protection from secondary tumor challenge, by stimulating LSECs to efficiently cross-prime tumor antigens to naïve CD8<sup>+</sup> T cells (<xref ref-type="fig" rid="fig7">Figure 7F</xref>).</p><p>In terms of future clinical applications, our strategy could be used as perioperative neoadjuvant immunotherapy in CRC patients undergoing resection of their primary tumor who are at high risk for developing metachronous liver metastases (<xref ref-type="bibr" rid="bib31">Engstrand et al., 2019</xref>; <xref ref-type="bibr" rid="bib101">van Gestel et al., 2014</xref>). Indeed, several technologies have already been developed for the sustained release of drugs, such as osmotic pumps, electronic devices, hyaluronic acid-based hydrogels (<xref ref-type="bibr" rid="bib73">Park et al., 2018</xref>; <xref ref-type="bibr" rid="bib89">Stewart et al., 2018</xref>; <xref ref-type="bibr" rid="bib111">Yun and Huang, 2016</xref>), FDA-approved polymer miscellas – such as pegylated (PEG)-IFNα (<xref ref-type="bibr" rid="bib34">Foser et al., 2003</xref>; <xref ref-type="bibr" rid="bib42">Glue et al., 2000</xref>) – and IFNα cell/gene therapy approaches (<xref ref-type="bibr" rid="bib16">Catarinella et al., 2016</xref>), which could quickly translate our results into clinical practice. Of note, the use of clinically approved doses of pegylated-IFNα has shown improved serum stability and clinical efficacy and reduced side effects, with serum IFNα concentrations similar to those achieved in our system (<xref ref-type="bibr" rid="bib34">Foser et al., 2003</xref>; <xref ref-type="bibr" rid="bib42">Glue et al., 2000</xref>).</p><p>All in all, the results of this study support the use of continuous low doses of IFNα as an antimetastatic drug during the perioperative period, due to its ability to transform a metastases-prone liver into a metastases-resistant organ.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Animal studies</title><p>Eight- to 10-week-old C57BL/6 J and BALB/c mice were purchased from Charles River Laboratory, Calco, Italy. CB6 mice were obtained by crossing <italic>Mus musculus</italic> inbred C57BL/6 J male mice (H-2b restricted) with <italic>Mus musculus</italic> inbred BALB/c female mice (H-2d restricted), to produce H-2bxd F1 hybrids. <italic>Ifnar1<sup>fl/fl</sup></italic> mice on a C57BL/6 J background (B6(Cg)-<italic>Ifnar1</italic>tm1.1Ees/J, JAX:028256), <italic>Alb</italic><sup>Cre</sup> (B6.Cg-Speer6-ps1Tg(<italic>Alb</italic>-cre)21Mgn/J, JAX:003574), <italic>Pdgfrb</italic><sup>CreERT2</sup> (B6.Cg-Tg(Pdgfrb-cre/ERT2)6096Rha/J JAX:029684), <italic>Itgax</italic><sup>Cre</sup> (CD11c, B6.Cg-Tg(<italic>Itgax</italic>-cre)1-1Reiz/J, JAX:008068), and Rosa26-ZsGreen (B6.Cg-Gt(ROSA)26Sortm6(CAG-ZsGreen1)Hze/J, JAX:007906) reporter mice were purchased from the Jackson Laboratory. <italic>Cdh5</italic>(PAC)<sup>-CreERT2</sup> mice (<italic>VeCad</italic><sup>CreERT2</sup>) (<xref ref-type="bibr" rid="bib102">Wang et al., 2010</xref>) were kindly provided by S. Brunelli (UniMib, Milan). NOD-scid IL2Rγnull (NSG) immunodeficient mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, JAX:005557) and OT-I mice (C57BL/6-Tg(TcraTcrb)1100Mgb/Crl, JAX:003831) were purchased from Charles River Laboratory.</p><p>The conditional deletion of <italic>Ifnar1</italic> was obtained by crossing mice carrying loxP-flanked <italic>Ifnar1</italic> (<xref ref-type="bibr" rid="bib77">Prigge et al., 2015</xref>) with transgenic mice expressing Cre recombinase under the control of either endothelial cell (<italic>VeCad</italic><sup>CreERT2</sup>), stellate cell (<italic>Pdgfrb</italic><sup>CreERT2</sup>), hepatocyte (<italic>Alb</italic><sup>Cre</sup>) and dendritic cell (<italic>Itgax</italic><sup>Cre</sup>) promoters. To induce the Cre recombination and <italic>Ifnar1</italic> deletion into <italic>VeCad</italic><sup>CreERT2</sup>, Cre recombinase was induced by three subcutaneous injections of Tamoxifen 50 mg/kg at p5, p6 and p7, as previously described (<xref ref-type="bibr" rid="bib97">Tirone et al., 2018</xref>), while <italic>Pdgfrb</italic><sup>CreERT2</sup> adult mice were treated by three consecutive ip injections of Tamoxifen 100 mg/kg. Upon treatment, the exon3 of <italic>Ifnar1</italic> is excised resulting in a loss of <italic>Ifnar1</italic> in endothelial and stellate cells. To ensure that <italic>Ifnar1</italic> exon 3 of was efficiently excised hepatic DNA was isolated from the liver of 8-week-old <italic>VeCad<sup>Ifnar1_KO</sup></italic>, <italic>Pdgfrb<sup>Ifnar1_KO</sup></italic>, <italic>Alb<sup>Ifnar1_KO</sup></italic> and <italic>Itgax<sup>Ifnar1</sup></italic><sup>_KO</sup> mice and polymerase chain reaction (PCR) analysis using <italic>Ifnar1</italic> intron 3-forward and <italic>Ifnar1</italic> intron 3-reverse oligonucleotides was performed. To control for possible changes in the microbiota composition of <italic>VeCad<sup>Ifnar1_KO</sup></italic>, <italic>Pdgfrb<sup>Ifnar1_KO</sup></italic>, <italic>Alb<sup>Ifnar1_KO</sup></italic> and <italic>Itgax<sup>Ifnar1</sup></italic><sup>_KO</sup> and <italic>Ifnar1<sup>fl/fl</sup></italic> littermates, mice from each litter and cage were randomly allocated into the experimental groups and were co-housed or systematically exposed to beddings of the other groups to ensure the same exposure to the microbiota.</p></sec><sec id="s4-2"><title>Study approval</title><p>All animal experiments were approved by the Animal Care and Use Committee of the San Raffaele Scientific Institute (<underline>SRSI,</underline> IACUC 691, 808 and 1042) and were conducted in specific pathogen-free (SPF) facility in microisolator cages under a 12 hr light/dark cycle with free access to water and standard mouse diet (Teklad Global 18% Protein Rodent Diet, Harlan).</p></sec><sec id="s4-3"><title>CRC cell lines</title><p>CT26 (H-2d, BALB/c-derived) cell line was purchased from ATCC. MC38 (H-2b, C57BL/6-derived), have been previously described (<xref ref-type="bibr" rid="bib16">Catarinella et al., 2016</xref>). MC38 cells were transduced with a PGK-GFP lentiviral vector, cloned and sorted by FACS to establish MC38<sup>GFP</sup> fluorescently tagged cell lines (<xref ref-type="bibr" rid="bib94">Talamini et al., 2021</xref>). All cells were routinely tested for mycoplasma contamination using the N-GARDE Mycoplasma PCR reagent set (EuroClone). CT26 and CT26<sup>LM3</sup> cells were cultured under standard condition at 37 °C in a humid atmosphere with 5% CO<sub>2</sub> in RPMI GlutaMAX medium (Gibco) supplemented with 10% FBS (Lonza) and 1% penicillin/streptomycin (P/S) (Gibco). MC38, MC38<sup>GFP</sup>, MC38<italic><sup>Ifnar1</sup></italic><sup>_KO</sup> and cells were cultured under standard condition at 37 °C in a humid atmosphere with 5% CO<sub>2</sub> in DMEM GlutaMAX medium (Gibco) supplemented with 10% FBS (Lonza) and 1% P/S (Gibco). Cell number and dimension was routinely assessed by automated CytoSMART cell counter (Corning). Details of murine cell lines used in the experiments (source of cell lines, background and origin of cancer) are mentioned in key resource table. The tumor cell lines MC38, MC38<sup>GFP</sup>, MC38<italic><sup>Ifnar1</sup></italic><sup>_KO</sup> and CT26 were passaged in vivo once before use in experiments.</p></sec><sec id="s4-4"><title>Mouse models of liver metastases</title><p>Eight-to ten-week-old sex- and age-matched mice were injected with 5x10<sup>3</sup> CT26 or 5x10<sup>4</sup> MC38 CRC cell lines either through intrasplenic or superior mesenteric vein injections as previously described (<xref ref-type="bibr" rid="bib16">Catarinella et al., 2016</xref>; <xref ref-type="bibr" rid="bib100">van der Bij et al., 2010</xref>). For early time point experiments, 7x10<sup>5</sup> MC38<sup>GFP</sup> cells were injected in the superior mesenteric vein of anesthetized mice as described (<xref ref-type="bibr" rid="bib100">van der Bij et al., 2010</xref>). For intrasplenic or superior mesenteric vein injections, deep anesthesia was induced by isoflurane inhalation (5% induction and 2% for maintenance in 2 l/min oxygen). The indicated number of CRC cells was injected into spleen or the superior mesenteric vein using a 29 G needle and to prevent excessive bleeding vein puncture was compressed with a sterile and absorbable hemostatic gauze (TABOTAMP). The peritoneum and skin were sutured with silk 4.0 and 7 mm wound clips as described (<xref ref-type="bibr" rid="bib16">Catarinella et al., 2016</xref>). This experimental setting may mimic the vascular spreading of CRC cells during primary tumor resection and, thus, preventive IFNα infusion may be considered as a neoadjuvant treatment.</p></sec><sec id="s4-5"><title>Mouse model of orthotopic colorectal cancer liver metastases</title><p>The generation of highly metastatic CT26 CRC cells was obtained by three consecutive rounds of in vivo selection as previously reported (<xref ref-type="bibr" rid="bib112">Zhang et al., 2013</xref>). Briefly, 2x10<sup>6</sup> CT26 cells were first injected subcutaneously into the right flank of immunodeficient NSG mice. After 28 days, tumors were excised, dissected, sliced into small fragments, and digested for 30 min at 37 °C in DMEM containing collagenase type IV (200 units/ml; Sigma-Aldrich) and Dnase I (100 units/ml; Sigma-Aldrich). The resulting cell suspension defined as CT26<sup>sc</sup>, were maintained at 4 °C, filtered through a 70 μm nylon cell strainer (BD Biosciences, Bedford, MA), washed in PBS, and grown in RPMI 10% FBS. Sub-confluent CT26<sup>sc</sup> cells were harvested, resuspended in PBS:Matrigel (1:1) (Corning, MERK) and then injected into the cecal wall of immune competent anesthetized (isoflurane, 5% induction and 2% for maintenance in 2 l/min oxygen), CB6 recipient mice as described (<xref ref-type="bibr" rid="bib112">Zhang et al., 2013</xref>). Briefly, a midline incision was made to exteriorize the cecum. Using a 33 G micro-injector (Hamilton, USA), 10 µl of a 50% Matrigel solution (BD Bioscience, USA) containing 2x10<sup>5</sup> CT26<sup>sc</sup> cells were injected into the cecum wall. To avoid intraperitoneal spreading of CT26<sup>sc</sup>, the injection site was sealed with tissue adhesive (3 M Vetbond, USA) and washed with 70% alcohol. The cecum was replaced in the peritoneal cavity, and the abdominal wall and skin incision was sutured with silk 4.0 and 7 mm wound clips as described (<xref ref-type="bibr" rid="bib16">Catarinella et al., 2016</xref>). Twenty-eight days after injection, mice were euthanized and single cell suspensions of liver metastatic lesions, defined as CT26<sup>LM1</sup>, were obtained as described above. This cycle was repeated twice to obtain the highly metastatic CT26<sup>LM3</sup> cells.</p></sec><sec id="s4-6"><title>Recombinant mouse IFNα therapy</title><p>Continuous intraperitoneal IFNα delivery (IFNα1 carrier-free, Biolegend, San Diego, CA, USA) was achieved by intraperitoneal implantation of mini-osmotic pumps (MOP, ALZET, Cupertino, CA, USA) able to deliver either 50, 150, or 1050 ng IFNα a day for 14 or 28 days. NaCl-containing MOP were used as controls. Within each specific experiment, mice of each genotype were randomly assigned to receive either NaCl- or IFNα-containing MOP. MOP filling, priming and implantation within the peritoneum was performed following manufacturer’s instructions. To avoid MRI artifacts due to the presence of metallic components within MOP, the day before MRI acquisition, MOP were removed from the peritoneum. To directly investigate responsiveness of liver cells to IFNα, signaling downstream of <italic>Ifnar1</italic> receptor was assessed by measuring pSTAT1 by IHC 30 min after an ip injection of NaCl or 1 μg IFNα, a dose able to synchronize pSTAT1 expression in all <italic>Ifnar1</italic> expressing cells (<xref ref-type="bibr" rid="bib63">Lin et al., 2016</xref>).</p></sec><sec id="s4-7"><title>Tumor rechallenge of IFNα cured mice</title><p>IFNα-cured mice that were designated as MC38-tumor free for at least 50 days after challenge, were subcutaneously rechallenged with 5x10<sup>3</sup> MC38 cells resuspended in 200 µl of PBS:Matrigel (1:1). Age-matched naïve syngeneic mice were used as control. Tumor volumes were measured twice a week and euthanized for ethical reasons when tumor size reached ~500 mm<sup>3</sup>.</p></sec><sec id="s4-8"><title>Magnetic resonance imaging (MRI)</title><p>All MRI studies were carried out at the Experimental Imaging Center of SRSI on a preclinical 7-Tesla MR scanner (Bruker, BioSpec 70/30 USR, Paravision 6.0.1, Germany) equipped with 450/675 mT/m gradients (slew rate: 3400/4500 T/m/s; rise time 140 µs), coupled with a dedicated 4 channels volumetric mouse body coil. All images were acquired in vivo, under inhalational anesthesia (Isoflurane, 3% for induction and 2% for maintenance in 1 L/min oxygen) with mice laid prone on the imaging table. A dedicated temperature control system was used to prevent hypothermia; respiratory rate and body temperature were continuously monitored (SA Instruments, Inc, Stony Brook, NY, USA) during the whole MRI scan. An intravenous injection of gadoxetic acid (Gd-EOB-DTPA; Primovist, Bayer Schering Pharma) at a dose of 0.05 μmol/g of body weight was administered via the tail vein before placing the mice on the scanner table. As previously described (<xref ref-type="bibr" rid="bib87">Sitia et al., 2012</xref>), the MRI studies relied on an axial fat-saturated T2-weighted sequence (TurboRARE-T2: TR = 3394ms, TE = 33ms, voxel-size=0.125 × 0.09 x0.8mm, averages = 3) acquired immediately after Gd-EOB-DTPA injection and an axial fat-saturated T1-weighted scan (RARE-T1: TR = 581ms, TE = 8.6ms, voxel-size=0.125 × 0.07 x0.8mm, averages = 4) acquired thereafter, during the hepatobiliary phase (HBP) of contrast excretion (starting from 10 min after Gd-EOB-DTPA injection). Two board certified radiologists skilled in clinical and preclinical abdominal MR imaging, blinded to any other information, reviewed all MRI studies using an open-source image visualization and quantification software (Mipav, 5.3.4 and later versions, Biomedical Imaging Research Services Section, ISL, CIT, National Institute of Health, USA). Liver metastases were identified as focal lesions showing slight hyper-intensity on T2-weighted images and concurrent hypo-intensity on contrast-enhanced HBP T1-weighted images. Liver metastases segmentation was performed by manual drawing of regions-of-interest (ROIs) on each slice, yielding volumes-of-interest (VOIs; lesion area x slice thickness) for the entire sequence. The total CRC metastatic mass was obtained by summing up the volumes of all single VOIs that were semi-automatically provided by the software.</p></sec><sec id="s4-9"><title>MC38 gene editing</title><p>To knockout <italic>Ifnar1</italic> in MC38 cell line, we used GeneArt CRISPR Nuclease Vector with OFP Reporter Kit (ThermoFisher Scientific). Target-specific CRISPR RNA guides (crRNA) were designed using GeneArt CRISPR Search and Design Tool (ThermoFisher Scientific) and the two following crRNAs with the fewest predicted off-target effects were selected: crRNA1: <named-content content-type="sequence">TAGACGTCTATATTCTCAGGGTTTT</named-content>; crRNA2: <named-content content-type="sequence">ATGTAGACGTCTATATTCTCGTTTT</named-content>. Annealed crRNAs were cloned in GeneArt CRISPR Nuclease Vector with OFP according to the manufacturer’s instructions and vector constructs were used to transform OneShot TOP10 chemically competent <italic>E. coli</italic> cells (ThermoFisher Scientific). Vectors were validated by Sanger sequencing of DNA from 10 colonies for each crRNA (LightRun GATC Carlo Erba). To express the CRISPR–Cas9 system transiently, 2 μg of each vector were used to transfect 5x10<sup>5</sup> MC38 cell line with Lipofectamine 2000 (ThermoFisher Scientific) in Opti-MEM medium (ThermoFisher Scientific). After 3 days, transfection efficiency was evaluated measuring the orange fluorescence protein (OFP) by FACS (LSRFortessa) and data analysed using FlowJo v10.5. OFP positive bulk populations were single-cell cloned in 96-well plates and a total of 12 clones screened for mismatches by T7E1 assay (New England Biolabs). Briefly, genomic DNA from MC38 clones was extracted by Qiamp mini kit (Qiagen) and amplified within the exon 2 of <italic>Ifnar1</italic> locus using the following oligos: <italic>Ifnar1</italic> exon2 forward, <named-content content-type="sequence">TCCAAGACTCCTGCTGTC </named-content>and <italic>Ifnar1</italic> exon2 reverse: <named-content content-type="sequence">GCACTTTTACTTGCTCGGT</named-content>. The PCR products were denaturated and annealed according to manufacture protocol (New England Biolabs). The digestion reaction was run onto 2% agarose gel to identify mismatched clones. Genetic validation of T7E1-positive clones was assessed by cloning the PCR products with TOPO TA Cloning, Dual Promoter, Kit (ThermoFisher Scientific) and subsequently 10 clones per cell line were sequenced (LightRun GATC Carlo Erba). Functional validation of <italic>Ifnar1</italic> knockout MC38 cells was determined by RT-PCR for the ISG <italic>Irf7</italic> after 4 hr of in vitro stimulation with 300 ng/ml IFNα, using MC38 transfected non-edited WT clone as control (MC38).</p></sec><sec id="s4-10"><title>Peripheral blood analyses</title><p>At the indicated time points after IFNα administration, whole anti-coagulated blood of MOP-NaCl and MOP-IFNα-treated mice was collected from the retro-orbital plexus of anesthetized animals (isoflurane, 5% for induction and 2% for maintenance in 2 l/min oxygen) using Na-heparin coated capillaries (Hirschmann Laborgeräte GmbH, Germany) and vials (Microvette, Sarstedt, Germany). Hematologic parameters were evaluated using an automated cell counter (ProCyte Dx, IDEXX Laboratories, USA). The extent of hepatocellular injury was monitored by measuring serum ALT (sALT) activity at several time points after IFNα treatment, as previously described (<xref ref-type="bibr" rid="bib87">Sitia et al., 2012</xref>).</p></sec><sec id="s4-11"><title>Measurement of plasma IFNα by ELISA</title><p>Circulating levels of IFNα were quantified in plasma collected from NaCl controls or IFNα-treated mice at indicated time points using VeriKine-HS Mouse IFNα all Subtype ELISA Kit (PBL) according to the manufacturer’s instructions. The IFNα titer in the samples was determine by plotting the optical density (OD) subtracted of blank OD to eliminate background, using a 4-parameter logistic fit for the standard curve by using Prism v8 (GraphPad). Detection range is comprised between 2.38 and 152 pg/ml of IFNα.</p></sec><sec id="s4-12"><title>RNA extraction and quantitative real-time PCR gene expression analyses</title><p>Total RNA was isolated from liver homogenates of MOP-NaCl control and MOP-IFNα-treated mice by using the ReliaPrep RNA Tissue Miniprep System (Promega) and DNAse TURBO (Thermo Fisher Scientific) following manufacturer’s recommendation. The extracted RNA was subsequently retro-transcribed to cDNA as previously described (<xref ref-type="bibr" rid="bib86">Sitia et al., 2011</xref>). Quantitative real-time PCR analysis was performed utilizing the ViiA7 Fast Real-Time PCR System (Applied Biosystems). The ISG, <italic>Irf7</italic> (Mm00516793_g1) as well as the housekeeping <italic>Gapdh</italic> (Mm 99999915_g1) were quantified by using the indicated FAM-MGB labeled TaqMan Gene Expression Assays (Applied Biosystems). Gene expression was determined as the difference between the threshold cycle (Ct) of the gene of interest (Goi) and the Ct of the housekeeping (<italic>Gapdh</italic>) of the same sample (∆Ct). The fold-change expression of each Goi was calculated over its basal expression in the control sample by the formula 2<sup>-∆∆Ct</sup> as described (<xref ref-type="bibr" rid="bib87">Sitia et al., 2012</xref>).</p></sec><sec id="s4-13"><title>Immunohistochemistry</title><p>At time of autopsy for each mouse, livers were perfused with PBS, harvested and different pieces were sampled, fixed in zinc-formalin, processed and embedded in paraffin for histological and immunohistochemical analysis, as previously described (<xref ref-type="bibr" rid="bib87">Sitia et al., 2012</xref>). Immunohistochemical staining using a Bond RX Automated Immunohistochemistry (Leica Microsystems GmbH, Wetzlar, Germany) was performed on 3-μm-thick sections. First, tissues were deparaffinized and pre-treated with the Epitope Retrieval Solution [ER1 Citrate Buffer for Ki-67 (dilution 1:200, clone SP6, Thermo Fisher Scientific) and F4/80 (dilution 1:200, clone A3-1, Bio-Rad); ER2 EDTA for CD3 (dilution 1:100, clone SP7, Abcam),CD34 (dilution 1:300, clone MEC14.7, Biolegend) and pSTAT1 (dilution 1:800, clone 58D6, Cell Signaling)] at 100 °C for 30 min. After washing steps, peroxidase blocking was carried out for 10 min using the Bond Polymer Refine Detection Kit DS9800 (Leica Microsystems GmbH). Then, tissues were washed and incubated for 1 hr RT with the primary antibody diluted in IHC Antibody Diluent (Novocastra, Leica RE7133). Subsequently, tissues were incubated with polymer-HRP or Rat-on-Mouse HRP (Biocare Medical, RT517H), developed with DAB-Chromogen for 10 min and counterstained with Hematoxilin for 5 min. For image acquisition and analysis, eSlide Manager (Aperio Leica Biosystems) was used. All images were acquired using the Aperio AT2 system (Leica Biosystems). Quantifications were performed by automated image analysis software through dedicated macros of the ImageScope program, customized following manufacturer’s instructions (Leica Biosystems). The images shown were identified as representative area of interest within the total area of the specimen analyzed and exported as ImageScope snapshots.</p></sec><sec id="s4-14"><title>Immunofluorescence and confocal microscopy</title><p>Livers were perfused with PBS, harvested and fixed over-night in 4% paraformaldehyde (PFA), equilibrated in 30% sucrose in PBS over-night at 4 °C prior to embedding in OCT (Bio-Optica) for quick freezing at –80 °C. Thirty-μm-thick cryosections were adhered to Superfrost Plus slides (Thermo Scientific). For immunofluorescence staining, sections were blocked and permeabilized with PBS containing 5% FBS and 0.1% Triton X-100 (Sigma-Aldrich) for 30 min at room temperature and subsequently incubated with 10% of donkey serum (DS; Sigma-Aldrich) in PBS for 30–60 min at room temperature. Staining with primary and secondary antibodies, were performed with staining buffer (PBS with 1.5% DS, 0.2% Triton X-100 and 1% BSA), using the following antibodies and dilutions: anti-PDGFRβ/CD140b (dilution 1:200, clone APB5, eBioscience)+anti rat AF647 (dilution 1:200, Jackson IR); anti-CD11c AF647, (dilution 1:100, clone N418, Biolegend); anti-GFP (dilution 1:100, rabbit polyclonal, A11122 Thermo Fisher Scientific)+anti-rabbit AF 488 (dilution 1:200, Thermo Fisher Scientific); anti-CD31/PECAM-1 (dilution 1:300, goat polyclonal, AF3628 R&amp;D Systems)+anti goat AF546 (dilution 1:200, Thermo Fisher Scientific); anti-Heparan Sulfate (dilution 1:50, clone F58-10E4, Amsbio)+anti IgM conjugated to APC (dilution 100, clone II/41, Thermo Fisher Scientific); anti-LYVE-1 (dilution 1:300, rabbit polyclonal, Novus Biologicals)+anti-rabbit AF647 (dilution 1:200, Thermo Fisher Scientific); anti-Collagen type IV (dilution 1:100, rabbit polyclonal, Abcam)+anti-rabbit AF488 (dilution 1:200, Thermo Fisher Scientific); anti-Laminin (dilution 1:300, rabbit polyclonal, Sigma-Aldrich)+anti-rabbit AF488 (dilution 1:200, Thermo Fisher Scientific); anti-CD54/ICAM1 (dilution 1:100, clone YN1/1.7.4, Biolegend)+anti rat AF647 (dilution 1:200, Jackson IR); anti-CD62E/E-selectin (dilution 1:100, clone 10E9.6, BD Bioscience)+anti rat AF647 (dilution 1:200, Jackson IR). Confocal images were acquired using a Leica SP8 confocal systems (Leica Microsystems) that are available at the SRSI Advanced Light and Electron Microscopy BioImaging Center (ALEMBIC). Fifteen–20 μm z-stacks were projected in 2D and processed using Fiji image processing software (<xref ref-type="bibr" rid="bib83">Schindelin et al., 2012</xref>). Localization of MC38<sup>GFP</sup> tumor cells within liver vessels, 20–30 square xy sections (1024x1,024 pixel) confocal xyz stacks, from NaCl- and IFNα-treated mice, were acquired with 0.5 µm z-spacing on a Leica TCS SP8. The Imaris Surpass View and Surface Creation Wizard were used to create 3D renderings of MC38<sup>GFP</sup> cells and CD31<sup>+</sup> liver vessels as previously reported (<xref ref-type="bibr" rid="bib43">Guidotti et al., 2015</xref>). A tumor cell was considered intravascular when at least 95% of its surface-reconstructed body was inside the vessel lumen in all the acquired sections projected in the horizontal (xy), transversal (yz) and longitudinal (xz) planes. Entire liver sections were acquired using MAVIG RS-G4 confocal microscope (MAVIG GmbH Research, Germany) to quantify the number of MC38<sup>GFP</sup> tumor cells in relation to the total liver area. The quantification of the percentage of liver area covered by endothelial markers and extracellular matrix components, such as Heparan Sulfate, Laminin, Collagen type IV, ICAM1 and E-Selectin, was evaluated using ImageJ software, applying the same threshold to the different experimental groups for each channel and measuring the percentage of area limited to threshold. Colocalization analysis of GFP in the different Cre recombinant mouse models was performed using an unsupervised ImageJ plugin algorithm termed Colocalization, which was developed by Pierre Bourdoncle (Institut Jacques Monod, Service Imagerie, Paris; 2003–2004).</p></sec><sec id="s4-15"><title>Scanning and transmission electron microscopy</title><p>Electron microscopy (EM) fixative composition was 2,5% glutaraldehyde, 2% paraformaldehyde, 2 mM CaCl<sub>2</sub> and 2% sucrose in 0.1 M Na cacodylate buffer (pH 7,4). For the analysis of endothelial GCX, the EM fixative was supplemented with 2% Lanthanum nitrate (MERK) as previously reported (<xref ref-type="bibr" rid="bib47">Inagawa et al., 2018</xref>). Warm PBS and EM fixative at 35–37°C was used to ensure tissue integrity. When mice were under deep anesthesia, with a single ip injection of 50–60 mg/kg Tribromoethanol (Avertin), a Y incision was made in the abdomen to expose the liver and the portal vein. The portal vein was cannulated with an appropriately sized IV cannula of 22 G and the liver was perfused with 15 ml of warm PBS at a constant rate of 3 rpm using a peristaltic pump (Peri-Star Pro, 2Biological Instruments) as previously reported (<xref ref-type="bibr" rid="bib43">Guidotti et al., 2015</xref>). In situ fixation was achieved by perfusing EM fixative for approximately 5 min at 3 rpm. Fixed liver was harvested and cut into 5 mm blocks using a scalpel. Liver blocks were ulteriorly immersed in EM fixative for 24–72 hr at 4 °C and finally EM fixative was replaced with 0.1 M sodium cacodylate buffer and stored at 4 °C until processed for TEM or SEM analysis. Liver blocks were post-fixed in 1% osmium tetroxide (OsO<sub>4</sub>), 1,5% potassium ferricyanide(K<sub>4</sub>[Fe(CN)<sub>6</sub>]) in 0.1 M Na Cacodylate buffer for 1 hr on ice. Afterwards, for SEM, 150-µm-thick sections were obtained from perfused livers using a vibratome (Leica VT1000S). Sections were further post-fixed in 1% OsO<sub>4</sub> in 0.1 M Na Cacodylate, dehydrated through a series of increasing concentration of ethanol and immersed in absolute hexamethyldisilazane (HMDS) that was left to evaporate overnight. Dried sections were sputter-coated with Chromium using a Quorum Q150T ES sputter coater. Sections were then mounted on SEM stubs using conductive adhesive tape and observed in a field-emission scanning electron microscope Gemini 500 (ZEISS, Oberkochen, Germany). The LSEC fenestra measurements were performed from SEM microphotographs taken under a magnification of 20,000 X, using three independent samples from each experimental condition [NaCl-<italic>Ifnar1<sup>fl/fl</sup></italic> (n=3), IFNα-<italic>Ifnar1<sup>fl/fl</sup></italic> (n=3), NaCl-<italic>VeCad<sup>Ifnar1_KO</sup></italic> (n=3) and IFNα-<italic>VeCad<sup>Ifnar1_KO</sup></italic> mice (n=3)] and a total area of about 720 µm<sup>2</sup> of sinusoids was analyzed for each mouse. After 40 days of IFNα discontinuation, two randomly selected liver micrographs of IFNα-<italic>Ifnar1<sup>fl/fl</sup></italic> (n=3) were analyzed to determine LSEC fenestra measurements and a total area of approximately 300 µm<sup>2</sup> of sinusoidal surface was analyzed. All measurements were made using the ImageJ software, as previously described (<xref ref-type="bibr" rid="bib22">Cogger et al., 2015</xref>). Briefly, the flattened area of the liver sinusoid was selected and longest diameter of each fenestrae was measured. Gaps larger than 250 nm were excluded from the analysis. The average fenestration diameter (defined as the average of all fenestrae diameters excluding gaps area), the fenestration area (π r2, where r, the radius, was calculated from the individual fenestrae diameter <italic>r</italic>=d/2, without gaps area), the porosity [ Σ(π r2)/(total area analyzed – Σ(area of gaps))×100; expressed as a percentage], and the fenestration frequency [total number of fenestrations/(total sinusoidal area analyzed – Σ(area of gaps)); expressed as μm2] have been calculated. Surface roughness analysis of endothelial GCX was determined using Image J software. The flattened area of the liver sinusoid was analyzed, with the SurfChartJ1Q plugin to determine the roughness deviation of all points from a plane after background subtraction, known as Ra coefficient, as previously reported (<xref ref-type="bibr" rid="bib74">Pavlović et al., 2012</xref>). A representative area within the flatten liver sinusoidal surface was used to generate a 3D surface plot image.</p><p>For TEM, tissue pieces were rinsed in Na Cacodylate buffer, washed with distilled water (dH2O) and en bloc stained with 0.5% uranyl acetate in dH<sub>2</sub>O overnight at 4 °C in the dark. Finally, samples were rinsed in dH<sub>2</sub>O, dehydrated with increasing concentrations of ethanol, embedded in Epon resin and cured in an oven at 60 °C for 48 hr. Ultrathin sections (70–90 nm) were obtained using an ultramicrotome (UC7, Leica microsystem, Vienna, Austria), collected, stained with uranyl acetate and Sato’s lead solutions, and observed in a Transmission Electron Microscope Talos L120C (FEI, Thermo Fisher Scientific) operating at 120kV. Images were acquired with a Ceta CCD camera (FEI, Thermo Fisher Scientific). TEM microphotographs were taken under a magnification of 3.400 X, using three independent samples from each experimental condition and a total area of approximately 2.575 µm<sup>2</sup> was analyzed for each mouse. LSECs thickness and the width of the space of Disse were measured using ImageJ software. For collagen deposition analysis, at least 10 randomly selected sinusoids from each mouse were analyzed as previously reported (<xref ref-type="bibr" rid="bib40">Gissen and Arias, 2015</xref>; <xref ref-type="bibr" rid="bib103">Warren et al., 2007</xref>).</p></sec><sec id="s4-16"><title>Isolation of liver non-parenchymal cells (NPCs)</title><p>Liver NPCs, including leukocytes, were isolated from NaCl control or IFNα-treated mice 7 days after MOP implantation, as previously described (<xref ref-type="bibr" rid="bib8">Bénéchet et al., 2019</xref>). Briefly, after euthanasia, the liver was perfused through the vena cava with 5–8 ml of PBS to remove most blood cells. Livers were weighted and 50% of the tissue was sliced in small pieces and incubated 30 min at 37 °C in 10 ml of digestion medium (RPMI GlutaMAX medium [Gibco] containing 200 U/ml of collagenase type IV [Sigma-Aldrich] and 100 U/ml of DNAse I [Sigma-Aldrich]). Remaining undigested fragments were syringed with an 18 G needle and filtered through a 70 µm cell strainer to obtain a single cell suspension. Cells were centrifuged 3 min at 50 g at room temperature and the pellet containing hepatocytes was discarded. The resultant cell suspension of NPCs was incubated for 30 s with ACK lysis buffer (Lonza) to deplete red blood cells, washed with cold RPMI. NPCs were counted and processed for flow cytometry analysis or sorting.</p></sec><sec id="s4-17"><title>Isolation of splenocytes and naïve CD8<sup>+</sup> T cells</title><p>Spleens were obtained from <italic>Ifnar1<sup>fl/fl</sup></italic> and <italic>VeCad<sup>Ifnar1</sup></italic><sup>_KO</sup> mice 21 days after MC38 cells challenge and placed in a 70 μm cell strainer on a petri dish containing 10 ml of plain RPMI, ground with a syringe plunger to obtain a cell suspension and washed three times with plain RPMI as previously described (<xref ref-type="bibr" rid="bib87">Sitia et al., 2012</xref>). The cell suspension was centrifugated at 400 g for 5 min at room temperature, the resuspended pellet was incubated for 30 s with ACK lysis buffer and neutralized with RPMI. Resultant splenocytes were counted and processed for FACS analysis. Splenocytes derived from OT1 mice were prepared as described above and naïve CD8<sup>+</sup> T cells were isolated using EasySep Mouse Naïve CD8<sup>+</sup> T cell isolation kit (STEMCELL Technologies) following manufacturer’s instructions.</p></sec><sec id="s4-18"><title>Flow cytometry and cell sorting</title><p>Cells were resuspended in PBS and LIVE/DEAD Fixable Near-IR or Green dead cell dyes (Thermo Fisher Scientific) and incubated 15 min at RT in the dark for cell viability assessment. Subsequently, cells were blocked with FACS buffer (PBS supplemented with 2% FBS) containing InVivo Mab anti-mouse CD16/CD32 (BioXCell) and stained for surface markers using the following antibodies: anti-CD45R/B220 (clone RA3-6B2, Biolegend), anti-CD11b (clone M1/70, Biolegend), anti-mouse CD11c (clone N418, Biolegend), anti-CD3 (clone 145–2 C11, Thermo Fisher Scientific), anti-CD45 (clone 30-F11, Bioegend), anti-CD8a (clone 53–6.7, Biolegend), anti-F4/80 (clone BM8, Biolegend), anti-CD126/IL-6RA (clone D7715A7, Biolegend), anti-CD18/ITGB2 (clone M18/2, Biolegend), anti-CD49d/ITGA4 (clone 9C10(MFR4.B), Biolegend), anti-H-2Kb/H-2Db (clone 28-8-6, Biolegend), anti-CD86 (clone GL-1, Biolegend), anti-CD146 (clone ME-9F1, Biolegend), anti-CD44 (clone IM7, Biolegend), anti-CD62L (clone MEL-14, Biolegend), anti-IFNγ (clone XMG1.2, BD Biosciences), anti-CD31 (clone MEC13.3, BD Biosciences)for 20 min at 4 °C. For intracellular IFNγ staining, cells were then fixed, permeabilized and stained following Foxp3/Transcription Factor Staining buffer set (Thermo Fisher Scientific) manufacturer’s guidelines. When preparing samples for FACS sorting, NPCs were directly blocked and stained with CD45-APC and CD31-BV421. Viability was evaluated by 7-AAD (Biolegend) staining that was added to samples 5 min before sorting. Cell sorting was performed on a BD FACSAria Fusion (BD Biosciences) equipped with four lasers: Blue (488 nm), Yellow/Green (561 nm), Red (640 nm) and Violet (405 nm). 85 µm nozzle was used and sheath fluid pressure was at 45 psi. A highly pure sorting modality (four-way purity sorting) was chosen. The drop delay was determined using BD FACS AccuDrop beads. Unstained and a single-stained controls have been used to set up compensation. Rainbow beads (SPHEROTM Rainbow Calibration Particles) were used to standardize the experiment and were run before each acquisition. Samples were sorted at 4 °C to slow down metabolic activities. Sorted cells were collected in 1.5 ml Eppendorf tubes containing 200 µl of DMEM 10% FBS medium and immediately processed for RNA extraction using ReliaPrep RNA Cell Miniprep System (Promega) and DNAse TURBO (Thermo Fisher Scientific) following manufacturer’s recommendation.</p></sec><sec id="s4-19"><title>Isolation of HECs, including LSECs and splenic DCs for in vitro studies</title><p>Mouse liver perfusion was performed as described in the section Electron Microscopy. After PBS perfusion, liver digestion was achieved in situ by perfusing warm digestion medium at 4 rpm for 10 min. The cava vein was squeezed tight several times to build up some pressure within the liver in order to fill all liver lobes with digestion medium. The resultant digested liver was excised, placed on a petri dish containing digestion medium and the Glisson’s capsule was removed. Disaggregated tissue was filtered using a 70-µm cell strainer and centrifuged at 50 g for 3 min to discard hepatocytes. The supernatant containing NPCs was counted and Kupffer cells (KC) were removed using anti-F4/80 Ultrapure microbeads (Miltenyi Biotec) following manufacturer’s guidelines. The flow-through of unlabeled NPCs was placed on top of a 25–50% Percoll gradient and centrifuged at 850 g for 20 min at RT without brake and the LSECs located at the 25/50% interface were collected. LSECs were counted and 10<sup>5</sup> cells were seeded in a 48-well plate and cultured in collagenated plates with EGM-2 medium (Lonza) for 3 days. For the isolation of splenic DC, spleens were slowly injected with 1 ml of digestion medium until they changed from dark maroon to reddish-orange color. Then, the spleen was minced and pipetted vigorously several times in digestion medium. The cell suspension was filtered using a 70 µm cell strainer, and larger undigested fragments were ulteriorly incubated with digestion medium at 37 °C for 30 min. After tissue digestion, splenocytes were centrifuged at 500 g for 5 min and washed three times with plain RPMI supplemented with 5 mM EDTA to disrupt DC-T cell complexes. Red blood cells were lysed with ACK lysis buffer and DCs cells were isolated using anti-CD11c microbeads UltraPure (Miltenyi) according to manufacturer’s instructions. CD11c<sup>+</sup> DCs were counted and seeded at 10<sup>5</sup> cells in a 48-well plate using RPMI GlutaMAX supplemented with 10% FBS, 1% P/S, 1 x Na Pyruvate (Gibco), 1 x MEM Non-essential Amino Acid Solution (Gibco), 20 µM β-mercaptoethanol and 40 ng/ml GM-CSF (BioXcell). Every 48 hr 200 µl of fresh medium were added to cultured cells and DCs were grown for 7 days to stimulate DCs differentiation.</p></sec><sec id="s4-20"><title>Antigen cross-priming</title><p>Prior to naïve CD8<sup>+</sup> T cell co-culture, HECs, including LSECs, and sDCs were stimulated for 18 hr with 1 µg/ml of SIINFEKL peptide (OVA 257–264, Proimmune) or with 1 mg/ml of low endotoxin soluble ovalbumin protein (sOVA; Sigma-Aldrich) in combination with NaCl or 5 ng/ml of IFNα. Subsequently, after extensive washes, cells were co-culture with 5x10<sup>5</sup> naive CD8<sup>+</sup>T cells isolated from OT-I mice in complete RPMI (containing 10% FBS and 50 µM β-mercaptoethanol) in combination with NaCl or 5 ng/ml of IFNα. After 3 days, CD8<sup>+</sup> T cells were stimulated for 4 hr with 1 µg/ml of SIINFEKL peptide, 5 µg/ml of Brefeldin A (Sigma-Aldrich) and 2.5% EL-4 supernatant in complete RPMI. Finally, the production of IFNγ and the expression of activation markers, such as CD44, were measured by FACS.</p></sec><sec id="s4-21"><title>RNA-seq and bioinformatic data analysis</title><p>RNA integrity, isolated from sorted liver CD31<sup>+</sup> cells, was evaluated using the Agilent 4100 TapeStation (Agilent Technologies) and samples with RNA integrity number (RIN) above 7.0 were used for subsequent RNA-Seq-based profiling. Libraries were prepared using the Illumina Stranded mRNA ligation kit, according to the manufacturer’s instructions. The RNA-Seq library was generated following the standard Illumina RNA-Seq protocol and sequenced on an Illumina NovaSeq 6000 machine (Illumina, San Diego, CA) obtaining an average of 40 millions of single-end reads per sample. The raw reads produced from sequencing were trimmed using Trimmomatic, version 0.32, to remove adapters and to exclude low-quality reads from the analysis. The remaining reads were then aligned to the murine genome GRCm38 using STAR, version 2.5.3 a. Reads were eventually assigned to the corresponding genomic features using featureCounts, according to the Gencode basic annotations (Gencode version M22). Quality of sequencing and alignment was assessed using FastQC, RseQC, and MultiQC tools. Expressed genes were defined as those genes showing at least 1 Count Per Million reads (CPM) on at least a selected number of samples, depending on the size of the compared groups (<xref ref-type="bibr" rid="bib19">Chen et al., 2016</xref>). Low-expressed genes that did not match these criteria were excluded from the corresponding dataset. Gene expression read counts were exported and analyzed in R environment (v. 4.0.3) to identify differentially expressed genes (DEGs), using the DESeq2 Bioconductor library (v. 1.30.1, <xref ref-type="bibr" rid="bib66">Love et al., 2014</xref>). P-values were adjusted using a threshold for false discovery rate (FDR)&lt;0.05 (<xref ref-type="bibr" rid="bib9">Benjamini and Hochberg, 1995</xref>). Significant genes were identified as those genes showing FDR &lt;0.05. Functional enrichment analysis was conducted using the enrichR R package (v. 3.0, <xref ref-type="bibr" rid="bib57">Kuleshov et al., 2016</xref>), starting from the lists of differentially expressed genes as defined by FDR &lt;0.05. Selected pathways were grouped and summarized according to their general biological functions and the hypergeometric test was performed to test the enrichment of these custom genesets, exploiting the hypeR R package (v. 1.8.0). Pre-ranked Gene Set Enrichment Analysis (GSEA <xref ref-type="bibr" rid="bib92">Subramanian et al., 2005</xref>) was performed for each DGE comparison, on all the expressed genes ranked for Log2 fold change. The gene-sets included in the GSEA analyses were obtained from Canonical Pathways, Hallmark and the Gene Ontology collections as they are reported in the MsigDB database.</p></sec><sec id="s4-22"><title>Statistical analysis</title><p>In all experiments, values are expressed as mean values ± SEM. Statistical significance was estimated by two-tailed non-parametric Mann-Whitney test (e.g. to evaluate differences generated as a consequence of tumor growth) or by one-way ANOVA with Tukey’s multiple comparison test when more than two groups were analyzed. Contingency tables were tested by two-tailed Fisher’s exact test and Chi-square test. Statistical significance of survival experiments was calculated by log-rank/Mantel-Cox test. All statistical analyses were performed with Prism 8 (GraphPad Software) and were reported in Figure legends. p-values &lt;0.05 were considered statistically significant and reported on graphs. If not mentioned, differences were not statistically significant.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>LGG is a member of the board of directors at Genenta Science and Epsilon Bio and participates in advisory boards/consultancies for Gilead Sciences, Roche, Arbutus Biopharma and Antios Therapeutics</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Validation, Investigation, Visualization, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con10"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con11"><p>Resources, Supervision</p></fn><fn fn-type="con" id="con12"><p>Methodology</p></fn><fn fn-type="con" id="con13"><p>Methodology</p></fn><fn fn-type="con" id="con14"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con15"><p>Resources, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal experiments were approved by the Animal Care and Use Committee of the San Raffaele Scientific Institute (IACUC 691, 808 and 1042) and were conducted in specific pathogen-free (SPF) facility in microisolator cages under a 12-hour light/dark cycle with free access to water and standard mouse diet (Teklad Global 18% Protein Rodent Diet, Harlan).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media xlink:href="elife-80690-transrepform1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Sequencing data have been deposited in the Gene Expression Omnibus (GEO) database under the accession number GSE186203 for intrahepatic CD31 bulk RNA-seq. All data generated or analyzed during this study are included in the manuscript and supporting files.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>LM</given-names></name><name><surname>Alvarez-Moya</surname><given-names>BA</given-names></name><name><surname>Bezzecchi</surname><given-names>E</given-names></name><name><surname>Scotti</surname><given-names>GM</given-names></name><name><surname>Sitia</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Continuous sensing of IFNα by hepatic endothelial cells shapes a vascular antimetastatic barrier</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE186203">GSE186203</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors thank B Mendicino, C.B. Ekalle-Soppo, E Daoud, P Giangregorio, M Nicoloso, M Raso, A Fiocchi, P Marra, T Canu, D Lazarevic, E Capitolo, S Bianchessi, V Berno, A Raimondi, A Loffreda, T Catelani, M Mainetti and P Di Lucia for technical support; M Silva for secretarial assistance, C Tacchetti, P Dellabona and all the San Raffaele AIRC 5X1000 team for helpful discussion. SV Kotenko for help with pSTAT1 IHC protocol. Confocal immunofluorescence histology and electron microscopy was carried out at Alembic, an advanced microscopy laboratory established by the San Raffaele Scientific Institute and the Vita-Salute San Raffaele University. The use of Imaris software was provided by M Iannacone. Acquisition of SEM images was carried out at the Interdepartmental Microscopy Platform of the University of Milan Bicocca. Flow cytometry was carried out at FRACTAL, a flow cytometry resource and advanced cytometry technical applications laboratory established by the San Raffaele Scientific Institute. FRACTAL is an ISO 9001 certified facility and as such all the instruments and equipment are subject to a strict maintenance and functionality check plan. NLT is the recipient of a Swiss National Science Foundation Fellowship P2GEP3_171976; VB is the recipient of a Fondazione Umberto Veronesi “Post-doctoral Fellowships 2019”; AM is the recipient of a Francesco Fronzaroli Memorial fellowship and conducted this study as partial fulfilment of his PhD in Molecular Medicine within the program in Basic and Applied Immunology and Oncology at Vita-Salute San Raffaele University. LGG is supported by the Italian Association for Cancer Research (AIRC) Grant 22737, Lombardy Open Innovation Grant 229452, PRIN Grant 2017MPCWPY from the Italian Ministry of Education, University and Research, Funded Research Agreements from Gilead Sciences and Avalia Therapeutics; GS is supported by Italian Association for Cancer Research (AIRC) grants 18468, 22820 and AIRC 5 per Mille, grant 22737.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aichele</surname><given-names>P</given-names></name><name><surname>Unsoeld</surname><given-names>H</given-names></name><name><surname>Koschella</surname><given-names>M</given-names></name><name><surname>Schweier</surname><given-names>O</given-names></name><name><surname>Kalinke</surname><given-names>U</given-names></name><name><surname>Vucikuja</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Cd8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion</article-title><source>Journal of Immunology</source><volume>176</volume><fpage>4525</fpage><lpage>4529</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.176.8.4525</pub-id><pub-id pub-id-type="pmid">16585541</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ananth</surname><given-names>AA</given-names></name><name><surname>Tai</surname><given-names>L-H</given-names></name><name><surname>Lansdell</surname><given-names>C</given-names></name><name><surname>Alkayyal</surname><given-names>AA</given-names></name><name><surname>Baxter</surname><given-names>KE</given-names></name><name><surname>Angka</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Tanese de Souza</surname><given-names>C</given-names></name><name><surname>Stephenson</surname><given-names>KB</given-names></name><name><surname>Parato</surname><given-names>K</given-names></name><name><surname>Bramson</surname><given-names>JL</given-names></name><name><surname>Bell</surname><given-names>JC</given-names></name><name><surname>Lichty</surname><given-names>BD</given-names></name><name><surname>Auer</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Surgical stress abrogates pre-existing protective T cell mediated anti-tumor immunity leading to postoperative cancer recurrence</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0155947</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0155947</pub-id><pub-id pub-id-type="pmid">27196057</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Argilés</surname><given-names>G</given-names></name><name><surname>Tabernero</surname><given-names>J</given-names></name><name><surname>Labianca</surname><given-names>R</given-names></name><name><surname>Hochhauser</surname><given-names>D</given-names></name><name><surname>Salazar</surname><given-names>R</given-names></name><name><surname>Iveson</surname><given-names>T</given-names></name><name><surname>Laurent-Puig</surname><given-names>P</given-names></name><name><surname>Quirke</surname><given-names>P</given-names></name><name><surname>Yoshino</surname><given-names>T</given-names></name><name><surname>Taieb</surname><given-names>J</given-names></name><name><surname>Martinelli</surname><given-names>E</given-names></name><name><surname>Arnold</surname><given-names>D</given-names></name><collab>ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up</article-title><source>Annals of Oncology</source><volume>31</volume><fpage>1291</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2020.06.022</pub-id><pub-id pub-id-type="pmid">32702383</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Augustin</surname><given-names>G</given-names></name><name><surname>Bruketa</surname><given-names>T</given-names></name><name><surname>Korolija</surname><given-names>D</given-names></name><name><surname>Milosevic</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Lower incidence of hepatic metastases of colorectal cancer in patients with chronic liver diseases: meta-analysis</article-title><source>Hepato-Gastroenterology</source><volume>60</volume><fpage>1164</fpage><lpage>1168</lpage><pub-id pub-id-type="doi">10.5754/hge11561</pub-id><pub-id pub-id-type="pmid">23803379</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badia-Ramentol</surname><given-names>J</given-names></name><name><surname>Linares</surname><given-names>J</given-names></name><name><surname>Gómez-Llonin</surname><given-names>A</given-names></name><name><surname>Calon</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Minimal residual disease, metastasis and immunity</article-title><source>Biomolecules</source><volume>11</volume><elocation-id>130</elocation-id><pub-id pub-id-type="doi">10.3390/biom11020130</pub-id><pub-id pub-id-type="pmid">33498251</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baiocchini</surname><given-names>A</given-names></name><name><surname>Del Nonno</surname><given-names>F</given-names></name><name><surname>Taibi</surname><given-names>C</given-names></name><name><surname>Visco-Comandini</surname><given-names>U</given-names></name><name><surname>D’Offizi</surname><given-names>G</given-names></name><name><surname>Piacentini</surname><given-names>M</given-names></name><name><surname>Falasca</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Liver sinusoidal endothelial cells (lsecs) modifications in patients with chronic hepatitis C</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>8760</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-45114-1</pub-id><pub-id pub-id-type="pmid">31217430</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakos</surname><given-names>O</given-names></name><name><surname>Lawson</surname><given-names>C</given-names></name><name><surname>Rouleau</surname><given-names>S</given-names></name><name><surname>Tai</surname><given-names>LH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity</article-title><source>Journal for Immunotherapy of Cancer</source><volume>6</volume><elocation-id>86</elocation-id><pub-id pub-id-type="doi">10.1186/s40425-018-0398-7</pub-id><pub-id pub-id-type="pmid">30176921</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bénéchet</surname><given-names>AP</given-names></name><name><surname>De Simone</surname><given-names>G</given-names></name><name><surname>Di Lucia</surname><given-names>P</given-names></name><name><surname>Cilenti</surname><given-names>F</given-names></name><name><surname>Barbiera</surname><given-names>G</given-names></name><name><surname>Le Bert</surname><given-names>N</given-names></name><name><surname>Fumagalli</surname><given-names>V</given-names></name><name><surname>Lusito</surname><given-names>E</given-names></name><name><surname>Moalli</surname><given-names>F</given-names></name><name><surname>Bianchessi</surname><given-names>V</given-names></name><name><surname>Andreata</surname><given-names>F</given-names></name><name><surname>Zordan</surname><given-names>P</given-names></name><name><surname>Bono</surname><given-names>E</given-names></name><name><surname>Giustini</surname><given-names>L</given-names></name><name><surname>Bonilla</surname><given-names>WV</given-names></name><name><surname>Bleriot</surname><given-names>C</given-names></name><name><surname>Kunasegaran</surname><given-names>K</given-names></name><name><surname>Gonzalez-Aseguinolaza</surname><given-names>G</given-names></name><name><surname>Pinschewer</surname><given-names>DD</given-names></name><name><surname>Kennedy</surname><given-names>PTF</given-names></name><name><surname>Naldini</surname><given-names>L</given-names></name><name><surname>Kuka</surname><given-names>M</given-names></name><name><surname>Ginhoux</surname><given-names>F</given-names></name><name><surname>Cantore</surname><given-names>A</given-names></name><name><surname>Bertoletti</surname><given-names>A</given-names></name><name><surname>Ostuni</surname><given-names>R</given-names></name><name><surname>Guidotti</surname><given-names>LG</given-names></name><name><surname>Iannacone</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming</article-title><source>Nature</source><volume>574</volume><fpage>200</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1620-6</pub-id><pub-id pub-id-type="pmid">31582858</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title><source>Journal of the Royal Statistical Society</source><volume>57</volume><fpage>289</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1111/j.2517-6161.1995.tb02031.x</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blériot</surname><given-names>C</given-names></name><name><surname>Ginhoux</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Understanding the heterogeneity of resident liver macrophages</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>2694</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.02694</pub-id><pub-id pub-id-type="pmid">31803196</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bocci</surname><given-names>V</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Pharmacology and side-effects of interferons</article-title><source>Antiviral Research</source><volume>24</volume><fpage>111</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/0166-3542(94)90059-0</pub-id><pub-id pub-id-type="pmid">7526785</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolger</surname><given-names>AM</given-names></name><name><surname>Lohse</surname><given-names>M</given-names></name><name><surname>Usadel</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Trimmomatic: a flexible trimmer for illumina sequence data</article-title><source>Bioinformatics</source><volume>30</volume><fpage>2114</fpage><lpage>2120</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu170</pub-id><pub-id pub-id-type="pmid">24695404</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Böttcher</surname><given-names>JP</given-names></name><name><surname>Schanz</surname><given-names>O</given-names></name><name><surname>Garbers</surname><given-names>C</given-names></name><name><surname>Zaremba</surname><given-names>A</given-names></name><name><surname>Hegenbarth</surname><given-names>S</given-names></name><name><surname>Kurts</surname><given-names>C</given-names></name><name><surname>Beyer</surname><given-names>M</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Kastenmüller</surname><given-names>W</given-names></name><name><surname>Rose-John</surname><given-names>S</given-names></name><name><surname>Knolle</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Il-6 trans-signaling-dependent rapid development of cytotoxic CD8+ T cell function</article-title><source>Cell Reports</source><volume>8</volume><fpage>1318</fpage><lpage>1327</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.07.008</pub-id><pub-id pub-id-type="pmid">25199826</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boukhaled</surname><given-names>GM</given-names></name><name><surname>Harding</surname><given-names>S</given-names></name><name><surname>Brooks</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Opposing roles of type I interferons in cancer immunity</article-title><source>Annual Review of Pathology</source><volume>16</volume><fpage>167</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathol-031920-093932</pub-id><pub-id pub-id-type="pmid">33264572</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brattain</surname><given-names>MG</given-names></name><name><surname>Strobel-Stevens</surname><given-names>J</given-names></name><name><surname>Fine</surname><given-names>D</given-names></name><name><surname>Webb</surname><given-names>M</given-names></name><name><surname>Sarrif</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="1980">1980</year><article-title>Establishment of mouse colonic carcinoma cell lines with different metastatic properties</article-title><source>Cancer Research</source><volume>40</volume><fpage>2142</fpage><lpage>2146</lpage><pub-id pub-id-type="pmid">6992981</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catarinella</surname><given-names>M</given-names></name><name><surname>Monestiroli</surname><given-names>A</given-names></name><name><surname>Escobar</surname><given-names>G</given-names></name><name><surname>Fiocchi</surname><given-names>A</given-names></name><name><surname>Tran</surname><given-names>NL</given-names></name><name><surname>Aiolfi</surname><given-names>R</given-names></name><name><surname>Marra</surname><given-names>P</given-names></name><name><surname>Esposito</surname><given-names>A</given-names></name><name><surname>Cipriani</surname><given-names>F</given-names></name><name><surname>Aldrighetti</surname><given-names>L</given-names></name><name><surname>Iannacone</surname><given-names>M</given-names></name><name><surname>Naldini</surname><given-names>L</given-names></name><name><surname>Guidotti</surname><given-names>LG</given-names></name><name><surname>Sitia</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Ifnα gene/cell therapy curbs colorectal cancer colonization of the liver by acting on the hepatic microenvironment</article-title><source>EMBO Molecular Medicine</source><volume>8</volume><fpage>155</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.15252/emmm.201505395</pub-id><pub-id pub-id-type="pmid">26769348</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>AF</given-names></name><name><surname>Groom</surname><given-names>AC</given-names></name><name><surname>MacDonald</surname><given-names>IC</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Dissemination and growth of cancer cells in metastatic sites</article-title><source>Nature Reviews. Cancer</source><volume>2</volume><fpage>563</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1038/nrc865</pub-id><pub-id pub-id-type="pmid">12154349</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>EY</given-names></name><name><surname>Tan</surname><given-names>CM</given-names></name><name><surname>Kou</surname><given-names>Y</given-names></name><name><surname>Duan</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Meirelles</surname><given-names>GV</given-names></name><name><surname>Clark</surname><given-names>NR</given-names></name><name><surname>Ma’ayan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool</article-title><source>BMC Bioinformatics</source><volume>14</volume><elocation-id>128</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-14-128</pub-id><pub-id pub-id-type="pmid">23586463</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Lun</surname><given-names>ATL</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>From reads to genes to pathways: differential expression analysis of RNA-Seq experiments using rsubread and the edger quasi-likelihood pipeline</article-title><source>F1000Research</source><volume>5</volume><elocation-id>1438</elocation-id><pub-id pub-id-type="doi">10.12688/f1000research.8987.2</pub-id><pub-id pub-id-type="pmid">27508061</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheon</surname><given-names>H</given-names></name><name><surname>Borden</surname><given-names>EC</given-names></name><name><surname>Stark</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Interferons and their stimulated genes in the tumor microenvironment</article-title><source>Seminars in Oncology</source><volume>41</volume><fpage>156</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1053/j.seminoncol.2014.02.002</pub-id><pub-id pub-id-type="pmid">24787290</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>FC-L</given-names></name><name><surname>Chok</surname><given-names>KS-H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Colorectal liver metastases: an update on multidisciplinary approach</article-title><source>World Journal of Hepatology</source><volume>11</volume><fpage>150</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.4254/wjh.v11.i2.150</pub-id><pub-id pub-id-type="pmid">30820266</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cogger</surname><given-names>VC</given-names></name><name><surname>O’Reilly</surname><given-names>JN</given-names></name><name><surname>Warren</surname><given-names>A</given-names></name><name><surname>Le Couteur</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A standardized method for the analysis of liver sinusoidal endothelial cells and their fenestrations by scanning electron microscopy</article-title><source>Journal of Visualized Experiments</source><volume>e52698</volume><elocation-id>e52698</elocation-id><pub-id pub-id-type="doi">10.3791/52698</pub-id><pub-id pub-id-type="pmid">25993325</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crist</surname><given-names>SB</given-names></name><name><surname>Ghajar</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>When a house is not a home: a survey of antimetastatic niches and potential mechanisms of disseminated tumor cell suppression</article-title><source>Annual Review of Pathology</source><volume>16</volume><fpage>409</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathmechdis-012419-032647</pub-id><pub-id pub-id-type="pmid">33276706</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Atkin</surname><given-names>W</given-names></name><name><surname>Lenz</surname><given-names>HJ</given-names></name><name><surname>Lynch</surname><given-names>HT</given-names></name><name><surname>Minsky</surname><given-names>B</given-names></name><name><surname>Nordlinger</surname><given-names>B</given-names></name><name><surname>Starling</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Colorectal cancer</article-title><source>Lancet</source><volume>375</volume><fpage>1030</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)60353-4</pub-id><pub-id pub-id-type="pmid">20304247</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curtsinger</surname><given-names>JM</given-names></name><name><surname>Gerner</surname><given-names>MY</given-names></name><name><surname>Lins</surname><given-names>DC</given-names></name><name><surname>Mescher</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Signal 3 availability limits the CD8 T cell response to a solid tumor</article-title><source>Journal of Immunology</source><volume>178</volume><fpage>6752</fpage><lpage>6760</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.11.6752</pub-id><pub-id pub-id-type="pmid">17513722</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeLeve</surname><given-names>LD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Liver sinusoidal endothelial cells in hepatic fibrosis</article-title><source>Hepatology</source><volume>61</volume><fpage>1740</fpage><lpage>1746</lpage><pub-id pub-id-type="doi">10.1002/hep.27376</pub-id><pub-id pub-id-type="pmid">25131509</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denève</surname><given-names>E</given-names></name><name><surname>Riethdorf</surname><given-names>S</given-names></name><name><surname>Ramos</surname><given-names>J</given-names></name><name><surname>Nocca</surname><given-names>D</given-names></name><name><surname>Coffy</surname><given-names>A</given-names></name><name><surname>Daurès</surname><given-names>JP</given-names></name><name><surname>Maudelonde</surname><given-names>T</given-names></name><name><surname>Fabre</surname><given-names>JM</given-names></name><name><surname>Pantel</surname><given-names>K</given-names></name><name><surname>Alix-Panabières</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Capture of viable circulating tumor cells in the liver of colorectal cancer patients</article-title><source>Clinical Chemistry</source><volume>59</volume><fpage>1384</fpage><lpage>1392</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2013.202846</pub-id><pub-id pub-id-type="pmid">23695297</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Palma</surname><given-names>M</given-names></name><name><surname>Mazzieri</surname><given-names>R</given-names></name><name><surname>Politi</surname><given-names>LS</given-names></name><name><surname>Pucci</surname><given-names>F</given-names></name><name><surname>Zonari</surname><given-names>E</given-names></name><name><surname>Sitia</surname><given-names>G</given-names></name><name><surname>Mazzoleni</surname><given-names>S</given-names></name><name><surname>Moi</surname><given-names>D</given-names></name><name><surname>Venneri</surname><given-names>MA</given-names></name><name><surname>Indraccolo</surname><given-names>S</given-names></name><name><surname>Falini</surname><given-names>A</given-names></name><name><surname>Guidotti</surname><given-names>LG</given-names></name><name><surname>Galli</surname><given-names>R</given-names></name><name><surname>Naldini</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Tumor-Targeted interferon-alpha delivery by tie2-expressing monocytes inhibits tumor growth and metastasis</article-title><source>Cancer Cell</source><volume>14</volume><fpage>299</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2008.09.004</pub-id><pub-id pub-id-type="pmid">18835032</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobrzanski</surname><given-names>MJ</given-names></name><name><surname>Reome</surname><given-names>JB</given-names></name><name><surname>Dutton</surname><given-names>RW</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor</article-title><source>Journal of Immunology</source><volume>164</volume><fpage>916</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.164.2.916</pub-id><pub-id pub-id-type="pmid">10623840</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Efremova</surname><given-names>M</given-names></name><name><surname>Rieder</surname><given-names>D</given-names></name><name><surname>Klepsch</surname><given-names>V</given-names></name><name><surname>Charoentong</surname><given-names>P</given-names></name><name><surname>Finotello</surname><given-names>F</given-names></name><name><surname>Hackl</surname><given-names>H</given-names></name><name><surname>Hermann-Kleiter</surname><given-names>N</given-names></name><name><surname>Löwer</surname><given-names>M</given-names></name><name><surname>Baier</surname><given-names>G</given-names></name><name><surname>Krogsdam</surname><given-names>A</given-names></name><name><surname>Trajanoski</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>32</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-02424-0</pub-id><pub-id pub-id-type="pmid">29296022</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engstrand</surname><given-names>J</given-names></name><name><surname>Strömberg</surname><given-names>C</given-names></name><name><surname>Nilsson</surname><given-names>H</given-names></name><name><surname>Freedman</surname><given-names>J</given-names></name><name><surname>Jonas</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Synchronous and metachronous liver metastases in patients with colorectal cancer-towards a clinically relevant definition</article-title><source>World Journal of Surgical Oncology</source><volume>17</volume><elocation-id>228</elocation-id><pub-id pub-id-type="doi">10.1186/s12957-019-1771-9</pub-id><pub-id pub-id-type="pmid">31878952</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fioravanti</surname><given-names>J</given-names></name><name><surname>González</surname><given-names>I</given-names></name><name><surname>Medina-Echeverz</surname><given-names>J</given-names></name><name><surname>Larrea</surname><given-names>E</given-names></name><name><surname>Ardaiz</surname><given-names>N</given-names></name><name><surname>González-Aseguinolaza</surname><given-names>G</given-names></name><name><surname>Prieto</surname><given-names>J</given-names></name><name><surname>Berraondo</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties</article-title><source>Hepatology</source><volume>53</volume><fpage>1864</fpage><lpage>1873</lpage><pub-id pub-id-type="doi">10.1002/hep.24306</pub-id><pub-id pub-id-type="pmid">21425312</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flanigan</surname><given-names>RC</given-names></name><name><surname>Salmon</surname><given-names>SE</given-names></name><name><surname>Blumenstein</surname><given-names>BA</given-names></name><name><surname>Bearman</surname><given-names>SI</given-names></name><name><surname>Roy</surname><given-names>V</given-names></name><name><surname>McGrath</surname><given-names>PC</given-names></name><name><surname>Caton</surname><given-names>JR</given-names><suffix>Jr</suffix></name><name><surname>Munshi</surname><given-names>N</given-names></name><name><surname>Crawford</surname><given-names>ED</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer</article-title><source>The New England Journal of Medicine</source><volume>345</volume><fpage>1655</fpage><lpage>1659</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa003013</pub-id><pub-id pub-id-type="pmid">11759643</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foser</surname><given-names>S</given-names></name><name><surname>Weyer</surname><given-names>K</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Certa</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Improved biological and transcriptional activity of monopegylated interferon-alpha-2a isomers</article-title><source>The Pharmacogenomics Journal</source><volume>3</volume><fpage>312</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1038/sj.tpj.6500204</pub-id><pub-id pub-id-type="pmid">14569259</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franciszkiewicz</surname><given-names>K</given-names></name><name><surname>Boissonnas</surname><given-names>A</given-names></name><name><surname>Boutet</surname><given-names>M</given-names></name><name><surname>Combadière</surname><given-names>C</given-names></name><name><surname>Mami-Chouaib</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response</article-title><source>Cancer Research</source><volume>72</volume><fpage>6325</fpage><lpage>6332</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-2027</pub-id><pub-id pub-id-type="pmid">23222302</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>C</given-names></name><name><surname>Peng</surname><given-names>P</given-names></name><name><surname>Loschko</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Pham</surname><given-names>P</given-names></name><name><surname>Cui</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>KP</given-names></name><name><surname>Krug</surname><given-names>AB</given-names></name><name><surname>Jiang</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Plasmacytoid dendritic cells cross-prime naive CD8 T cells by transferring antigen to conventional dendritic cells through exosomes</article-title><source>PNAS</source><volume>117</volume><fpage>23730</fpage><lpage>23741</lpage><pub-id pub-id-type="doi">10.1073/pnas.2002345117</pub-id><pub-id pub-id-type="pmid">32879009</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuertes</surname><given-names>MB</given-names></name><name><surname>Woo</surname><given-names>S-R</given-names></name><name><surname>Burnett</surname><given-names>B</given-names></name><name><surname>Fu</surname><given-names>Y-X</given-names></name><name><surname>Gajewski</surname><given-names>TF</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Type I interferon response and innate immune sensing of cancer</article-title><source>Trends in Immunology</source><volume>34</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.it.2012.10.004</pub-id><pub-id pub-id-type="pmid">23122052</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerl</surname><given-names>K</given-names></name><name><surname>Miquerol</surname><given-names>L</given-names></name><name><surname>Todorov</surname><given-names>VT</given-names></name><name><surname>Hugo</surname><given-names>CPM</given-names></name><name><surname>Adams</surname><given-names>RH</given-names></name><name><surname>Kurtz</surname><given-names>A</given-names></name><name><surname>Kurt</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Inducible glomerular erythropoietin production in the adult kidney</article-title><source>Kidney International</source><volume>88</volume><fpage>1345</fpage><lpage>1355</lpage><pub-id pub-id-type="doi">10.1038/ki.2015.274</pub-id><pub-id pub-id-type="pmid">26398496</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gessani</surname><given-names>S</given-names></name><name><surname>Conti</surname><given-names>L</given-names></name><name><surname>Del Cornò</surname><given-names>M</given-names></name><name><surname>Belardelli</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Type I interferons as regulators of human antigen presenting cell functions</article-title><source>Toxins</source><volume>6</volume><fpage>1696</fpage><lpage>1723</lpage><pub-id pub-id-type="doi">10.3390/toxins6061696</pub-id><pub-id pub-id-type="pmid">24866026</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gissen</surname><given-names>P</given-names></name><name><surname>Arias</surname><given-names>IM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structural and functional hepatocyte polarity and liver disease</article-title><source>Journal of Hepatology</source><volume>63</volume><fpage>1023</fpage><lpage>1037</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2015.06.015</pub-id><pub-id pub-id-type="pmid">26116792</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glinskii</surname><given-names>OV</given-names></name><name><surname>Huxley</surname><given-names>VH</given-names></name><name><surname>Glinsky</surname><given-names>GV</given-names></name><name><surname>Pienta</surname><given-names>KJ</given-names></name><name><surname>Raz</surname><given-names>A</given-names></name><name><surname>Glinsky</surname><given-names>VV</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs</article-title><source>Neoplasia</source><volume>7</volume><fpage>522</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1593/neo.04646</pub-id><pub-id pub-id-type="pmid">15967104</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glue</surname><given-names>P</given-names></name><name><surname>Rouzier-Panis</surname><given-names>R</given-names></name><name><surname>Raffanel</surname><given-names>C</given-names></name><name><surname>Sabo</surname><given-names>R</given-names></name><name><surname>Gupta</surname><given-names>SK</given-names></name><name><surname>Salfi</surname><given-names>M</given-names></name><name><surname>Jacobs</surname><given-names>S</given-names></name><name><surname>Clement</surname><given-names>RP</given-names></name><collab>The Hepatitis C Intervention Therapy Group</collab></person-group><year iso-8601-date="2000">2000</year><article-title>A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C</article-title><source>Hepatology</source><volume>32</volume><fpage>647</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1053/jhep.2000.16661</pub-id><pub-id pub-id-type="pmid">10960463</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guidotti</surname><given-names>LG</given-names></name><name><surname>Inverso</surname><given-names>D</given-names></name><name><surname>Sironi</surname><given-names>L</given-names></name><name><surname>Di Lucia</surname><given-names>P</given-names></name><name><surname>Fioravanti</surname><given-names>J</given-names></name><name><surname>Ganzer</surname><given-names>L</given-names></name><name><surname>Fiocchi</surname><given-names>A</given-names></name><name><surname>Vacca</surname><given-names>M</given-names></name><name><surname>Aiolfi</surname><given-names>R</given-names></name><name><surname>Sammicheli</surname><given-names>S</given-names></name><name><surname>Mainetti</surname><given-names>M</given-names></name><name><surname>Cataudella</surname><given-names>T</given-names></name><name><surname>Raimondi</surname><given-names>A</given-names></name><name><surname>Gonzalez-Aseguinolaza</surname><given-names>G</given-names></name><name><surname>Protzer</surname><given-names>U</given-names></name><name><surname>Ruggeri</surname><given-names>ZM</given-names></name><name><surname>Chisari</surname><given-names>FV</given-names></name><name><surname>Isogawa</surname><given-names>M</given-names></name><name><surname>Sitia</surname><given-names>G</given-names></name><name><surname>Iannacone</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Immunosurveillance of the liver by intravascular effector CD8 (+) T cells</article-title><source>Cell</source><volume>161</volume><fpage>486</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.03.005</pub-id><pub-id pub-id-type="pmid">25892224</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gül</surname><given-names>N</given-names></name><name><surname>Bögels</surname><given-names>M</given-names></name><name><surname>Grewal</surname><given-names>S</given-names></name><name><surname>van der Meer</surname><given-names>AJ</given-names></name><name><surname>Rojas</surname><given-names>LB</given-names></name><name><surname>Fluitsma</surname><given-names>DM</given-names></name><name><surname>van den Tol</surname><given-names>MP</given-names></name><name><surname>Hoeben</surname><given-names>KA</given-names></name><name><surname>van Marle</surname><given-names>J</given-names></name><name><surname>de Vries</surname><given-names>HE</given-names></name><name><surname>Beelen</surname><given-names>RHJ</given-names></name><name><surname>van Egmond</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Surgery-Induced reactive oxygen species enhance colon carcinoma cell binding by disrupting the liver endothelial cell lining</article-title><source>Gut</source><volume>60</volume><fpage>1076</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1136/gut.2010.224717</pub-id><pub-id pub-id-type="pmid">21278144</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herndon</surname><given-names>TM</given-names></name><name><surname>Demko</surname><given-names>SG</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>K</given-names></name><name><surname>Gootenberg</surname><given-names>JE</given-names></name><name><surname>Cohen</surname><given-names>MH</given-names></name><name><surname>Keegan</surname><given-names>P</given-names></name><name><surname>Pazdur</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>U.S. food and drug administration approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma</article-title><source>The Oncologist</source><volume>17</volume><fpage>1323</fpage><lpage>1328</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2012-0123</pub-id><pub-id pub-id-type="pmid">23002124</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horowitz</surname><given-names>M</given-names></name><name><surname>Neeman</surname><given-names>E</given-names></name><name><surname>Sharon</surname><given-names>E</given-names></name><name><surname>Ben-Eliyahu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Exploiting the critical perioperative period to improve long-term cancer outcomes</article-title><source>Nature Reviews. Clinical Oncology</source><volume>12</volume><fpage>213</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2014.224</pub-id><pub-id pub-id-type="pmid">25601442</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inagawa</surname><given-names>R</given-names></name><name><surname>Okada</surname><given-names>H</given-names></name><name><surname>Takemura</surname><given-names>G</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Takada</surname><given-names>C</given-names></name><name><surname>Yano</surname><given-names>H</given-names></name><name><surname>Ando</surname><given-names>Y</given-names></name><name><surname>Usui</surname><given-names>T</given-names></name><name><surname>Hotta</surname><given-names>Y</given-names></name><name><surname>Miyazaki</surname><given-names>N</given-names></name><name><surname>Tsujimoto</surname><given-names>A</given-names></name><name><surname>Zaikokuji</surname><given-names>R</given-names></name><name><surname>Matsumoto</surname><given-names>A</given-names></name><name><surname>Kawaguchi</surname><given-names>T</given-names></name><name><surname>Doi</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>S</given-names></name><name><surname>Kumada</surname><given-names>K</given-names></name><name><surname>Ushikoshi</surname><given-names>H</given-names></name><name><surname>Toyoda</surname><given-names>I</given-names></name><name><surname>Ogura</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Ultrastructural alteration of pulmonary capillary endothelial glycocalyx during endotoxemia</article-title><source>Chest</source><volume>154</volume><fpage>317</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2018.03.003</pub-id><pub-id pub-id-type="pmid">29555594</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Indraccolo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Interferon-Alpha as angiogenesis inhibitor: learning from tumor models</article-title><source>Autoimmunity</source><volume>43</volume><fpage>244</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.3109/08916930903510963</pub-id><pub-id pub-id-type="pmid">20166871</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>F</given-names></name><name><surname>Wisse</surname><given-names>E</given-names></name><name><surname>De Geest</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The role of liver sinusoidal cells in hepatocyte-directed gene transfer</article-title><source>The American Journal of Pathology</source><volume>176</volume><fpage>14</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2010.090136</pub-id><pub-id pub-id-type="pmid">19948827</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeon</surname><given-names>S</given-names></name><name><surname>Juhn</surname><given-names>JH</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Hong</surname><given-names>T</given-names></name><name><surname>Paek</surname><given-names>J</given-names></name><name><surname>Yim</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Saturable human neopterin response to interferon-α assessed by a pharmacokinetic-pharmacodynamic model</article-title><source>Journal of Translational Medicine</source><volume>11</volume><elocation-id>240</elocation-id><pub-id pub-id-type="doi">10.1186/1479-5876-11-240</pub-id><pub-id pub-id-type="pmid">24088361</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karmaus</surname><given-names>PWF</given-names></name><name><surname>Chi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genetic dissection of dendritic cell homeostasis and function: lessons from cell type-specific gene ablation</article-title><source>Cellular and Molecular Life Sciences</source><volume>71</volume><fpage>1893</fpage><lpage>1906</lpage><pub-id pub-id-type="doi">10.1007/s00018-013-1534-7</pub-id><pub-id pub-id-type="pmid">24366237</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katlinski</surname><given-names>KV</given-names></name><name><surname>Gui</surname><given-names>J</given-names></name><name><surname>Katlinskaya</surname><given-names>YV</given-names></name><name><surname>Ortiz</surname><given-names>A</given-names></name><name><surname>Chakraborty</surname><given-names>R</given-names></name><name><surname>Bhattacharya</surname><given-names>S</given-names></name><name><surname>Carbone</surname><given-names>CJ</given-names></name><name><surname>Beiting</surname><given-names>DP</given-names></name><name><surname>Girondo</surname><given-names>MA</given-names></name><name><surname>Peck</surname><given-names>AR</given-names></name><name><surname>Puré</surname><given-names>E</given-names></name><name><surname>Chatterji</surname><given-names>P</given-names></name><name><surname>Rustgi</surname><given-names>AK</given-names></name><name><surname>Diehl</surname><given-names>JA</given-names></name><name><surname>Koumenis</surname><given-names>C</given-names></name><name><surname>Rui</surname><given-names>H</given-names></name><name><surname>Fuchs</surname><given-names>SY</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment</article-title><source>Cancer Cell</source><volume>31</volume><fpage>194</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.01.004</pub-id><pub-id pub-id-type="pmid">28196594</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>SC</given-names></name><name><surname>Pillarisetty</surname><given-names>VG</given-names></name><name><surname>Bleier</surname><given-names>JI</given-names></name><name><surname>Shah</surname><given-names>AB</given-names></name><name><surname>DeMatteo</surname><given-names>RP</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Liver sinusoidal endothelial cells are insufficient to activate T cells</article-title><source>Journal of Immunology</source><volume>173</volume><fpage>230</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.173.1.230</pub-id><pub-id pub-id-type="pmid">15210779</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klebanoff</surname><given-names>CA</given-names></name><name><surname>Gattinoni</surname><given-names>L</given-names></name><name><surname>Torabi-Parizi</surname><given-names>P</given-names></name><name><surname>Kerstann</surname><given-names>K</given-names></name><name><surname>Cardones</surname><given-names>AR</given-names></name><name><surname>Finkelstein</surname><given-names>SE</given-names></name><name><surname>Palmer</surname><given-names>DC</given-names></name><name><surname>Antony</surname><given-names>PA</given-names></name><name><surname>Hwang</surname><given-names>ST</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Waldmann</surname><given-names>TA</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells</article-title><source>PNAS</source><volume>102</volume><fpage>9571</fpage><lpage>9576</lpage><pub-id pub-id-type="doi">10.1073/pnas.0503726102</pub-id><pub-id pub-id-type="pmid">15980149</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Köhne</surname><given-names>CH</given-names></name><name><surname>Wilke</surname><given-names>H</given-names></name><name><surname>Hiddemann</surname><given-names>W</given-names></name><name><surname>Bokemeyer</surname><given-names>C</given-names></name><name><surname>Lohrmann</surname><given-names>HP</given-names></name><name><surname>Bodenstein</surname><given-names>H</given-names></name><name><surname>Preiss</surname><given-names>J</given-names></name><name><surname>Rauschecker</surname><given-names>H</given-names></name><name><surname>Hill</surname><given-names>H</given-names></name><name><surname>Kaufer</surname><given-names>C</given-names></name><name><surname>Fischer</surname><given-names>JT</given-names></name><name><surname>Ohl</surname><given-names>U</given-names></name><name><surname>Urbanitz</surname><given-names>D</given-names></name><name><surname>Balleisen</surname><given-names>L</given-names></name><name><surname>Schmoll</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Phase II evaluation of 5-fluourouracil plus folinic acid and alpha 2b-interferon in metastatic colorectal cancer</article-title><source>Oncology</source><volume>54</volume><fpage>96</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1159/000227670</pub-id><pub-id pub-id-type="pmid">9075778</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>T</given-names></name><name><surname>Okabayashi</surname><given-names>K</given-names></name><name><surname>Hasegawa</surname><given-names>H</given-names></name><name><surname>Tsuruta</surname><given-names>M</given-names></name><name><surname>Shigeta</surname><given-names>K</given-names></name><name><surname>Kitagawa</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The impact of hepatic fibrosis on the incidence of liver metastasis from colorectal cancer</article-title><source>British Journal of Cancer</source><volume>115</volume><fpage>34</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1038/bjc.2016.155</pub-id><pub-id pub-id-type="pmid">27280634</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuleshov</surname><given-names>MV</given-names></name><name><surname>Jones</surname><given-names>MR</given-names></name><name><surname>Rouillard</surname><given-names>AD</given-names></name><name><surname>Fernandez</surname><given-names>NF</given-names></name><name><surname>Duan</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Koplev</surname><given-names>S</given-names></name><name><surname>Jenkins</surname><given-names>SL</given-names></name><name><surname>Jagodnik</surname><given-names>KM</given-names></name><name><surname>Lachmann</surname><given-names>A</given-names></name><name><surname>McDermott</surname><given-names>MG</given-names></name><name><surname>Monteiro</surname><given-names>CD</given-names></name><name><surname>Gundersen</surname><given-names>GW</given-names></name><name><surname>Ma’ayan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Enrichr: a comprehensive gene set enrichment analysis web server 2016 update</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>W90</fpage><lpage>W97</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw377</pub-id><pub-id pub-id-type="pmid">27141961</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lens</surname><given-names>MB</given-names></name><name><surname>Dawes</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials</article-title><source>Journal of Clinical Oncology</source><volume>20</volume><fpage>1818</fpage><lpage>1825</lpage><pub-id pub-id-type="doi">10.1200/JCO.2002.07.070</pub-id><pub-id pub-id-type="pmid">11919239</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Trinh</surname><given-names>R</given-names></name><name><surname>Ren</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Shang</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Morrison</surname><given-names>SL</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer</article-title><source>Oncoimmunology</source><volume>6</volume><elocation-id>e1290038</elocation-id><pub-id pub-id-type="doi">10.1080/2162402X.2017.1290038</pub-id><pub-id pub-id-type="pmid">28405526</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Tang</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Histological responses of peginterferon alpha add-on therapy in patients with chronic hepatitis B with advanced liver fibrosis after long-term nucleos (T) ide analog treatment</article-title><source>Journal of Viral Hepatitis</source><volume>26 Suppl 1</volume><fpage>50</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1111/jvh.13152</pub-id><pub-id pub-id-type="pmid">31380590</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Ren</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Bian</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Fu</surname><given-names>YX</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>4586</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-06890-y</pub-id><pub-id pub-id-type="pmid">30389912</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li Destri</surname><given-names>G</given-names></name><name><surname>Castaing</surname><given-names>M</given-names></name><name><surname>Ferlito</surname><given-names>F</given-names></name><name><surname>Minutolo</surname><given-names>V</given-names></name><name><surname>Di Cataldo</surname><given-names>A</given-names></name><name><surname>Puleo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Rare hepatic metastases of colorectal cancer in livers with symptomatic HBV and HCV hepatitis</article-title><source>Annali Italiani Di Chirurgia</source><volume>84</volume><fpage>323</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">22722140</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>JD</given-names></name><name><surname>Feng</surname><given-names>N</given-names></name><name><surname>Sen</surname><given-names>A</given-names></name><name><surname>Balan</surname><given-names>M</given-names></name><name><surname>Tseng</surname><given-names>HC</given-names></name><name><surname>McElrath</surname><given-names>C</given-names></name><name><surname>Smirnov</surname><given-names>SV</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Yasukawa</surname><given-names>LL</given-names></name><name><surname>Durbin</surname><given-names>RK</given-names></name><name><surname>Durbin</surname><given-names>JE</given-names></name><name><surname>Greenberg</surname><given-names>HB</given-names></name><name><surname>Kotenko</surname><given-names>SV</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Distinct roles of type I and type III interferons in intestinal immunity to homologous and heterologous rotavirus infections</article-title><source>PLOS Pathogens</source><volume>12</volume><elocation-id>e1005600</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005600</pub-id><pub-id pub-id-type="pmid">27128797</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Link</surname><given-names>K-H</given-names></name><name><surname>Kornmann</surname><given-names>M</given-names></name><name><surname>Staib</surname><given-names>L</given-names></name><name><surname>Redenbacher</surname><given-names>M</given-names></name><name><surname>Kron</surname><given-names>M</given-names></name><name><surname>Beger</surname><given-names>HG</given-names></name><collab>Study Group Oncology of Gastrointestinal Tumors</collab></person-group><year iso-8601-date="2005">2005</year><article-title>Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha</article-title><source>Annals of Surgery</source><volume>242</volume><fpage>178</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1097/01.sla.0000171033.65639.a9</pub-id><pub-id pub-id-type="pmid">16041207</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Sample preparation method for isolation of single-cell types from mouse liver for proteomic studies</article-title><source>Proteomics</source><volume>11</volume><fpage>3556</fpage><lpage>3564</lpage><pub-id pub-id-type="doi">10.1002/pmic.201100157</pub-id><pub-id pub-id-type="pmid">21751380</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-Seq data with deseq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madisen</surname><given-names>L</given-names></name><name><surname>Zwingman</surname><given-names>TA</given-names></name><name><surname>Sunkin</surname><given-names>SM</given-names></name><name><surname>Oh</surname><given-names>SW</given-names></name><name><surname>Zariwala</surname><given-names>HA</given-names></name><name><surname>Gu</surname><given-names>H</given-names></name><name><surname>Ng</surname><given-names>LL</given-names></name><name><surname>Palmiter</surname><given-names>RD</given-names></name><name><surname>Hawrylycz</surname><given-names>MJ</given-names></name><name><surname>Jones</surname><given-names>AR</given-names></name><name><surname>Lein</surname><given-names>ES</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A robust and high-throughput CRE reporting and characterization system for the whole mouse brain</article-title><source>Nature Neuroscience</source><volume>13</volume><fpage>133</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1038/nn.2467</pub-id><pub-id pub-id-type="pmid">20023653</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mak</surname><given-names>KM</given-names></name><name><surname>Mei</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Basement membrane type IV collagen and laminin: an overview of their biology and value as fibrosis biomarkers of liver disease</article-title><source>The Anatomical Record</source><volume>300</volume><fpage>1371</fpage><lpage>1390</lpage><pub-id pub-id-type="doi">10.1002/ar.23567</pub-id><pub-id pub-id-type="pmid">28187500</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>MJ</given-names></name><name><surname>King</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Physical biology in cancer. 3. the role of cell glycocalyx in vascular transport of circulating tumor cells</article-title><source>American Journal of Physiology-Cell Physiology</source><volume>306</volume><fpage>C89</fpage><lpage>C97</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00285.2013</pub-id><pub-id pub-id-type="pmid">24133067</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montoya</surname><given-names>M</given-names></name><name><surname>Schiavoni</surname><given-names>G</given-names></name><name><surname>Mattei</surname><given-names>F</given-names></name><name><surname>Gresser</surname><given-names>I</given-names></name><name><surname>Belardelli</surname><given-names>F</given-names></name><name><surname>Borrow</surname><given-names>P</given-names></name><name><surname>Tough</surname><given-names>DF</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Type I interferons produced by dendritic cells promote their phenotypic and functional activation</article-title><source>Blood</source><volume>99</volume><fpage>3263</fpage><lpage>3271</lpage><pub-id pub-id-type="doi">10.1182/blood.v99.9.3263</pub-id><pub-id pub-id-type="pmid">11964292</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Offeddu</surname><given-names>GS</given-names></name><name><surname>Hajal</surname><given-names>C</given-names></name><name><surname>Foley</surname><given-names>CR</given-names></name><name><surname>Wan</surname><given-names>Z</given-names></name><name><surname>Ibrahim</surname><given-names>L</given-names></name><name><surname>Coughlin</surname><given-names>MF</given-names></name><name><surname>Kamm</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The cancer glycocalyx mediates intravascular adhesion and extravasation during metastatic dissemination</article-title><source>Communications Biology</source><volume>4</volume><elocation-id>255</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-021-01774-2</pub-id><pub-id pub-id-type="pmid">33637851</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>E</given-names></name><name><surname>Nour</surname><given-names>AS</given-names></name><name><surname>Harris</surname><given-names>EN</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Prominent receptors of liver sinusoidal endothelial cells in liver homeostasis and disease</article-title><source>Frontiers in Physiology</source><volume>11</volume><elocation-id>873</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2020.00873</pub-id><pub-id pub-id-type="pmid">32848838</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>CG</given-names></name><name><surname>Hartl</surname><given-names>CA</given-names></name><name><surname>Schmid</surname><given-names>D</given-names></name><name><surname>Carmona</surname><given-names>EM</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Goldberg</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases</article-title><source>Science Translational Medicine</source><volume>10</volume><elocation-id>eaar1916</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aar1916</pub-id><pub-id pub-id-type="pmid">29563317</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlović</surname><given-names>Ž</given-names></name><name><surname>Risović</surname><given-names>D</given-names></name><name><surname>Novaković</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Comparative study of direct and indirect image-based profilometry in characterization of surface roughness</article-title><source>Surface and Interface Analysis</source><volume>44</volume><fpage>825</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1002/sia.4889</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Postic</surname><given-names>C</given-names></name><name><surname>Shiota</surname><given-names>M</given-names></name><name><surname>Niswender</surname><given-names>KD</given-names></name><name><surname>Jetton</surname><given-names>TL</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Moates</surname><given-names>JM</given-names></name><name><surname>Shelton</surname><given-names>KD</given-names></name><name><surname>Lindner</surname><given-names>J</given-names></name><name><surname>Cherrington</surname><given-names>AD</given-names></name><name><surname>Magnuson</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase</article-title><source>The Journal of Biological Chemistry</source><volume>274</volume><fpage>305</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.1.305</pub-id><pub-id pub-id-type="pmid">9867845</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poynard</surname><given-names>T</given-names></name><name><surname>McHutchison</surname><given-names>J</given-names></name><name><surname>Manns</surname><given-names>M</given-names></name><name><surname>Trepo</surname><given-names>C</given-names></name><name><surname>Lindsay</surname><given-names>K</given-names></name><name><surname>Goodman</surname><given-names>Z</given-names></name><name><surname>Ling</surname><given-names>MH</given-names></name><name><surname>Albrecht</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C</article-title><source>Gastroenterology</source><volume>122</volume><fpage>1303</fpage><lpage>1313</lpage><pub-id pub-id-type="doi">10.1053/gast.2002.33023</pub-id><pub-id pub-id-type="pmid">11984517</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prigge</surname><given-names>JR</given-names></name><name><surname>Hoyt</surname><given-names>TR</given-names></name><name><surname>Dobrinen</surname><given-names>E</given-names></name><name><surname>Capecchi</surname><given-names>MR</given-names></name><name><surname>Schmidt</surname><given-names>EE</given-names></name><name><surname>Meissner</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Type I IFNs act upon hematopoietic progenitors to protect and maintain hematopoiesis during Pneumocystis lung infection in mice</article-title><source>Journal of Immunology</source><volume>195</volume><fpage>5347</fpage><lpage>5357</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1501553</pub-id><pub-id pub-id-type="pmid">26519535</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reitsma</surname><given-names>S</given-names></name><name><surname>Slaaf</surname><given-names>DW</given-names></name><name><surname>Vink</surname><given-names>H</given-names></name><name><surname>van Zandvoort</surname><given-names>MAMJ</given-names></name><name><surname>oude Egbrink</surname><given-names>MGA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The endothelial glycocalyx: composition, functions, and visualization</article-title><source>Pflugers Archiv</source><volume>454</volume><fpage>345</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1007/s00424-007-0212-8</pub-id><pub-id pub-id-type="pmid">17256154</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>A</given-names></name><name><surname>Regnault</surname><given-names>A</given-names></name><name><surname>Kleijmeer</surname><given-names>M</given-names></name><name><surname>Ricciardi-Castagnoli</surname><given-names>P</given-names></name><name><surname>Amigorena</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells</article-title><source>Nature Cell Biology</source><volume>1</volume><fpage>362</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1038/14058</pub-id><pub-id pub-id-type="pmid">10559964</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Spiess</surname><given-names>P</given-names></name><name><surname>Lafreniere</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes</article-title><source>Science</source><volume>233</volume><fpage>1318</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1126/science.3489291</pub-id><pub-id pub-id-type="pmid">3489291</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sallusto</surname><given-names>F</given-names></name><name><surname>Geginat</surname><given-names>J</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Central memory and effector memory T cell subsets: function, generation, and maintenance</article-title><source>Annual Review of Immunology</source><volume>22</volume><fpage>745</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.22.012703.104702</pub-id><pub-id pub-id-type="pmid">15032595</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sargent</surname><given-names>D</given-names></name><name><surname>Sobrero</surname><given-names>A</given-names></name><name><surname>Grothey</surname><given-names>A</given-names></name><name><surname>O’Connell</surname><given-names>MJ</given-names></name><name><surname>Buyse</surname><given-names>M</given-names></name><name><surname>Andre</surname><given-names>T</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Green</surname><given-names>E</given-names></name><name><surname>Labianca</surname><given-names>R</given-names></name><name><surname>O’Callaghan</surname><given-names>C</given-names></name><name><surname>Seitz</surname><given-names>JF</given-names></name><name><surname>Francini</surname><given-names>G</given-names></name><name><surname>Haller</surname><given-names>D</given-names></name><name><surname>Yothers</surname><given-names>G</given-names></name><name><surname>Goldberg</surname><given-names>R</given-names></name><name><surname>de Gramont</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials</article-title><source>Journal of Clinical Oncology</source><volume>27</volume><fpage>872</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.19.5362</pub-id><pub-id pub-id-type="pmid">19124803</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname><given-names>J</given-names></name><name><surname>Arganda-Carreras</surname><given-names>I</given-names></name><name><surname>Frise</surname><given-names>E</given-names></name><name><surname>Kaynig</surname><given-names>V</given-names></name><name><surname>Longair</surname><given-names>M</given-names></name><name><surname>Pietzsch</surname><given-names>T</given-names></name><name><surname>Preibisch</surname><given-names>S</given-names></name><name><surname>Rueden</surname><given-names>C</given-names></name><name><surname>Saalfeld</surname><given-names>S</given-names></name><name><surname>Schmid</surname><given-names>B</given-names></name><name><surname>Tinevez</surname><given-names>J-Y</given-names></name><name><surname>White</surname><given-names>DJ</given-names></name><name><surname>Hartenstein</surname><given-names>V</given-names></name><name><surname>Eliceiri</surname><given-names>K</given-names></name><name><surname>Tomancak</surname><given-names>P</given-names></name><name><surname>Cardona</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreiber</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The molecular basis for differential type I interferon signaling</article-title><source>The Journal of Biological Chemistry</source><volume>292</volume><fpage>7285</fpage><lpage>7294</lpage><pub-id pub-id-type="doi">10.1074/jbc.R116.774562</pub-id><pub-id pub-id-type="pmid">28289098</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>SI</given-names></name><name><surname>Lim</surname><given-names>SB</given-names></name><name><surname>Yoon</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>CW</given-names></name><name><surname>Yu</surname><given-names>CS</given-names></name><name><surname>Kim</surname><given-names>TW</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Comparison of recurrence patterns between ≤5 years and &gt; 5 years after curative operations in colorectal cancer patients</article-title><source>Journal of Surgical Oncology</source><volume>108</volume><fpage>9</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1002/jso.23349</pub-id><pub-id pub-id-type="pmid">23754582</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sitia</surname><given-names>G</given-names></name><name><surname>Iannacone</surname><given-names>M</given-names></name><name><surname>Aiolfi</surname><given-names>R</given-names></name><name><surname>Isogawa</surname><given-names>M</given-names></name><name><surname>van Rooijen</surname><given-names>N</given-names></name><name><surname>Scozzesi</surname><given-names>C</given-names></name><name><surname>Bianchi</surname><given-names>ME</given-names></name><name><surname>von Andrian</surname><given-names>UH</given-names></name><name><surname>Chisari</surname><given-names>FV</given-names></name><name><surname>Guidotti</surname><given-names>LG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Kupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitis</article-title><source>PLOS Pathogens</source><volume>7</volume><elocation-id>e1002061</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1002061</pub-id><pub-id pub-id-type="pmid">21655107</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sitia</surname><given-names>G</given-names></name><name><surname>Aiolfi</surname><given-names>R</given-names></name><name><surname>Di Lucia</surname><given-names>P</given-names></name><name><surname>Mainetti</surname><given-names>M</given-names></name><name><surname>Fiocchi</surname><given-names>A</given-names></name><name><surname>Mingozzi</surname><given-names>F</given-names></name><name><surname>Esposito</surname><given-names>A</given-names></name><name><surname>Ruggeri</surname><given-names>ZM</given-names></name><name><surname>Chisari</surname><given-names>FV</given-names></name><name><surname>Iannacone</surname><given-names>M</given-names></name><name><surname>Guidotti</surname><given-names>LG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B</article-title><source>PNAS</source><volume>109</volume><fpage>E2165</fpage><lpage>E2172</lpage><pub-id pub-id-type="doi">10.1073/pnas.1209182109</pub-id><pub-id pub-id-type="pmid">22753481</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sorensen</surname><given-names>KK</given-names></name><name><surname>Smedsrod</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><chapter-title>The liver sinusoidal endothelial cell: basic biology and pathobiology</chapter-title><person-group person-group-type="editor"><name><surname>Sorensen</surname><given-names>KK</given-names></name></person-group><source>The Liver: Biology and Pathobiology</source><edition>Sixth</edition><publisher-name>John Wiley &amp; Sons Ltd</publisher-name><fpage>422</fpage><lpage>434</lpage></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>SA</given-names></name><name><surname>Domínguez-Robles</surname><given-names>J</given-names></name><name><surname>Donnelly</surname><given-names>RF</given-names></name><name><surname>Larrañeta</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Implantable polymeric drug delivery devices: classification, manufacture, materials, and clinical applications</article-title><source>Polymers</source><volume>10</volume><elocation-id>E1379</elocation-id><pub-id pub-id-type="doi">10.3390/polym10121379</pub-id><pub-id pub-id-type="pmid">30961303</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>JD</given-names></name><name><surname>Chervin</surname><given-names>AS</given-names></name><name><surname>Kranz</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>T-Cell receptor binding affinities and kinetics: impact on T-cell activity and specificity</article-title><source>Immunology</source><volume>126</volume><fpage>165</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2008.03015.x</pub-id><pub-id pub-id-type="pmid">19125887</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Lai</surname><given-names>S</given-names></name><name><surname>Jeong</surname><given-names>J</given-names></name><name><surname>Jung</surname><given-names>Y</given-names></name><name><surname>McConnell</surname><given-names>M</given-names></name><name><surname>Utsumi</surname><given-names>T</given-names></name><name><surname>Iwakiri</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Single-Cell transcriptomics reveals zone-specific alterations of liver sinusoidal endothelial cells in cirrhosis</article-title><source>Cellular and Molecular Gastroenterology and Hepatology</source><volume>11</volume><fpage>1139</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1016/j.jcmgh.2020.12.007</pub-id><pub-id pub-id-type="pmid">33340713</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA</source><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talamini</surname><given-names>L</given-names></name><name><surname>Picchetti</surname><given-names>P</given-names></name><name><surname>Ferreira</surname><given-names>LM</given-names></name><name><surname>Sitia</surname><given-names>G</given-names></name><name><surname>Russo</surname><given-names>L</given-names></name><name><surname>Violatto</surname><given-names>MB</given-names></name><name><surname>Travaglini</surname><given-names>L</given-names></name><name><surname>Fernandez Alarcon</surname><given-names>J</given-names></name><name><surname>Righelli</surname><given-names>L</given-names></name><name><surname>Bigini</surname><given-names>P</given-names></name><name><surname>De Cola</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Organosilica cages target hepatic sinusoidal endothelial cells avoiding macrophage filtering</article-title><source>ACS Nano</source><volume>15</volume><fpage>9701</fpage><lpage>9716</lpage><pub-id pub-id-type="doi">10.1021/acsnano.1c00316</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanjore</surname><given-names>H</given-names></name><name><surname>Kalluri</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The role of type IV collagen and basement membranes in cancer progression and metastasis</article-title><source>The American Journal of Pathology</source><volume>168</volume><fpage>715</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2006.051321</pub-id><pub-id pub-id-type="pmid">16507886</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tauriello</surname><given-names>DVF</given-names></name><name><surname>Palomo-Ponce</surname><given-names>S</given-names></name><name><surname>Stork</surname><given-names>D</given-names></name><name><surname>Berenguer-Llergo</surname><given-names>A</given-names></name><name><surname>Badia-Ramentol</surname><given-names>J</given-names></name><name><surname>Iglesias</surname><given-names>M</given-names></name><name><surname>Sevillano</surname><given-names>M</given-names></name><name><surname>Ibiza</surname><given-names>S</given-names></name><name><surname>Cañellas</surname><given-names>A</given-names></name><name><surname>Hernando-Momblona</surname><given-names>X</given-names></name><name><surname>Byrom</surname><given-names>D</given-names></name><name><surname>Matarin</surname><given-names>JA</given-names></name><name><surname>Calon</surname><given-names>A</given-names></name><name><surname>Rivas</surname><given-names>EI</given-names></name><name><surname>Nebreda</surname><given-names>AR</given-names></name><name><surname>Riera</surname><given-names>A</given-names></name><name><surname>Attolini</surname><given-names>CS-O</given-names></name><name><surname>Batlle</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Tgfβ drives immune evasion in genetically reconstituted colon cancer metastasis</article-title><source>Nature</source><volume>554</volume><fpage>538</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1038/nature25492</pub-id><pub-id pub-id-type="pmid">29443964</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tirone</surname><given-names>M</given-names></name><name><surname>Tran</surname><given-names>NL</given-names></name><name><surname>Ceriotti</surname><given-names>C</given-names></name><name><surname>Gorzanelli</surname><given-names>A</given-names></name><name><surname>Canepari</surname><given-names>M</given-names></name><name><surname>Bottinelli</surname><given-names>R</given-names></name><name><surname>Raucci</surname><given-names>A</given-names></name><name><surname>Di Maggio</surname><given-names>S</given-names></name><name><surname>Santiago</surname><given-names>C</given-names></name><name><surname>Mellado</surname><given-names>M</given-names></name><name><surname>Saclier</surname><given-names>M</given-names></name><name><surname>François</surname><given-names>S</given-names></name><name><surname>Careccia</surname><given-names>G</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>De Marchis</surname><given-names>F</given-names></name><name><surname>Conti</surname><given-names>V</given-names></name><name><surname>Ben Larbi</surname><given-names>S</given-names></name><name><surname>Cuvellier</surname><given-names>S</given-names></name><name><surname>Casalgrandi</surname><given-names>M</given-names></name><name><surname>Preti</surname><given-names>A</given-names></name><name><surname>Chazaud</surname><given-names>B</given-names></name><name><surname>Al-Abed</surname><given-names>Y</given-names></name><name><surname>Messina</surname><given-names>G</given-names></name><name><surname>Sitia</surname><given-names>G</given-names></name><name><surname>Brunelli</surname><given-names>S</given-names></name><name><surname>Bianchi</surname><given-names>ME</given-names></name><name><surname>Vénéreau</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>High mobility group box 1 orchestrates tissue regeneration via CXCR4</article-title><source>The Journal of Experimental Medicine</source><volume>215</volume><fpage>303</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1084/jem.20160217</pub-id><pub-id pub-id-type="pmid">29203538</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toyoshima</surname><given-names>Y</given-names></name><name><surname>Kitamura</surname><given-names>H</given-names></name><name><surname>Xiang</surname><given-names>H</given-names></name><name><surname>Ohno</surname><given-names>Y</given-names></name><name><surname>Homma</surname><given-names>S</given-names></name><name><surname>Kawamura</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Kamiyama</surname><given-names>T</given-names></name><name><surname>Tanino</surname><given-names>M</given-names></name><name><surname>Taketomi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Il6 modulates the immune status of the tumor microenvironment to facilitate metastatic colonization of colorectal cancer cells</article-title><source>Cancer Immunology Research</source><volume>7</volume><fpage>1944</fpage><lpage>1957</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-18-0766</pub-id><pub-id pub-id-type="pmid">31554639</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valastyan</surname><given-names>S</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Tumor metastasis: molecular insights and evolving paradigms</article-title><source>Cell</source><volume>147</volume><fpage>275</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.09.024</pub-id><pub-id pub-id-type="pmid">22000009</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Bij</surname><given-names>GJ</given-names></name><name><surname>Bögels</surname><given-names>M</given-names></name><name><surname>Otten</surname><given-names>MA</given-names></name><name><surname>Oosterling</surname><given-names>SJ</given-names></name><name><surname>Kuppen</surname><given-names>PJ</given-names></name><name><surname>Meijer</surname><given-names>S</given-names></name><name><surname>Beelen</surname><given-names>RHJ</given-names></name><name><surname>van Egmond</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy</article-title><source>Journal of Hepatology</source><volume>53</volume><fpage>677</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2010.04.023</pub-id><pub-id pub-id-type="pmid">20619916</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Gestel</surname><given-names>YRBM</given-names></name><name><surname>de Hingh</surname><given-names>IHJT</given-names></name><name><surname>van Herk-Sukel</surname><given-names>MPP</given-names></name><name><surname>van Erning</surname><given-names>FN</given-names></name><name><surname>Beerepoot</surname><given-names>LV</given-names></name><name><surname>Wijsman</surname><given-names>JH</given-names></name><name><surname>Slooter</surname><given-names>GD</given-names></name><name><surname>Rutten</surname><given-names>HJT</given-names></name><name><surname>Creemers</surname><given-names>G-JM</given-names></name><name><surname>Lemmens</surname><given-names>VEPP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Patterns of metachronous metastases after curative treatment of colorectal cancer</article-title><source>Cancer Epidemiology</source><volume>38</volume><fpage>448</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1016/j.canep.2014.04.004</pub-id><pub-id pub-id-type="pmid">24841870</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Nakayama</surname><given-names>M</given-names></name><name><surname>Pitulescu</surname><given-names>ME</given-names></name><name><surname>Schmidt</surname><given-names>TS</given-names></name><name><surname>Bochenek</surname><given-names>ML</given-names></name><name><surname>Sakakibara</surname><given-names>A</given-names></name><name><surname>Adams</surname><given-names>S</given-names></name><name><surname>Davy</surname><given-names>A</given-names></name><name><surname>Deutsch</surname><given-names>U</given-names></name><name><surname>Lüthi</surname><given-names>U</given-names></name><name><surname>Barberis</surname><given-names>A</given-names></name><name><surname>Benjamin</surname><given-names>LE</given-names></name><name><surname>Mäkinen</surname><given-names>T</given-names></name><name><surname>Nobes</surname><given-names>CD</given-names></name><name><surname>Adams</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis</article-title><source>Nature</source><volume>465</volume><fpage>483</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1038/nature09002</pub-id><pub-id pub-id-type="pmid">20445537</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>A</given-names></name><name><surname>Bertolino</surname><given-names>P</given-names></name><name><surname>Benseler</surname><given-names>V</given-names></name><name><surname>Fraser</surname><given-names>R</given-names></name><name><surname>McCaughan</surname><given-names>GW</given-names></name><name><surname>Le Couteur</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Marked changes of the hepatic sinusoid in a transgenic mouse model of acute immune-mediated hepatitis</article-title><source>Journal of Hepatology</source><volume>46</volume><fpage>239</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2006.08.022</pub-id><pub-id pub-id-type="pmid">17125874</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>JS</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Atkins</surname><given-names>MB</given-names></name><name><surname>Disis</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Toxicities of immunotherapy for the practitioner</article-title><source>Journal of Clinical Oncology</source><volume>33</volume><fpage>2092</fpage><lpage>2099</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.60.0379</pub-id><pub-id pub-id-type="pmid">25918278</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkinson</surname><given-names>AL</given-names></name><name><surname>Qurashi</surname><given-names>M</given-names></name><name><surname>Shetty</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The role of sinusoidal endothelial cells in the axis of inflammation and cancer within the liver</article-title><source>Frontiers in Physiology</source><volume>11</volume><elocation-id>990</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2020.00990</pub-id><pub-id pub-id-type="pmid">32982772</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winkler</surname><given-names>M</given-names></name><name><surname>Staniczek</surname><given-names>T</given-names></name><name><surname>Kürschner</surname><given-names>SW</given-names></name><name><surname>Schmid</surname><given-names>CD</given-names></name><name><surname>Schönhaber</surname><given-names>H</given-names></name><name><surname>Cordero</surname><given-names>J</given-names></name><name><surname>Kessler</surname><given-names>L</given-names></name><name><surname>Mathes</surname><given-names>A</given-names></name><name><surname>Sticht</surname><given-names>C</given-names></name><name><surname>Neßling</surname><given-names>M</given-names></name><name><surname>Uvarovskii</surname><given-names>A</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X-J</given-names></name><name><surname>von Figura</surname><given-names>G</given-names></name><name><surname>Hartmann</surname><given-names>D</given-names></name><name><surname>Mogler</surname><given-names>C</given-names></name><name><surname>Dobreva</surname><given-names>G</given-names></name><name><surname>Schledzewski</surname><given-names>K</given-names></name><name><surname>Géraud</surname><given-names>C</given-names></name><name><surname>Koch</surname><given-names>P-S</given-names></name><name><surname>Goerdt</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling</article-title><source>Journal of Hepatology</source><volume>74</volume><fpage>380</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2020.08.033</pub-id><pub-id pub-id-type="pmid">32916216</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wohlfeil</surname><given-names>SA</given-names></name><name><surname>Häfele</surname><given-names>V</given-names></name><name><surname>Dietsch</surname><given-names>B</given-names></name><name><surname>Schledzewski</surname><given-names>K</given-names></name><name><surname>Winkler</surname><given-names>M</given-names></name><name><surname>Zierow</surname><given-names>J</given-names></name><name><surname>Leibing</surname><given-names>T</given-names></name><name><surname>Mohammadi</surname><given-names>MM</given-names></name><name><surname>Heineke</surname><given-names>J</given-names></name><name><surname>Sticht</surname><given-names>C</given-names></name><name><surname>Olsavszky</surname><given-names>V</given-names></name><name><surname>Koch</surname><given-names>P-S</given-names></name><name><surname>Géraud</surname><given-names>C</given-names></name><name><surname>Goerdt</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hepatic endothelial Notch activation protects against liver metastasis by regulating endothelial-tumor cell adhesion independent of angiocrine signaling</article-title><source>Cancer Research</source><volume>79</volume><fpage>598</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-1752</pub-id><pub-id pub-id-type="pmid">30530502</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>MJ</given-names></name><name><surname>Hoos</surname><given-names>A</given-names></name><name><surname>Bauer</surname><given-names>J</given-names></name><name><surname>Boettcher</surname><given-names>S</given-names></name><name><surname>Knust</surname><given-names>M</given-names></name><name><surname>Weber</surname><given-names>A</given-names></name><name><surname>Simonavicius</surname><given-names>N</given-names></name><name><surname>Schneider</surname><given-names>C</given-names></name><name><surname>Lang</surname><given-names>M</given-names></name><name><surname>Stürzl</surname><given-names>M</given-names></name><name><surname>Croner</surname><given-names>RS</given-names></name><name><surname>Konrad</surname><given-names>A</given-names></name><name><surname>Manz</surname><given-names>MG</given-names></name><name><surname>Moch</surname><given-names>H</given-names></name><name><surname>Aguzzi</surname><given-names>A</given-names></name><name><surname>van Loo</surname><given-names>G</given-names></name><name><surname>Pasparakis</surname><given-names>M</given-names></name><name><surname>Prinz</surname><given-names>M</given-names></name><name><surname>Borsig</surname><given-names>L</given-names></name><name><surname>Heikenwalder</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the Jak2-Stat5 and p38MAPK pathway</article-title><source>Cancer Cell</source><volume>22</volume><fpage>91</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.05.023</pub-id><pub-id pub-id-type="pmid">22789541</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Fu</surname><given-names>ML</given-names></name><name><surname>Weichselbaum</surname><given-names>RR</given-names></name><name><surname>Gajewski</surname><given-names>TF</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>YX</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses</article-title><source>Cancer Cell</source><volume>25</volume><fpage>37</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2013.12.004</pub-id><pub-id pub-id-type="pmid">24434209</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Dai</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Shen</surname><given-names>G</given-names></name><name><surname>Luo</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Immune modulation of liver sinusoidal endothelial cells by melittin nanoparticles suppresses liver metastasis</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>574</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-08538-x</pub-id><pub-id pub-id-type="pmid">30718511</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yun</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Routes for drug delivery: sustained-release devices</article-title><source>Developments in Ophthalmology</source><volume>55</volume><fpage>84</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1159/000434692</pub-id><pub-id pub-id-type="pmid">26501913</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Davis</surname><given-names>C</given-names></name><name><surname>Ryan</surname><given-names>J</given-names></name><name><surname>Janney</surname><given-names>C</given-names></name><name><surname>Peña</surname><given-names>MMO</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Development and characterization of a reliable mouse model of colorectal cancer metastasis to the liver</article-title><source>Clinical &amp; Experimental Metastasis</source><volume>30</volume><fpage>903</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1007/s10585-013-9591-8</pub-id><pub-id pub-id-type="pmid">23748471</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">C57BL/6 J</td><td align="left" valign="bottom">Charles River, Italy</td><td align="left" valign="bottom">Strain code: 632</td><td align="left" valign="bottom">Inbred</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">BALB/c</td><td align="left" valign="bottom">Charles River Lab</td><td align="left" valign="bottom">Strain code: 028</td><td align="left" valign="bottom">Inbred</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ)</td><td align="left" valign="bottom">Charles River Lab</td><td align="left" valign="bottom">Strain code: 614</td><td align="left" valign="bottom">Immun odeficient</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Ifnar1<sup>fl/fl</sup></italic> (B6(Cg)-<italic>Ifnar1</italic>tm1.1Ees/J)</td><td align="left" valign="bottom">Jackson Lab</td><td align="left" valign="bottom"><italic>JAX:028256</italic></td><td align="left" valign="bottom">C57BL/6 J background</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Alb</italic><sup>Cre</sup> (B6.Cg-Speer6-ps1Tg(<italic>Alb</italic>-cre)21Mgn/J)</td><td align="left" valign="bottom">Jackson Lab</td><td align="left" valign="bottom">JAX:003574</td><td align="left" valign="bottom">C57BL/6 J background</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Pdgfrb</italic><sup>CreERT2</sup> (B6.Cg-Tg(Pdgfrb-cre/ERT2)6096Rha/J)</td><td align="left" valign="bottom">Jackson Lab</td><td align="left" valign="bottom">JAX:029684</td><td align="left" valign="bottom">C57BL/6 J background</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Itgax</italic><sup>Cre</sup> (CD11c, B6.Cg-Tg(<italic>Itgax</italic>-cre)1-1Reiz/J)</td><td align="left" valign="bottom">Jackson Lab</td><td align="left" valign="bottom">JAX:008068</td><td align="left" valign="bottom">C57BL/6 J background</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Rosa26-ZsGreen (B6.Cg-Gt(ROSA)26Sortm6(CAG-ZsGreen1)Hze/J)</td><td align="left" valign="bottom">Jackson Lab</td><td align="left" valign="bottom">JAX:007906</td><td align="left" valign="bottom">C57BL/6 J background</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>VeCad</italic><sup>CreERT2</sup> (<italic>Cdh5</italic>(PAC)<sup>-CreERT2</sup> mice)</td><td align="left" valign="bottom">Taconic, Models for life</td><td align="left" valign="bottom">Provided by S. Brunelli (UniMib, Milan)</td><td align="left" valign="bottom">C57BL/6 J background</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">OT-I mice (C57BL/6-Tg(TcraTcrb)<break/>1100Mgb/Crl)</td><td align="left" valign="bottom">Charles River Lab</td><td align="left" valign="bottom">JAX:003831</td><td align="left" valign="bottom">C57BL/6 J background</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD126, IL-6RA, (clone: D7715A7) (Rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 115806, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313676">AB_313676</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-CD18, ITGB2 (clone M18/2) (Rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 101402, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312811">AB_312811</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD49d, ITGA4, (clone 9C10(MFR4.B)) (Rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 103706, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313046">AB_313046</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-H-2K<sup>b</sup>/H-2D<sup>b</sup> (clone 28-8-6) (Mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 114605, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313596">AB_313596</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD86 (clone GL-1) (Rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 105007, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313150">AB_313150</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD146 (clone ME-9F1) (Rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 134704, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2143527">AB_2143527</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD44 (clone IM7) (Rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 103044, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2650923">AB_2650923</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD62L (clone MEL-14) (Rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 104420, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_493376">AB_493376</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti- CD16/CD32, (Rat monoclonal)</td><td align="left" valign="bottom">BioXCell</td><td align="left" valign="bottom">Cat# BE0307; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2736987">AB_2736987</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GFP, (Rabbit polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Sci</td><td align="left" valign="bottom">Cat# A11122, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_221569">AB_221569</ext-link></td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GFP (clone FM264G) (Rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 338008, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2563288">AB_2563288</ext-link></td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD31, PECAM1, (Goat polyclonal)</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# AF3628, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2161028">AB_2161028</ext-link></td><td align="left" valign="bottom">IF (1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-PDGFRβ, CD140b (clone APB5) (Rat monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 14-1402-82, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_467493">AB_467493</ext-link></td><td align="left" valign="bottom">IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD11c, (clone N418)(Armenian hamster monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat#117312, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_492850">AB_492850</ext-link></td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Heparan Sulfate (clone F58-10E4) (Mouse monoclonal)</td><td align="left" valign="bottom">Amsbio</td><td align="left" valign="bottom">Cat# 370255 S, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10891554">AB_10891554</ext-link></td><td align="left" valign="bottom">IF (1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-LYVE-1 (Rabbit polyclonal)</td><td align="left" valign="bottom">Novus Biol</td><td align="left" valign="bottom">Cat# NB600-1008, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10000497">AB_10000497</ext-link></td><td align="left" valign="bottom">IF (1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Collagen type IV (Rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab19808, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_445160">AB_445160</ext-link></td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Laminin (Rabbit polyclonal)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# L9393, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_477163">AB_477163</ext-link></td><td align="left" valign="bottom">IF (1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD54, ICAM1 (clone YN1/1.7.4) (Rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat#116101, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313692">AB_313692</ext-link></td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD62E, E-selectin (clone 10E9.6) (Rat monoclonal)</td><td align="left" valign="bottom">BD Bioscience</td><td align="left" valign="bottom">Cat#550290, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_393585">AB_393585</ext-link></td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Rabbit AF488 (Donkey polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Sci</td><td align="left" valign="bottom">Cat#32790, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2762833">AB_2762833</ext-link></td><td align="left" valign="bottom">IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Goat AF546 (Donkey polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Sci</td><td align="left" valign="bottom">Cat#A-11056, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2534103">AB_2534103</ext-link></td><td align="left" valign="bottom">IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Rat AF647 (Donkey polyclonal)</td><td align="left" valign="bottom">Jackson IR</td><td align="left" valign="bottom">Cat#712-605-153,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2340694">AB_2340694</ext-link></td><td align="left" valign="bottom">IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-IgM conjugated to APC (clone II/41) (Rat monoclonal)</td><td align="left" valign="bottom">Thermo Fisher Sci</td><td align="left" valign="bottom">Cat#17-5790-82, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_469458">AB_469458</ext-link></td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Ki-67 (clone SP6) (Rabbit recombinant antibody)</td><td align="left" valign="bottom">Thermo Fisher Sci</td><td align="left" valign="bottom">Cat# MA5-14520, RID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10979488">AB_10979488</ext-link></td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD34 (clone MEC14.7) (Rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 119301, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_345279">AB_345279</ext-link></td><td align="left" valign="bottom">IHC (1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-F4/80 (clone A3-1) (Rat monoclonal)</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">Cat# MCA497, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2098196">AB_2098196</ext-link></td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD3 (clone SP7) (Rabbit monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab21703, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_446487">AB_446487</ext-link></td><td align="left" valign="bottom">IHC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-pSTAT1 (Clone 58D6) (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# BK9167S, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_561284">AB_561284</ext-link></td><td align="left" valign="bottom">IHC (1:800)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD11c microbeads ultrapure</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">Cat# 130-125-835</td><td align="left" valign="bottom">100 µL per 10⁸ total cells</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-F4/80 microbeads ultrapure</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">Cat# 130-110-443</td><td align="left" valign="bottom">100 µL per 10⁸ total cells</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">InVivoMAb Anti-mouse GM-CSF(clone MP1-22E9) (Rat monoclonal)</td><td align="left" valign="bottom">BioXcell</td><td align="left" valign="bottom">Cat# BE0259 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2687738">AB_2687738</ext-link></td><td align="char" char="." valign="bottom">40 ng/ml</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant mouse IFNα1, carrier-free</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 751802</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">NH2-SIINFEKL-COOH (SL-8 peptide)</td><td align="left" valign="bottom">Proimmune</td><td align="left" valign="bottom">Cat# GMPT5995</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Albumin from chicken egg white (ovalbumin)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# 55039</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Gadoxetic acid (Primovist; Gd-EOB-DTPA)</td><td align="left" valign="bottom">Bayer Schering Pharma</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Tamoxifen</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat# T5648-5G</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Lipofectamine 2000</td><td align="left" valign="bottom">Thermo Fisher Sci</td><td align="left" valign="bottom">Cat# 11668019</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Paraformaldehyde <break/>powder</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# 158127</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sodium Cacodylate powder</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# C0250</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">25% EM grade Glutaraldehyde</td><td align="left" valign="bottom">ProSciTech</td><td align="left" valign="bottom">Cat# C001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Osmium tetroxide</td><td align="left" valign="bottom">ProSciTech</td><td align="left" valign="bottom">Cat# C011</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Lanthanum (III) nitrate hexahydrate</td><td align="left" valign="bottom">MERK</td><td align="left" valign="bottom">Cat# 331937–11 G</td><td align="char" char="." valign="bottom">2%</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Zinc formalin fixative</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# Z2902-3.75L</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Fibronectin human plasma</td><td align="left" valign="bottom">MERK</td><td align="left" valign="bottom">Cat# F2006-1MG</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Percoll</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# P4937-500ML</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Matrigel Matrix</td><td align="left" valign="bottom">BD Bioscience</td><td align="left" valign="bottom">Cat# 354248</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">7-AAD Viability staining solution</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 420404</td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">EGM-2MV endothelial cell growth medium-2 BulletKit</td><td align="left" valign="bottom">Lonza</td><td align="left" valign="bottom">Cat# CC-3202</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Brefeldin A</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# B7651</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">VeriKine-HS Mouse IFNα All-Subtype ELISA Kit</td><td align="left" valign="bottom">PBL Assay Sci</td><td align="left" valign="bottom">Cat# 42115–1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">GeneArt CRISPR Nuclease Vector with OFP Reporter Kit</td><td align="left" valign="bottom">Thermo Fisher Sci</td><td align="left" valign="bottom">Cat# A21174</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">TOPO TA Cloning Kit</td><td align="left" valign="bottom">Thermo Fisher Sci</td><td align="left" valign="bottom">Cat# 450641</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">CellTiter-Glo Luminescent Cell Viability Assay</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat# G7570</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">ReliaPrep RNA Cell Miniprep System</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat# Z6011</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">ReliaPrep RNA Tissue Miniprep System</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat# Z6111</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">TURBO DNA-free kit</td><td align="left" valign="bottom">Ambion</td><td align="left" valign="bottom">Cat# AM1907</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">QIAamp DNA Mini kit</td><td align="left" valign="bottom">Qiagen</td><td align="left" valign="bottom">Cat# 51304</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">RNeasy Mini Kit</td><td align="left" valign="bottom">Qiagen</td><td align="left" valign="bottom">Cat# 74104</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">Procyte kit</td><td align="left" valign="bottom">Idexx</td><td align="left" valign="bottom">Cat# 9926306–00</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">Live/Dead fixable near-IR dead cell stain kit</td><td align="left" valign="bottom">Thermo Fisher Sci</td><td align="left" valign="bottom">Cat# L34975</td><td align="left" valign="bottom">FC (1:500)</td></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">Live/Dead fixable Green dead cell stain kit</td><td align="left" valign="bottom">Thermo Fisher Sci</td><td align="left" valign="bottom">Cat# L34970</td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">DNAse TURBO</td><td align="left" valign="bottom">Thermo Fisher Sci</td><td align="left" valign="bottom">Cat# AM1907</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">Foxp3/Transcription Factor Staining buffer set</td><td align="left" valign="bottom">Thermo Fisher Sci</td><td align="left" valign="bottom">Cat# 00-5523-00</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell lines (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">CT26</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# CRL-2638, RID:CVCL_7256</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell lines (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">MC38</td><td align="left" valign="bottom">Kindly provided by P. Berraondo López - Centro de Investigación Médica Aplicada (Spain)</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_B288">CVCL_B288</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ifnar1</italic> intron 3 forward</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib77">Prigge et al., 2015</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ACTCAGGTTCG<break/>CTCCATCAG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ifnar1</italic> intron 3 reverse</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib77">Prigge et al., 2015</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GCACATTGACCATT<break/>ACAAGAGTAG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ifnar1</italic> exon2 forward</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TCCAAGACTCC<break/>TGCTGTC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ifnar1</italic> exon2 reverse</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GCACTTTTAC<break/>TTGCTCGGT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Itgax</italic><sup>Cre</sup> forward</td><td align="left" valign="bottom">Jackson Lab</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ACTTGGCAGCTG<break/>TCTCCAAG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Itgax</italic><sup>Cre</sup> reverse</td><td align="left" valign="bottom">Jackson Lab</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GTGGCAGATGG<break/>CGCGGCA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>ALB</italic><sup>Cre</sup> forward</td><td align="left" valign="bottom">Jackson Lab</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CCAGGCTAAGTGCC<break/>TTCTCTACA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>ALB</italic><sup>Cre</sup> reverse</td><td align="left" valign="bottom">Jackson Lab</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AATGCTTCTGTCC<break/>GTTTGCCGGT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Pdgfrb</italic><sup>Cre</sup> forward</td><td align="left" valign="bottom">Jackson Lab</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GAACTGTCACC<break/>GGGAGGA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Pdgfrb</italic><sup>Cre</sup> reverse</td><td align="left" valign="bottom">Jackson Lab</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AGGCAAATTTT<break/>GGTGTACGG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>VeCad</italic><sup>Cre</sup> forward</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib102">Wang et al., 2010</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GCCTGCATTACCG<break/>GTCGATGCAACG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>VeCad</italic><sup>Cre</sup> reverse</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib102">Wang et al., 2010</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GTGGCAGATGGCG<break/>CGGCAACACCAT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">RosaZsgreen forward</td><td align="left" valign="bottom">Jackson Lab</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AACCAGAAGTGG<break/>CACCTGAC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">RosaZsgreen reverse</td><td align="left" valign="bottom">Jackson Lab</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GGCATTAAAGC<break/>AGCGTATCC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">crRNA1</td><td align="left" valign="bottom">Thermo Fisher Sci</td><td align="left" valign="bottom">CRISPR RNA guide</td><td align="left" valign="bottom">TAGACGTCTATATT<break/>CTCAGGGTTTT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">crRNA2</td><td align="left" valign="bottom">Thermo Fisher Sci</td><td align="left" valign="bottom">CRISPR RNA guide</td><td align="left" valign="bottom">ATGTAGACGTCTAT<break/>ATTCTCGTTTT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mm00516793_g1</td><td align="left" valign="bottom">Thermo Fisher Sci</td><td align="left" valign="bottom">Taqman probe <italic>Irf7</italic></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mm00836412_m1</td><td align="left" valign="bottom">Thermo Fisher Sci</td><td align="left" valign="bottom">Taqman probe <italic>Oas1</italic></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mm 99999915_g1</td><td align="left" valign="bottom">Thermo Fisher Sci</td><td align="left" valign="bottom">Taqman probe <italic>Gapdh</italic></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithms</td><td align="left" valign="bottom">FlowJo v10.5 or greater</td><td align="left" valign="bottom">Tree Star</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_008520">SCR_008520</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithms</td><td align="left" valign="bottom">Prism version 8 or greater</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithms</td><td align="left" valign="bottom">ImageScope software</td><td align="left" valign="bottom">Leica Biosystems</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014311">SCR_014311</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithms</td><td align="left" valign="bottom">Imaris version 7.2.3</td><td align="left" valign="bottom">Bitplane</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_007370">SCR_007370</ext-link>;</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithms</td><td align="left" valign="bottom">Fiji software or ImageJ software</td><td align="left" valign="bottom">NIH</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002285">SCR_002285</ext-link>;<break/>003070</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithms</td><td align="left" valign="bottom">MIPAV v5.3.4 or greater</td><td align="left" valign="bottom">CIT, NIH</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_007371">SCR_007371</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithms</td><td align="left" valign="bottom">EsivisionPro 3.2 software</td><td align="left" valign="bottom">Soft Imaging Sys</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithms</td><td align="left" valign="bottom">OsiriX DICOM viewer version 3.9.2 or greater</td><td align="left" valign="bottom">Pixmeo SARL</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithms</td><td align="left" valign="bottom">Trimmomatic version 0.32</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib12">Bolger et al., 2014</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_011848">SCR_011848</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithms</td><td align="left" valign="bottom">STAR aligner version 2.5.3 a</td><td align="left" valign="bottom">STAR SRL</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_004463">SCR_004463</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithms</td><td align="left" valign="bottom">GENECODE version M22</td><td align="left" valign="bottom">Ensmbl 97</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithms</td><td align="left" valign="bottom">R-4.0.3 software</td><td align="left" valign="bottom">R Core Team</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithms</td><td align="left" valign="bottom">DESeq2 version 1.30.1</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib66">Love et al., 2014</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithms</td><td align="left" valign="bottom">EnrichR R package version 3.3</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib18">Chen et al., 2013</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_020938">SCR_020938</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithms</td><td align="left" valign="bottom">GeneArt CRISPR Search and Design Tool</td><td align="left" valign="bottom">Thermo Fisher Sci</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Alzet osmotic pumps 1002</td><td align="left" valign="bottom">Alzet</td><td align="left" valign="bottom">Cat# 10104844</td><td align="left" valign="bottom">Mini osmotic pump (MOP)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Alzet osmotic pumps 1004</td><td align="left" valign="bottom">Alzet</td><td align="left" valign="bottom">Cat# 10104846</td><td align="left" valign="bottom">Mini osmotic pump (MOP)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">ProCyte Dx Hematology Analyzer</td><td align="left" valign="bottom">IDEXX Lab</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Instruments</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Bruker Horizontal 7-Tesla MRI scanner</td><td align="left" valign="bottom">BioSpec</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Instruments</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">ViiA7 Fast Real-Time PCR System</td><td align="left" valign="bottom">Applied Biosys</td><td align="left" valign="bottom">Cat# 4453543</td><td align="left" valign="bottom">Instruments</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Aperio Scanscope XT Leica</td><td align="left" valign="bottom">Leica Biosystems</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_018457">SCR_018457</ext-link></td><td align="left" valign="bottom">Instruments</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Leica SP8 LIGHTNING confocal microscope</td><td align="left" valign="bottom">Leica Biosystems</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_018169">SCR_018169</ext-link></td><td align="left" valign="bottom">Instruments</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">FEI Talos L120C G2 Transmission electron microscope</td><td align="left" valign="bottom">Thermo Fisher Sci</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Instruments</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Zeiss FEG Gemini 500 Scanning electron microscope</td><td align="left" valign="bottom">Zeiss</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Instruments</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">FACSCanto II High Throughput Sampler</td><td align="left" valign="bottom">BD Bioscience</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Instruments</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">FACS LSRFortessa</td><td align="left" valign="bottom">BD Bioscience</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Instruments</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">FACSAria Fusion</td><td align="left" valign="bottom">BD Bioscience</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Instruments</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Illumina NovaSeq 6000 machine</td><td align="left" valign="bottom">Illumina</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016387">SCR_016387</ext-link></td><td align="left" valign="bottom">Instruments</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Leica CM1520 Cryostat</td><td align="left" valign="bottom">Leica Biosystems</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_017543">SCR_017543</ext-link></td><td align="left" valign="bottom">Instruments</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Leica VT1000S Vibratome</td><td align="left" valign="bottom">Leica Biosystems</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016495">SCR_016495</ext-link></td><td align="left" valign="bottom">Instruments</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">EM UC7 ultramicrotome</td><td align="left" valign="bottom">Leica Biosystems</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016694">SCR_016694</ext-link></td><td align="left" valign="bottom">Instruments</td></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80690.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bautch</surname><given-names>Victoria L</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0130frc33</institution-id><institution>University of North Carolina, Chapel Hill</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>This study describing how continuous perioperative IFNα therapy stimulates hepatic endothelial cells to build up a physical vascular barrier that limits tumor cell entry into the liver and promotes long-term antitumor immunity provides novel evidence for anti-metastatic effects of IFNα via effects on the liver vascular compartment. This work is predicted to advance the field and will be of interest to scientists studying cancer, inflammation and liver function.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80690.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Bautch</surname><given-names>Victoria L</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0130frc33</institution-id><institution>University of North Carolina, Chapel Hill</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Rafii</surname><given-names>Shahin</given-names></name><role>Reviewer</role><aff><institution>Weill Cornell Medical College</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p>[Editors' note: this paper was reviewed by <ext-link ext-link-type="uri" xlink:href="https://www.reviewcommons.org/">Review Commons</ext-link>.]</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80690.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p>We thank the referees for their reviews and helpful comments. We have revised our manuscript based on these comments, adding new experimental data that should address the referees’ concerns.</p><disp-quote content-type="editor-comment"><p>Response to Reviewer #1:</p><p>1. Authors use an elegant orthotopic model of liver metastasis to confirm the effect of continuous IFNα on hepatic colonization (Figure 3). Although they extensively characterize the metastatic lesions, they do not show data on the potential impact of IFNα treatment in the primary caecum tumour. Authors should clarify if the described effects are taken place in the liver or/and in the caecum. It would be interesting to show if IFNα affects the primary tumour size, the extravasation of cancer cells and the immune infiltration since all these factors could have an impact in the number of liver lesions.</p></disp-quote><p>We thank the reviewer for acknowledging the importance of our results particularly in the context of the orthotopic mouse model we developed. We agree that displaying the results of continuous IFNα therapy on primary intracecal tumors, as well as the results pertaining to the few mice that develop microscopic or macroscopic liver metastasis, is important for the interpretation of our work. Thus, we evaluated the dimension of primary intracecal CRC lesions (Figure 3D,E) and we performed additional IHC characterization of the primary tumors (Figure S4A,B). The analysis showed that the dimension of the primary lesions and the markers we analyzed were non significantly modified by continuous IFNα therapy (Figure 3D,E and Figure S4A,B). These results favor the hypothesis that IFNα therapy does not modify the number of cells that spread from the primary tumors and seed into the liver, but it rather impinges on the intravascular containment of CRC cells circulating within the liver (Figure 3F). As said earlier, the data also highlight the possibility that CRC tumors may become refractory to IFNα or that the dose and schedule we adopted does not significantly affect the growth of established liver CRCs at late time points. The data are also consistent with results obtained with MC38<sup><italic>Ifnar1</italic>_KO</sup> CRC cells indicating that continuous IFNα therapy does not require <italic>Ifnar1</italic> expression by tumor cells to exert its antimetastatic function (Figure 4A,C-D). This is also in line with the high IFNα concentrations required to activate the &quot;tunable&quot; direct antiproliferative functions of this cytokine that exceed those achieved in our system (Catarinella <italic>et al.,</italic> 2016; Schreiber, 2017).</p><p>Text has been added in the revised manuscript at lines 175-197 and in the discussion lines 425-431.</p><p>2. Figure 3f right shows liver images without any obvious metastatic lesion. Since authors are analysing the effect of IFNα treatment in proliferation, vascularization and immune composition in liver tumours, they may show and quantify images with metastatic lesions and restrict the analysis to the tumour area.</p><p>Since the main finding of our manuscript regards the prevention of hepatic colonization by continuous IFNα therapy, we think that the original data presented in Figure 3G,H are representative of the overall efficacy of our strategy that confers protection in up to 60% of the mice carrying intramesenteric tumors of increasing dimensions (Figure 3H). We have thus maintained our original results, adding the quantification of all IHC data on groups of Sham control livers (n=6), as suggested. In any case, we also included the same IHC characterization of the few and small intrahepatic lesions that have bypassed the intravascular antimetastatic barrier (Figure S4C,D). Indeed, in agreement with the results observed in primary intracecal lesions, these metastatic lesions that developed in IFNαtreated mice showed similar markers of cell proliferation, neoangiogenesis, F4/80 macrophages and CD3<sup>+</sup> T cells, as control lesions detected in NaCl<sup>-</sup>treated mice. Once again, the results highlight the possibility that CRC tumors, once established as micro/macroscopic metastases, may become refractory and resistant to IFNα therapy by downregulating the <italic>Ifnar1</italic> in various components of the tumor microenvironment (Boukhaled <italic>et al.</italic>, 2021; Katlinski <italic>et al.</italic>, 2017). Text has been added in the revised manuscript at lines 175-197 and in the discussion lines 496-515.</p><disp-quote content-type="editor-comment"><p>3. Authors analyse the recombination efficiency of different mouse CRE lines by nonquantitative methods (PCR of hepatic genomic DNA and GFP expression by immunofluorescence in healthy liver). Since PDGFRβ-Cre/ERT2 and CD11c-Cre lines are used to exclude a role of IFNα on the targeted cells, authors should provide stronger evidences to support this. They may consider studing the ablation of Ifnar1 in FACS sorted fibroblasts and myeloid cells. Moreover, it would be important showing the proportion of GFP+ cells in the sorted populations to understand how broadly these stromal populations are targeted.</p></disp-quote><p>We thank the referee for raising this important issue, which is related to the relative efficiency of <italic>Ifnar1</italic> recombination in each of the Cre-expressing mouse models we have used in the study. To this regard, we newly performed an extensive colocalization analysis quantifying the percentage of GFP<sup>+</sup> cells that colocalize with cell specific markers (i.e., PDGFRβ, CD11c, F4/80 and CD31) of the various mouse models (PDGFRβ<sup>CreERT2</sup>, CD11c<sup>Cre</sup> and VeCad<sup>CreERT2</sup>, respectively) crossed with RosaZsGreen reporter mice.</p><p>Colocalization analysis of GFP in the different systems was performed using the ImageJ “colocalization” algorithm developed by Pierre Bourdoncle (Institut Jacques Monod, Service Imagerie, Paris; 2003–2004). The method allows the generation of unsupervised profiles of co-localized pixels between two channels. This methodology has been included in the section Methods and Protocols, line 806-809. Of note, we observed an almost complete recombination in liver fibroblast (GFP<sup>+</sup>/PDGFRβ<sup>+</sup>), with about 98.2 ± 0.72% hepatic stellate cells that co-expressed GFP<sup>+</sup> and PDGFRβ<sup>+</sup> signals (see the new Figure S5E). Similarly, hepatic DCs (GFP<sup>+</sup>/CD11c<sup>+</sup>) had 94.17 ± 2.16% colocalization, while F4/80<sup>+</sup> KCs or LCMs (GFP<sup>+</sup>/F4/80<sup>+</sup>) colocalized in 78.14 ± 5.03% (see the new Figure S5E). Finally, HECs, including LSECs, (GFP<sup>+</sup>/CD31<sup>+</sup>) showed 85.3 ± 5.03% colocalization (see the new Figure S5E,F), with no expression of GFP signals in cells other than CD31<sup>+</sup>. Note that these values indicate an almost complete colocalization of the Cre recombinase in the target cell types analyzed (see representative IF shown in Figure S5E). Text has been added in the revised manuscript at lines 225-233.</p><p>Moreover, DEGs analysis between NaCl<sup>-</sup>treated VeCad<italic><sup>Ifnar1_KO</sup></italic> and <italic>Ifnar1<sup>fl/fl</sup></italic> HECs showed a significant downregulation of <italic>Ifnar1</italic> expression in CD31+ VeCad<italic><sup>Ifnar1_KO</sup></italic> cells, with a log<sub>2</sub> fold-change of -0.387 and an adjusted p-value of 0.033, further confirming Cre recombination in HECs isolated from VeCad<italic><sup>Ifnar1_KO</sup></italic> mice (as depicted in the heatmap of Figure 6B; the 12<sup>th</sup> gene of the Type I IFN response is <italic>Ifnar1</italic>).</p><p>We have prepared all source images at higher dimension to better appreciate the colocalization within liver microvasculature. In addition, we performed several flow cytometry analyses to identify liver cell populations of Cre-recombinant mice that express <italic>Ifnar1</italic>. Unfortunately, the predicted low cellular surface expression of this molecule coupled with the experimental conditions needed to extract viable non-parenchymal cells from the liver have prevented us from obtaining informative results<italic>.</italic></p><disp-quote content-type="editor-comment"><p>4. Ifnar1 ablation in VeCad+ cells prevents the effect of IFNα on tumour growth (Figure 4d), suggesting the existence of anti-tumour mechanisms beyond the effects on hepatic colonization. Authors may consider checking proliferation, vascularization and immune infiltration in these tumours to enhance their conclusion.</p></disp-quote><p>We fully agree with the referee’s concern and as above mentioned, we have followed his/her suggestion and examined the existence of antitumor mechanisms beyond the effects on hepatic colonization in VeCad<sup><italic>Ifnar1</italic>_KO</sup> mice treated with NaCl or IFNα. To this end, 4 NaCl<sup>-</sup>Ifnar1<sup>fl/fl</sup>, 7 IFNα-Ifnar1<sup>fl/fl</sup>, 4 NaCl<sup>-</sup>VeCad<sup>Ifnar1_KO</sup> and 4 IFNα-VeCad<sup>Ifnar1_KO</sup> mice were intrasplenically injected with MC38 CRC cells (Figure S7A,B). Twenty-one days after injection, mice were euthanized and their livers analyzed for tumor size, proliferation, signs of angiogenesis (as denoted by CD34 staining) and immune infiltration (F4/80<sup>+</sup> macrophages and CD3<sup>+</sup> T cells). Consistent with data presented in Figure 4D, histological analysis showed that <italic>Ifnar1</italic><sup>fl/fl</sup> mice did not develop liver metastases in IFNα-treated mice. Furthermore, metastatic lesions detected in VeCad<sup><italic>Ifnar1</italic>_KO</sup> mice treated or not with IFNα did not show significant differences in Ki67 positivity, CD34 staining or the amount of F4/80<sup>+</sup> resident macrophages and CD3<sup>+</sup> T cells. This further supports that the antimetastatic potential of IFNα therapy may be primarily depend on the inhibition of hepatic trans-sinusoidal migration, a limiting step in the metastatic cascade that could secondarily influence colonization and outgrowth (Chambers <italic>et al.,</italic> 2002). Corresponding text has been added at lines 248-252.</p><disp-quote content-type="editor-comment"><p>5. Immune properties of LSECs are analysed in vivo by using a mouse CRE line that targets all endothelial cells, including those ones located in lymphoid organs, and evaluating T cell composition in the spleen. I found difficult to conclude that these properties are exerted directly by LSECs and not by other endothelial cells in vivo. To clarify the local effect of LSECs in modulating anti-tumour immunity, T cell composition and activation should be checked in tumours shortly after tamoxifen administration.</p></disp-quote><p>We thank the reviewer for pointing out this issue, which cannot not be tested directly because – as also mentioned by reviewer 2 – LSEC-specific Cre-recombinant driver mice do not exist. As also indicated in the cited literature, central memory T cells accumulate after peripheral priming in secondary lymphoid organs such as the spleen (Sallusto <italic>et al.,</italic> 2004; Stone <italic>et al.,</italic> 2009; Yu <italic>et al.,</italic> 2019). To this end, the generation and regulation of antitumor immunity is a highly orchestrated multistep process involving the uptake of tumor-associated antigens by professional APCs, their time-consuming migration to draining lymph nodes and the generation of protective T cells. Unlike other APCs, HECs/LSECs do not need to migrate to draining lymph nodes to activate effector T cells, leading to a rapid intrahepatic CD8<sup>+</sup> T cell activation.</p><p>In this context, LSECs must not only efficiently uptake, process and present CRC-derived antigens coming from intravascularly contained tumor cells, but they also require the attraction and retention within the liver micro-vasculature of T cell populations necessary for the generation of effective antitumor immune responses, where chemokines play an important role (Lalor <italic>et al.,</italic> 2002). As shown in Figure 6A-C, two prominent chemokines (<italic>Cxcl10</italic> and <italic>Cxcl9</italic>) required for T cell recruitment to the liver are specifically upregulated only in HECs/LSECs from IFNα-treated <italic>Ifnar1</italic><sup>fl/fl</sup> mice, whereas HECs from VeCad<sup>Ifnar1_KO</sup> mice maintained low expression of these chemoattractants in both NaCl<sup>-</sup> and IFNα-treated mice.</p><p>These data are also consistent with the in vitro cross-priming results (see Figure 7A,B) showing that in the absence of IFNα, HECs have a low capacity to prime naïve T cells (Katz <italic>et al.,</italic> 2004), indicating that LSEC-primed by tumor-derived antigens coming from apoptotic intravascular CRC metastatic cells play an important role in inducing tolerance (Berg <italic>et al.,</italic> 2006; Katz <italic>et al.</italic>, 2004), especially when CRC cells quickly extravasate and position within the space of Disse, likely becoming less accessible to intravascular patrolling by naïve and effector T cells (Benechet <italic>et al.,</italic> 2019; Guidotti <italic>et al.,</italic> 2015). On the contrary, in IFNα-treated Ifnar1<sup>fl/fl</sup> mice, CRC cells are rapidly contained in the liver microvasculature (Figure 5A,B) with CRC-derived antigens that could be immediately taken up by LSECs due to their anatomical proximity and efficient endocytosis capacity, which is among the highest of all cell types in the body (Sorensen, 2020). Here, the continuous sensing of IFNα by LSECs upregulates several genes related to antigen processing and presentation pathways (Figure 6B,D), leading to efficient cross-priming of tumor-specific CD8<sup>+</sup> T cells to the same extent as professional APCs, such as splenic DCs (Figure 7B).</p><p>Text has been added in the revised manuscript at lines 496-515.</p><p>Finally, regarding the suggestion to analyze the role of HECs/LSECs in inducing antitumor T cell immunity shortly after tamoxifen administration, while we agree that it would be interesting to analyze HEC/LSEC-mediated T cell activation by treating NaCl<sup>-</sup> and IFNαtreated <italic>Ifnar1</italic><sup>fl/fl</sup> and VeCad<sup>Ifnar1_KO</sup> mice with tamoxifen after CRC cell injection, we would like to point out that tamoxifen treatment will not only induce Cre recombination and <italic>Ifnar1</italic> loss on endothelial cells but it may also induce several “off-target” effects complicating the interpretation of the results. Indeed, tamoxifen is known to (i) inhibit the in vitro proliferation of several CRC cell lines (Ziv <italic>et al.,</italic> 1994), (ii) impair the growth of CRC liver metastases in vivo (Kuruppu <italic>et al.,</italic> 1998) and (iii) modify matrix stiffness to reduce tumor cell survival (Cortes <italic>et al.,</italic> 2019). Further, as IFNα modifies the hepatic vascular barrier and the accessibility of antigens by LSECs, the specific timing of tamoxifen treatment could also affect the immunological consequences of <italic>Ifnar1</italic> deletion making these experiment impractical. For these reasons, we’d like not to perform the suggested experiment with tamoxifen.</p><disp-quote content-type="editor-comment"><p>Response to Reviewer #2</p><p>1. First, the authors started their experiments with MC38 and CT26 CRC cell lines. At the end they just applied MC38. The rational behind this should be clearly stated. Second, as in their previous publication (Catarinella et al., 2016) F1 hybrids of C57BL/6 x BALB/c mice were used for the experiments. However, I believe that the genetic heterogeneity might be strongly increased by this approach which might lead to difficult reproducibility of the results.</p></disp-quote><p>We thank the referee for raising this important issue; additional text describing the reason of our choice has been introduced at lines: 203-205. We respectfully disagree with the comment that CB6F1 hybrids may increase genetic heterogeneity and impair reproducibility of our results. Each CB6F1 hybrid individual is genetically identical to its littermates, sharing 50% of genes of each parental mouse line and being tolerant to reciprocal MHC-I genes (thus permitting the correct engraftment of both cell lines). We agree that the use of mismatched backcrosses after the F1 generation would increase genetic heterogeneity and thus may affect outcome. This is also the reason why we could not perform experiments with CT26 in the <italic>Ifnar1</italic><sup>fl/fl</sup> conditional lines that are in C57BL/6 background and would have needed at least 10 generations of backcrossing in the BALB/c background before being suitable to such experiments. Finally, all experiments described in Figure 4, 5, 6 and 7 were performed in C57BL/6 mice using MC38 CRC cells with results that reproduced those obtained in CB6F1 hybrids, and very similarly to what we have previously reported with MC38 in C57BL/6 mice (see Figure 5 (Catarinella <italic>et al.</italic>, 2016)).</p><disp-quote content-type="editor-comment"><p>2. At page 16 the authors conclude that &quot;patients suffering from chronic liver fibrotic disease… display lower incidence of hepatic metastases&quot;. In the community there is contradictory data (see Kondo et al., BJC, 2016, https://www.nature.com/articles/bjc2016155). This should be precisely discussed, otherwise this claim should be removed.</p></disp-quote><p>We thank the referee for raising this issue and modified the discussion accordingly. Text has been added in the revised manuscript at lines 455-457.</p><disp-quote content-type="editor-comment"><p>3. In the Discussion section the interplay of other cell types within the hepatic niche should be stated. For example, in Toyoshima's study a direct anti-tumoral effect of dendritic cells releasing IFNα1 was demonstrated (see Toyoshima et al., Cancer Immunol Res, 2019, https://aacrjournals.org/cancerimmunolres/article/7/12/1944/469540/IL6-Modulatesthe-Immune-Status-of-the-Tumor). This further strengthens your data.</p></disp-quote><p>We agree with the reviewer's suggestion and added new text to recognized the interplay between different cell types such as dendritic cells within the hepatic niche (see new text at lines 505-515).</p><disp-quote content-type="editor-comment"><p>4. Last, multiple times the authors write about data that is &quot;not shown&quot;. Please either include these data in the manuscript or delete corresponding phrases because it is not possible for the reader to scrutinize it.</p></disp-quote><p>We fully agree with the referee’s concern and displayed all “not shown results” in Figure S1E and Figure S9C-I.</p><disp-quote content-type="editor-comment"><p>5. Besides, I suggest additional experiments further substantiating the study: To see if this effect of IFNα1 is cell type-specific liver metastasis of other solid tumors such as breast cancer or melanoma should be investigated.</p></disp-quote><p>We agree with the reviewer's suggestion, as also indicated in our original discussion. We believe that additional experiments with other solid tumor cell lines would be important to generalize the potential of perioperative IFNα therapy. In particular, we believe that pancreatic ductal adenocarcinoma (PDAC), a highly lethal disease that most commonly metastasizes to the liver (Lambert <italic>et al.,</italic> 2017), may benefit from our approach. It should be noted, however, that the pleotropic nature of IFNα allows this cytokine to inhibit tumor growth by several mechanisms. Above all, the ability of IFNα therapy to directly reduce tumor growth depends on the relative surface expression of Ifnar1 on each tumor cell and the ability to maintain such expression in the harsh tumor microenvironment during IFNα therapy. As the degradation of Ifnar1 by CRC tumors has been well described (Katlinski <italic>et al.</italic>, 2017), it is possible that CRC tumors thus escaping the antitumor properties of endogenous type I interferons may respond less efficiently to therapeutic IFNα regimens such as those herein described. This notion is consistent with our data on primary orthotopic tumors (Figure 3D,E), which are no longer responsive to continuous IFNα therapy as early as 7 days after implantation of CT26<sup>LM3</sup> cells. In addition, the definition of the HEC/LSEC antimetastatic barrier has been possible only because CRC cells are not directly susceptible to the IFNα antiproliferative activity, which we observed in vitro at extremely high IFNα dosages (Catarinella <italic>et al.</italic>, 2016) but not in vivo (as formally demonstrated by using MC38<italic><sup>Ifnar_ko</sup></italic> cells, Figure 4A). Properly addressing the reviewer’s comment would thus require extensive investigations involving the establishment of new mouse models of metastases from other solid tumors, starting from the in vitro and in vivo regulation of surface Ifnar1 expression in each tumor cell. We strongly believe that this work has merit but we think that it should be reported separately.</p><disp-quote content-type="editor-comment"><p>6. The authors applied a broad range of cell type-specific mice. However, a thorough characterization of the deletion of Ifnar1 in the corresponding cell types is missing. This is crucial for the manuscript.</p></disp-quote><p>We fully agree with the referee’s concern and as previously mentioned, we have improved the characterization of Ifnar1 deletion (see response to the same critique received from reviewer 1, comment 3).</p><disp-quote content-type="editor-comment"><p>7. The capillarization of the hepatic vascular niche is a crucial point in this story. I believe that the hepatic endothelium should be further characterized by additional vascular markers.</p></disp-quote><p>In response to the reviewer’s suggestion, we have included in our analysis the characterization of Lyve-1, a marker of hepatic capillarization (Pandey <italic>et al.,</italic> 2020; Wohlfeil <italic>et al.,</italic> 2019). Indeed, IFNα treatment of <italic>Ifnar1</italic><sup>fl/fl</sup> mice significantly increased the expression of Lyve-1, whereas IFNα treatment of VeCad<sup><italic>Ifnar1</italic>_KO</sup> mice showed no effect (Figure S9A,B), further corroborating our findings. Text has been added in the revised manuscript at lines 291-294. To better aid readers, we have prepared high-resolution images for each IF channel and have provided these data as source date for Figure S9A.</p><disp-quote content-type="editor-comment"><p>8. Last, the data and methods appear adequately presented and experiments seem to be reproducible. Just in Figure 4 the exact number of mice and replicates are not clearly presented. Otherwise, everything is fine.</p></disp-quote><p>We thank the reviewer for raising this issue, which apparently was not properly described in our original submission. We have now included the exact number of mice in each experimental group in the figure legend to Figure 4.</p><disp-quote content-type="editor-comment"><p>Minor comments</p><p>Overall the text and figures are accurately presented. However, I would like to add further minor comments:</p><p>9. In Figure 1 you present the IFNα dosing regimen. How do you explain the decrease in serum IFNα after day 2? Besides, the data points at day 0 should be excluded since measuring started from day 2! Why did you decide to treat for seven days until the start of the experiment? One could think 2 days might already be enough.</p></disp-quote><p>We thank the reviewer for raising these important points. Regarding the pharmacokineticpharmacodynamic (PK-PD) behavior of our approach, we do not believe that MOP reduced its pumping efficacy after day 2 (Theeuwes &amp; Yum, 1976), nor that counterregulatory mechanisms, such as the induction of anti-IFNα blocking antibodies, occurred in such a short time frame (Wang <italic>et al.,</italic> 2001). It is neither feasible that IFNα treatment significantly downregulated <italic>Ifnar1</italic> in the liver (as demonstrated by pSTAT1 activation after MOP treatment in Figure S1E). Rather, our results reflect the PK-PD behavior of other long-lasting formulations of IFNα, which depend on intrinsic pharmacological properties of IFNα already described in (Jeon <italic>et al.,</italic> 2013). Text has been added in the revised manuscript at lines 110-112.</p><p>We also corrected the figures in which we quantified serum IFNα. Indeed, blood was drawn one day before MOP implantation rather than on the same day of surgery to avoid additional blood loss, which could be a source of unnecessary stress for the animals. Therefore, we corrected the Results section and Figure S1A-C and Figure 1A,B.</p><p>The decision to start treatment 7 days rather than 2 days before seeding was made for several reasons: (i) this study follows our previous gene/cell therapy approach, in which the time interval between reconstitution of the transduced bone marrow with Tie2-IFNα and tumor challenge was at least 7-8 weeks. We therefore thought that 7 days might be a sufficient/necessary time period to induce similar phenotypes in the liver after continuous IFNα administration; (ii) 7 days is a time frame compatible with the perioperative period in humans (Horowitz <italic>et al.,</italic> 2015). Furthermore, the side effects that patients may experience after IFNα therapy are generally limited to the first few days after administration, allowing patients to benefit from IFNα-induced vascular antimetastatic barriers at the time of surgery without potential side effects of IFNα. Because oncologic guidelines recommend starting adjuvant chemotherapy at least 4 weeks after surgery in stage 2-3 CRC patients at risk of later developing liver metastases (Engstrand <italic>et al.,</italic> 2019; van Gestel <italic>et al.,</italic> 2014), our proposed perioperative time frame does not even conflict with these indications (Van Cutsem <italic>et al.,</italic> 2016).</p><p>We have included additional text in the lines 131-132 to motivate the timing of our regimens.</p><disp-quote content-type="editor-comment"><p>10. Figure 2: Did you check for metastases in other organs than the liver at the timepoint of euthanization, e.g. lungs. In the Discussion section you talk about a potential influence of IFNα1 on other organs. Therefore, I think that the mice should be thoroughly analyzed and the data presented. The manuscript will benefit from it.</p></disp-quote><p>We thank the reviewer for this valuable comment. Indeed, we always check for dissemination of CRC metastases on MRI analysis and necroscopy.</p><p>As stated at lines 146-147 and 158 CRC tumors seeded in the liver vasculature after colonizing the liver do not spread to other organs such as the lungs. Indeed, CRC cells intravascularly seeded in the portal circulation, are trapped at the beginning of hepatic sinusoids because their diameter is bigger than that of liver sinusoids (Figure S8A,B). These micro-anatomic peculiarities are also thought to impede the spreading of tumor cells from periportal to centrilobular areas and to the general circulation (Catarinella <italic>et al.</italic>, 2016; Vidal-Vanaclocha, 2008), and this is consistent with studies showing that in CRC patients undergoing surgery the majority of CRC-derived circulating tumor cells are found in the portal vein (Deneve <italic>et al.,</italic> 2013).</p><disp-quote content-type="editor-comment"><p>11. Overall, MRI pictures and pictures of IHC or IF are sometimes too small to see. Please provide pictures with larger magnification or enlarge the images.</p></disp-quote><p>We thank you for this suggestion and we have indeed increased the size of all MRI, IHC, and IF images to the maximum that will fit within the figure. In addition, we presented the images at the highest magnification available, without making digital enlargements that would significantly reduce resolution.</p><disp-quote content-type="editor-comment"><p>12. Figure 3 F, G: immune cell infiltration in the liver was analyzed. Please compare it to untreated, tumor-free wildtype liver tissue.</p></disp-quote><p>We appreciated the reviewer's suggestion and included the results of six Sham mice per each marker in our analysis.</p><p>The text was added on the figure legends to Figure 3H and Figure S4B,D.</p><disp-quote content-type="editor-comment"><p>13. Figure 6: the graphs are too small to be read, especially the volcano plot and the gene names of the heatmap.</p></disp-quote><p>We increased the font size of genes in the volcano plots and heatmap in Figure 6A,B, as suggested.</p><disp-quote content-type="editor-comment"><p>14. Figure S6: Pictures of co-immunofluorescences are presented. For the reader it is really hard to distinguish the stainings and to identify colocalized areas. Please provide pictures with one channel to better compare the marker expression.</p></disp-quote><p>We thank the reviewer for pointing this out and we have tried to make each panel as large as possible to fit into a two-column figure. We have also prepared high magnification images of each channel for all immunofluorescence images, which we provide as source data. We hope that this is sufficient to help readers to interpret our results without increasing the number of main or supplementary figures.</p><disp-quote content-type="editor-comment"><p>15. From page 8 onwards (section about transgenic mice) LSEC was used as kind of synonym for hepatic endothelial cells. Since there is still no LSEC-specific driver mouse, it should be stated &quot;hepatic endothelial cells&quot; instead.</p></disp-quote><p>We agree with this suggestion and thus have indicated that the results refer to HECs but include a large majority of LSECs. Indeed, LSECs make up the majority (~89%) of the total HEC population (Su <italic>et al.,</italic> 2021). In addition, some SEM and TEM analyses were performed only on LSECs, as well as the IF analyses. Therefore, we believe that LSECs play an important role in this process. Although not specifically suggested, we have also changed the title of our manuscript to reflect the reviewer's suggestion. Thus, we propose &quot;Continuous sensing of IFNα by hepatic endothelial cells shapes a vascular antimetastatic barrier&quot; as new title.</p><disp-quote content-type="editor-comment"><p>16. P. 11: there is a typo: Figure S6G,H</p></disp-quote><p>We corrected this typo.</p><disp-quote content-type="editor-comment"><p>17. P. 13: the authors describe Gata4 as inhibitor of subendothelial matrix deposition. This should be precisely written, since Gata4 originally is described as master-regulator of liver sinusoidal differentiation which leads to liver fibrosis development upon loss of Gata4. Besides, I came across a study of the same group that investigated the role of Notch signaling in hepatic CRC and melanoma metastasis (Wohlfeil et al., Cancer Res, 2019, https://aacrjournals.org/cancerres/article/79/3/598/638600/Hepatic-EndothelialNotch-Activation-Protects). Similar to your study they tie the reduction in hepatic metastasis to capillarization of the hepatic microvasculature.</p></disp-quote><p>We agree with this suggestion and modified text accordingly. We are also glad that our results agree with previous reported literature that has now been correctly cited at lines 351-356 and in the discussion lines 474-476.</p><disp-quote content-type="editor-comment"><p>18. The discussion reads like paraphrasing the Results section. The manuscript would clearly benefit if the Discussion section had been rewritten short and concisely.</p></disp-quote><p>We agree with this suggestion, and we have modified discussion accordingly. We are also willing to shorten the discussion by removing the schematic model that could possibly be used as a graphical abstract.</p><p>References</p><p>Benechet AP, De Simone G, Di Lucia P, Cilenti F, Barbiera G, Le Bert N, Fumagalli V, Lusito E, Moalli F, Bianchessi V et al. (2019) Dynamics and genomic landscape of CD8(+) T cells undergoing hepatic priming. Nature 574: 200-205</p><p>Berg M, Wingender G, Djandji D, Hegenbarth S, Momburg F, Hammerling G, Limmer A, Knolle P (2006) Cross-presentation of antigens from apoptotic tumor cells by liver sinusoidal endothelial cells leads to tumor-specific CD8<sup>+</sup> T cell tolerance. Eur J Immunol 36: 2960-2970</p><p>Boukhaled GM, Harding S, Brooks DG (2021) Opposing Roles of Type I Interferons in Cancer Immunity. Annu Rev Pathol 16: 167-198</p><p>Catarinella M, Monestiroli A, Escobar G, Fiocchi A, Tran NL, Aiolfi R, Marra P, Esposito A, Cipriani F, Aldrighetti L et al. (2016) IFNalpha gene/cell therapy curbs colorectal cancer colonization of the liver by acting on the hepatic microenvironment. EMBO Mol Med 8: 155-170</p><p>Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572</p><p>Cortes E, Lachowski D, Robinson B, Sarper M, Teppo JS, Thorpe SD, Lieberthal TJ, Iwamoto K, Lee DA, Okada-Hatakeyama M et al. (2019) Tamoxifen mechanically reprograms the tumor microenvironment via HIF-1A and reduces cancer cell survival. EMBO Rep 20</p><p>Deneve E, Riethdorf S, Ramos J, Nocca D, Coffy A, Daures JP, Maudelonde T, Fabre JM, Pantel K, Alix-Panabieres C (2013) Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem 59: 1384-1392</p><p>Engstrand J, Stromberg C, Nilsson H, Freedman J, Jonas E (2019) Synchronous and metachronous liver metastases in patients with colorectal cancer-towards a clinically relevant definition. World J Surg Oncol 17: 228</p><p>Guidotti LG, Inverso D, Sironi L, Di Lucia P, Fioravanti J, Ganzer L, Fiocchi A, Vacca M, Aiolfi R, Sammicheli S et al. (2015) Immunosurveillance of the liver by intravascular effector CD8(+) T cells. Cell 161: 486-500</p><p>Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S (2015) Exploiting the critical perioperative period to improve long-term cancer outcomes. Nature reviews Clinical oncology 12: 213-226</p><p>Jeon S, Juhn JH, Han S, Lee J, Hong T, Paek J, Yim DS (2013) Saturable human neopterin response to interferon-α assessed by a pharmacokinetic-pharmacodynamic model. Journal of translational medicine 11: 240</p><p>Katlinski KV, Gui J, Katlinskaya YV, Ortiz A, Chakraborty R, Bhattacharya S, Carbone CJ, Beiting DP, Girondo MA, Peck AR et al. (2017) Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. Cancer cell 31: 194-207</p><p>Katz SC, Pillarisetty VG, Bleier JI, Shah AB, DeMatteo RP (2004) Liver sinusoidal endothelial cells are insufficient to activate T cells. Journal of immunology 173: 230-235</p><p>Kuruppu D, Christophi C, Bertram JF, O'Brien PE (1998) Tamoxifen inhibits colorectal cancer metastases in the liver: a study in a murine model. Journal of gastroenterology and hepatology 13: 521-527</p><p>Lalor PF, Shields P, Grant A, Adams DH (2002) Recruitment of lymphocytes to the human liver. Immunol Cell Biol 80: 52-64</p><p>Lambert AW, Pattabiraman DR, Weinberg RA (2017) Emerging Biological Principles of Metastasis. Cell 168: 670-691</p><p>Pandey E, Nour AS, Harris EN (2020) Prominent Receptors of Liver Sinusoidal Endothelial Cells in Liver Homeostasis and Disease. Front Physiol 11: 873</p><p>Sallusto F, Geginat J, Lanzavecchia A (2004) Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22: 745-763</p><p>Schreiber G (2017) The molecular basis for differential type I interferon signaling. J Biol Chem 292: 7285-7294</p><p>Soares KC, Foley K, Olino K, Leubner A, Mayo SC, Jain A, Jaffee E, Schulick RD, Yoshimura K, Edil B et al. (2014) A preclinical murine model of hepatic metastases. J Vis Exp: 51677</p><p>Sorensen KK, Smedsrod, B. (2020) The Liver Sinusoidal Endothelial Cell: Basic Biology and Pathobiology. In: The Liver: Biology and Pathobiology, Sixth Edition pp. 422-434. John Wiley &amp; Sons Ltd.</p><p>Stone JD, Chervin AS, Kranz DM (2009) T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology 126: 165-176</p><p>Su T, Yang Y, Lai S, Jeong J, Jung Y, McConnell M, Utsumi T, Iwakiri Y (2021) Single-Cell Transcriptomics Reveals Zone-Specific Alterations of Liver Sinusoidal Endothelial Cells in Cirrhosis. Cell Mol Gastroenterol Hepatol 11: 1139-1161</p><p>Theeuwes F, Yum SI (1976) Principles of the design and operation of generic osmotic pumps for the delivery of semisolid or liquid drug formulations. Ann Biomed Eng 4: 343353</p><p>Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G et al. (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27: 1386-1422</p><p>van Gestel YR, de Hingh IH, van Herk-Sukel MP, van Erning FN, Beerepoot LV, Wijsman JH, Slooter GD, Rutten HJ, Creemers GJ, Lemmens VE (2014) Patterns of metachronous metastases after curative treatment of colorectal cancer. Cancer Epidemiol 38: 448-454</p><p>Vidal-Vanaclocha F (2008) The prometastatic microenvironment of the liver. Cancer microenvironment : official journal of the International Cancer Microenvironment Society 1: 113-129</p><p>Wang DS, Ohdo S, Koyanagi S, Takane H, Aramaki H, Yukawa E, Higuchi S (2001) Effect of dosing schedule on pharmacokinetics of α interferon and anti-α interferon neutralizing antibody in mice. Antimicrob Agents Chemother 45: 176-180</p><p>Wohlfeil SA, Hafele V, Dietsch B, Schledzewski K, Winkler M, Zierow J, Leibing T, Mohammadi MM, Heineke J, Sticht C et al. (2019) Hepatic Endothelial Notch Activation Protects against Liver Metastasis by Regulating Endothelial-Tumor Cell Adhesion Independent of Angiocrine Signaling. Cancer research 79: 598-610</p><p>Yu X, Chen L, Liu J, Dai B, Xu G, Shen G, Luo Q, Zhang Z (2019) Immune modulation of liver sinusoidal endothelial cells by melittin nanoparticles suppresses liver metastasis. Nat Commun 10: 574</p><p>Zhu Y, Karakhanova S, Huang X, Deng SP, Werner J, Bazhin AV (2014) Influence of interferon-α on the expression of the cancer stem cell markers in pancreatic carcinoma cells. Exp Cell Res 324: 146-156</p><p>Ziv Y, Gupta MK, Milsom JW, Vladisavljevic A, Brand M, Fazio VW (1994) The effect of tamoxifen and fenretinimide on human colorectal cancer cell lines in vitro. Anticancer Res 14: 2005-2009</p></body></sub-article></article>